"AHC","PY","nTotDoc","meanAUPerArt","meanAU_IN_PerArt","meanArtAU_IN","meanArtPer_AU_IN_FIRST","meanArtPer_AU_IN_LAST","meanArtPer_AU_IN_CORR","ArtOA","singleAuArt","Q1_nSJR","Q2_nSJR","Q3_nSJR","Q4_nSJR","Q1_percSJR","Q2_percSJR","Q3_percSJR","Q4_percSJR","meanTCperArt","mean_NTC","InternCoauthorship","AffCoauthorship","meanCitationTrend","GC_AUIN_wFractional","GC_AUIN_FIRSTname","GC_AUIN_LASTname","GC_AUIN_CORRESP","top_AU","top_AU_freq","top_AU_wFract","top_AU_freq_wFract","top_AUIN","top_AUIN_freq","top_AUIN_wFract","top_AUIN_freq_wFract","topAUbyCit","topAUbyCit_TC","topAUINbyCit","topAUINbyCit_TC","topAUINbyCit_norm_byYear","topAUINbyCit_TC_norm_byYear","topConcept_L0","topFreq_L0","topConcept_L1","topFreq_L1","topConcept_L2","topFreq_L2","topConcept_L3","topFreq_L3","topConcept_L4","topFreq_L4","topMESH","topMESH_n","topprimary_topic.display_name","topprimary_topic.display_name_n","topDE","topDE_n","topTI_TM","topTI_TM_n","topAB_TM","topAB_TM_n","nDoc_wALTM","percDoc_wALTM","altmetric_score_thirdQu","cited_by_accounts_count_thirdQu","cited_by_fbwalls_count_thirdQu","cited_by_feeds_count_thirdQu","cited_by_gplus_count_thirdQu","cited_by_msm_count_thirdQu","cited_by_patents_count_thirdQu","cited_by_peer_review_sites_count_thirdQu","cited_by_policies_count_thirdQu","cited_by_posts_count_thirdQu","cited_by_rdts_count_thirdQu","cited_by_rh_count_thirdQu","cited_by_tweeters_count_thirdQu","cited_by_videos_count_thirdQu","cited_by_wikipedia_count_thirdQu","cohorts.com_thirdQu","cohorts.doc_thirdQu","cohorts.pub_thirdQu","cohorts.sci_thirdQu","readers.citeulike_thirdQu","readers.connotea_thirdQu","readers.mendeley_thirdQu","readers_count_thirdQu","n_patentsDistinct","nPatentStatus_Abandoned","nPatentStatus_Granted","nPatentStatus_N/A","nPatentStatus_Pending","nPatentStatus_Active","nPatentStatus_Not-in-force","nPatentStatus_Expired - Fee Related","nPatentStatus_Withdrawn","nPatentStatus_Ceased","nPatentStatus_Revoked","nPatentStatus_Expired - Lifetime","nPatentPubType_Application","nPatentPubType_Grant","nPatentPubType_N/A","avg_citations_Patent","avg_Inventors_Patent","inventor_per_AUIN_100","avg_InstitutesInvolved_Patent","nPatent_singleInventor","n_Patents_CoAff","n_Jurisdiction_distinct","nJurisd_AU","nJurisd_CA","nJurisd_EP","nJurisd_IN","nJurisd_CN","nJurisd_US","nJurisd_DE","nJurisd_ES","nJurisd_IT","nJurisd_AT","nJurisd_BR","nJurisd_WO","nJurisd_JP","nJurisd_DK","nJurisd_IL","nJurisd_PT","nJurisd_PL","nJurisd_FR","nJurisd_SA","nJurisd_MY","nJurisd_KR","nJurisd_NL","nJurisd_CO","nJurisd_SM","nJurisd_SI","nJurisd_HR","nJurisd_RU","nJurisd_EA","nJurisd_MX","nJurisd_HK","nPatentKC_A1","nPatentKC_A","nPatentKC_A2","nPatentKC_B1","nPatentKC_D1","nPatentKC_T3","nPatentKC_B2","nPatentKC_T1","nPatentKC_A3","nPatentKC_C","nPatentKC_B","nPatentKC_C2","nPatentKC_C0","nPatentKC_A8","nPatentKC_E","nPatentKC_T4","nPatentKC_D0","nPatentKC_T2","nPatentKC_A0","nPatentKC_B8","nPatentKC_A4","nPatentKC_T8","nPatentKC_C1","nPatentKC_U1","nPatentKC_T5","nPatentKC_B3","nPatentKC_T7","nPatentKC_A9","top_Inventor names_Patent","top_Inventor names_Patent_n","top_Original assignee names_Patent","top_Original assignee names_Patent_n","top_Fields of Research (ANZSRC 2020)_Patent","top_Fields of Research (ANZSRC 2020)_Patent_n","top_RCDC Categories_Patent","top_RCDC Categories_Patent_n","top_HRCS RAC Categories_Patent","top_HRCS RAC Categories_Patent_n","top_IPCR_Patent","top_IPCR_Patent_n","top_CPC_Patent","top_CPC_Patent_n","n_clTrial","avg_durationYear_clTrial","avg_participants_clTrial","clTrial_perAUIN_100","nClTrial_w_AltmScore","cl_AltmS_rel","avg_sponsor_clTrial","nclTrialPhase_Phase 1","nclTrialPhase_Phase 1/2","nclTrialPhase_Phase 2","nclTrialPhase_Phase 2/3","nclTrialPhase_Phase 3","nclTrialPhase_Phase 3/4","nclTrialPhase_Phase 4","nclTrialPhase_N/A","nclTrialPhase_Post Authorisation Studies","nclTrial_StudyType_Interventional","nclTrial_StudyType_Observational","nclTrial_StudyType_Other","nclTrial_StudyType_Expanded access","nclTrial_StudyType_Active surveillance","nclTrial_StudyType_Non-interventional","nclTrial_StudyType_RCT","nclTrial_StudyType_CCT","nclTrial_Gender_All","nclTrial_Gender_Female","nclTrial_Gender_Male","nclTrial_Registry_ClinicalTrials.gov","nclTrial_Registry_EU-CTR","nclTrial_Registry_ENCePP","nclTrial_Registry_ISRCTN","nclTrial_Registry_ANZCTR","nclTrial_Registry_GCTR","nclTrial_Registry_PACTR","nclTrial_Registry_CTRI","nclTrial_Registry_ReBEC","nclTrial_Registry_UMIN-CTR","top_funder_country","top_funder_country_n","top_Fields of Research (ANZSRC 2020)_clTrial","top_Fields of Research (ANZSRC 2020)_clTrial_n","top_RCDC Categories_clTrial","top_RCDC Categories_clTrial_n","top_HRCS HC Categories_clTrial","top_HRCS HC Categories_clTrial_n","top_HRCS RAC Categories_clTrial","top_HRCS RAC Categories_clTrial_n","top_Cancer Types_clTrial","top_Cancer Types_clTrial_n","top_CSO Categories_clTrial","top_CSO Categories_clTrial_n","n_grants","avg_funding_EUR","avg_funding_EUR_perOrganization","avg_durationYear_grant","avg_Organization_per_grant","avg_countries_per_grant","perc_grant_internationalColl","avg_ResultingPublications_per_grant","totFundingOrgbyActivedGrant","avgPubByActivedFundingGrant_1000","top_Research Organization - standardized_Grants","top_Research Organization - standardized_n_Grants","top_Funder_Grants","top_Funder_n_Grants","top_Funder Group_Grants","top_Funder Group_n_Grants","top_Program_Grants","top_Program_n_Grants","top_Fields of Research (ANZSRC 2020)_Grants","top_Fields of Research (ANZSRC 2020)_n_Grants","top_RCDC Categories_Grants","top_RCDC Categories_n_Grants","top_HRCS HC Categories_Grants","top_HRCS HC Categories_n_Grants","top_HRCS RAC Categories_Grants","top_HRCS RAC Categories_n_Grants","top_Cancer Types_Grants","top_Cancer Types_n_Grants","top_CSO Categories_Grants","top_CSO Categories_n_Grants","top_Units of Assessment_Grants","top_Units of Assessment_n_Grants","top_Sustainable Development Goals_Grants","top_Sustainable Development Goals_n_Grants","n_dataset","top_Repository_Dataset","top_Repository_Dataset_n","top_Fields of Research (ANZSRC 2020)_Dataset","top_Fields of Research (ANZSRC 2020)_Dataset_n","top_RCDC Categories_Dataset","top_RCDC Categories_Dataset_n","top_HRCS HC Categories_Dataset","top_HRCS HC Categories_Dataset_n","top_HRCS RAC Categories_Dataset","top_HRCS RAC Categories_Dataset_n","top_Health Research Areas_Dataset","top_Health Research Areas_Dataset_n","top_Broad Research Areas_Dataset","top_Broad Research Areas_Dataset_n","top_Cancer Types_Dataset","top_Cancer Types_Dataset_n","top_Sustainable Development Goals_Dataset","top_Sustainable Development Goals_Dataset_n"
"IRCCS_IOV",2000,13,8.76923076923077,1.38461538461538,0.722222222222222,0,0.307692307692308,0,0.0769230769230769,0,2,2,2,6,0.15,0.15,0.15,0.46,34,0.750038975211765,0.384615384615385,1,NA,0.264628828351776,0,0.25,0,"ANITA DE ROSSI;PIERFRANCO CONTÉ;ALFREDO FALCONE;GIACOMO ALLEGRINI;MAURA FLOREANI;JAMES C. MULLOY;PAOLO AROSIO;LINSAY GRAY;CINZIA ORLANDINI;GIOVANNA CUTRONA;ANTONELLO DI PAOLO;S. SIVIERI;M. TIBERIO;CHIARA CASATI;I. FONTANA;ELEONORA NAPOLI;G. BARSANTI;ARCANGELO NOCERA;MONICA LENCIONI;VINCENZO CIMINALE","4;3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ANITA DE ROSSI;PIERFRANCO CONTÉ;ROSARIO RIZZUTO;VALÉRIE ROBERT;VALERIA TOSELLO;PAOLO PINTON;TULLIO POZZAN;ALFREDO FALCONE;GIACOMO ALLEGRINI;JAMES C. MULLOY;S. SIVIERI;M. TIBERIO;VINCENZO CIMINALE;GIOVANNI BIASI;CHRISTOPHE NICOT;ANTONELLA FACCHINETTI;JAKE FULLEN;GENOVEFFA FRANCHINI;L. CIONINI;CARMELO TIBALDI","0.45;0.34;0.2;0.2;0.2;0.2;0.2;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.17","ANITA DE ROSSI;PIERFRANCO CONTÉ;VINCENZO CIMINALE;PAOLA ZANOVELLO;STEFANO INDRACCOLO;GIAN LUCA DE SALVO;VITTORINA ZAGONEL;ANTONELLA FACCHINETTI;VALERIA TOSELLO;ROBERTA BERTORELLE;MARISA ZANCHETTA;ANTONIO ROSATO;ANNAROSA DEL MISTRO","4;3;1;1;1;1;1;1;1;1;1;1;1","ANITA DE ROSSI;PIERFRANCO CONTÉ;VALERIA TOSELLO;VINCENZO CIMINALE;ANTONELLA FACCHINETTI;PAOLA ZANOVELLO;ROBERTA BERTORELLE;ANTONIO ROSATO;ANNAROSA DEL MISTRO;GIAN LUCA DE SALVO;MARISA ZANCHETTA;STEFANO INDRACCOLO;VITTORINA ZAGONEL","0.45;0.34;0.2;0.17;0.17;0.14;0.14;0.14;0.14;0.11;0.11;0.09;0.09","ANITA DE ROSSI;PIERFRANCO CONTÉ;ALFREDO FALCONE;GIACOMO ALLEGRINI;A MELOSI;ANTONELLO DI PAOLO;FEDERICO INNOCENTI;G. BARSANTI;GUIDO BOCCI;M. BATTISTONI;MARIO DEL TACCA;ROMANO DANESI;CESARE ASTORI;ENRICA MORRA;ESTER ORLANDI;F. LUNGHI;I IACONA;LUCA ARCAINI;MARIA ANTONIETTA AVANZINI;MARIO LAZZARINO","137;108;102;102;97;97;97;97;97;97;97;97;64;64;64;64;64;64;64;64","ANITA DE ROSSI;PIERFRANCO CONTÉ;VITTORINA ZAGONEL;GIAN LUCA DE SALVO;MARISA ZANCHETTA;ANNAROSA DEL MISTRO;ROBERTA BERTORELLE;VINCENZO CIMINALE;STEFANO INDRACCOLO;VALERIA TOSELLO;ANTONIO ROSATO;PAOLA ZANOVELLO;ANTONELLA FACCHINETTI","137;108;64;48;48;34;34;32;30;30;25;25;16","ANITA DE ROSSI;PIERFRANCO CONTÉ;ANNAROSA DEL MISTRO;ANTONELLA FACCHINETTI;ANTONIO ROSATO;GIAN LUCA DE SALVO;MARISA ZANCHETTA;PAOLA ZANOVELLO;ROBERTA BERTORELLE;STEFANO INDRACCOLO;VALERIA TOSELLO;VINCENZO CIMINALE;VITTORINA ZAGONEL","4;3;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;CHEMISTRY;ENGINEERING;MATHEMATICS;PSYCHOLOGY;SOCIOLOGY","11;8;2;1;1;1;1","INTERNAL MEDICINE;GENETICS;IMMUNOLOGY;BIOCHEMISTRY;VIROLOGY;ONCOLOGY;PHARMACOLOGY;ENDOCRINOLOGY;PATHOLOGY;SURGERY;BIOTECHNOLOGY;CELL BIOLOGY;DEMOGRAPHY;DERMATOLOGY;DEVELOPMENTAL PSYCHOLOGY;ECOLOGY;ELECTRICAL ENGINEERING;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;MATHEMATICAL ANALYSIS;ORGANIC CHEMISTRY","8;6;6;4;4;3;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1","GENE;HUMAN IMMUNODEFICIENCY VIRUS (HIV);CHEMOTHERAPY;IMMUNE SYSTEM;IN VITRO;LYMPHOMA;METABOLITE;PHARMACOKINETICS;RECEPTOR;TOXICITY;VIRUS;ANEMIA;ANTIBODY;ANTIGEN;AREA UNDER THE CURVE;BASAL CELL;BOLUS (DIGESTION);CALCIUM;CANCER;CARCINOMA;CYTOKINE;DIARRHEA;DISTRIBUTION (MATHEMATICS);DNA;GIRL;HEPATOCELLULAR CARCINOMA;IN VIVO;INTERFERON;LESION;LUNG CANCER;LYMPHATIC SYSTEM;MULTIPLE SCLEROSIS;NAUSEA;ORAL ADMINISTRATION;POPULATION;RADIATION THERAPY;REGIMEN;SEX ORGAN;SPLEEN;STOMATITIS;TRANSFERRIN;TRANSMISSION (TELECOMMUNICATIONS);TRANSPLANTATION;TUMOR NECROSIS FACTOR ALPHA;TYPE (BIOLOGY);VOMITING;VULVA","6;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","GENOTYPE;VIRAL DISEASE;ACTIVE METABOLITE;AEQUORIN;ALLELE;ANTAGONIST;CD20;CD8;CHEMORADIOTHERAPY;CHEMOTHERAPY REGIMEN;CISPLATIN;CLONE (JAVA METHOD);CMAX;CYTOTOXICITY;DOXORUBICIN;EPSTEIN–BARR VIRUS;ERYTHROPOIESIS;FLUOROURACIL;FOLLICULAR LYMPHOMA;GENE REARRANGEMENT;GENETIC DISORDER;GENETIC DIVERSITY;HEAVY CHAIN;IMMUNOASSAY;IMMUNODEFICIENCY;INDUCTION CHEMOTHERAPY;INTERLEUKIN;MAJOR HISTOCOMPATIBILITY COMPLEX;MICROSOME;MONOCLONAL ANTIBODY;MUTATION;PERIPHERAL BLOOD MONONUCLEAR CELL;PHASES OF CLINICAL RESEARCH;RECOMBINANT DNA;RITUXIMAB;SORAFENIB;T CELL;T-CELL LYMPHOMA;VIRAL LOAD","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CD3;CYP3A;GENETIC VARIANTS;HAPLOTYPE;IFOSFAMIDE;INEFFECTIVE ERYTHROPOIESIS;INTRAVENOUS DRUG;LENTIVIRUS;MHC CLASS I;MONOCLONAL;PERIPHERAL T-CELL LYMPHOMA;PROBAND;RECEPTOR ANTAGONIST;T-CELL RECEPTOR;THYMIDYLATE SYNTHASE;VINORELBINE","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;ANTIMETABOLITES, ANTINEOPLASTIC;ANTINEOPLASTIC AGENTS;DOXORUBICIN;HIV-1;MALE;FLUOROURACIL;HIV INFECTIONS;TRANSFERRIN;ADENOCARCINOMA;ANTIBODIES, MONOCLONAL;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;CARCINOMA, NON-SMALL-CELL LUNG;CARCINOMA, SQUAMOUS CELL;COLORECTAL NEOPLASMS;ENZYME-LINKED IMMUNOSORBENT ASSAY;HISTOCOMPATIBILITY ANTIGENS CLASS I;HUMAN T-LYMPHOTROPIC VIRUS 1;HUMAN T-LYMPHOTROPIC VIRUS 2","11;7;6;6;6;6;6;5;5;5;4;4;4;4;4;4;4;4;4;4","HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN LUNG CANCER RESEARCH;BIOLUMINESCENCE IMAGING AND REPORTER SYSTEMS;DRUG METABOLISM AND PHARMACOGENOMICS;HEPATOCELLULAR CARCINOMA;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;HUMAN T-CELL LEUKEMIA VIRUS TYPE 1 INFECTION;INTEGRIN SIGNALING IN INFLAMMATION AND CANCER;REGULATION OF IRON METABOLISM AND ANEMIA;THERAPEUTIC ANTIBODIES: DEVELOPMENT, ENGINEERING, AND APPLICATIONS;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS","2;1;1;1;1;1;1;1;1;1;1;1","HIV;ACTIVE METABOLITE;AEQUORIN;BOLUS (DIGESTION);CHEMORADIOTHERAPY;CHEMOTHERAPY REGIMEN;CLONE (JAVA METHOD);CYP3A;DIHYDROPYRIMIDINE DEHYDROGENASE;ELECTRORETINOGRAPHY;FLUOROURACIL;FOLLICULAR LYMPHOMA;GENE REARRANGEMENT;GENETIC DISORDER;GIRL;HEAVY CHAIN;HEPATOCELLULAR CARCINOMA;HIV EPIDEMIOLOGY;HIV TRANSMISSION;HTLV-1","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HTLV TYPE;II STUDY;PHASE II;VIRUS INFECTION;ACQUIRED HUMAN;ADVANCED HEPATOCELLULAR;ANTAGONIST SOLUBLE;ANTITUMOR ACTIVITY;CALCIUM CONCENTRATION;CANCER PATIENTS;CCR GENOTYPE;CELL LUNG;CHEMORADIATION THERAPY;CLINICAL PHARMACOKINETIC;CO-RECEPTOR USAGE;COMMON TARGET;COMPARATIVE PHARMACOKINETIC;CONGENITAL HYPOTRANSFERRINEMIA;DEFECTS UNDERLYING;DELTA T-CELL;DISTINCT RISK;DOXORUBICIN ROLE;E-SELECTIN SERUM;ENZYME-LINKED IMMUNOASSAY;EPSTEIN-BARR VIRUS;EUROPEAN PATIENTS;FACTOR-ALPHA RECEPTOR;GAMMA DELTA;GENETIC DEFECTS;GENETIC VARIANTS","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","VIRAL LOAD;CCR GENOTYPE;CHEMOKINE RECEPTOR;CO-RECEPTOR USAGE;INFANTS VERSUS;LOG COPIESML;MATERNAL VIRAL;WTDELTA INFANTS;WTDELTA MOTHERS;ANALYSIS CONFIRMED;ASSAY CO-RECEPTOR;CC CHEMOKINE;CCR ALLELES;CCR DELTA;CELLS STABLY;CHAIN REACTION;CHILDREN EXPOSED;CHILDREN TRANSMISSION;CHILDS CCR;CO-RECEPTORSHIV- TRANSMISSION;COPIESML LOGISTIC;CXC CHEMOKINE;CXCR CO-RECEPTORSHIV-;DELIVERY WILD-TYPE;DELTA CCR;DELTA HETEROZYGOSITY;ENTIRE RANGE;EXPRESSING CCR;GENOTYPE VIRAL;HETEROZYGOSITY EXERTS","4;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_IOV",2001,27,7.92592592592593,1.22222222222222,0.818181818181818,0.111111111111111,0.222222222222222,0,0.148148148148148,0,4,2,2,18,0.15,0.07,0.07,0.67,12.63,0.276405301708212,0.185185185185185,0.814814814814815,NA,0.340049841094346,0.166666666666667,0.436363636363636,0,"PIERFRANCO CONTÉ;GUIDO SOTTI;CARMELO BENGALA;CINZIA ORLANDINI;L. RICCARDI;BO JÖNSSON;SVEN‐ERIK STRAND;GIOVANNI SCARZELLO;SARA DONATI;ANNA MIRIAM BENINI;MICHAEL LJUNGBERG;VALENTINA GUARNERI;F. MILANO;GIORGIO SALADINI;SLAVIK TABAKOV;ELISABETTA LANDUCCI;L. MUSÍLEK;ALESSANDRA GENNARI;A. LITCHEV;B. SALVADORI","7;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","PIERFRANCO CONTÉ;GUIDO SOTTI;V. LORUSSO;E. CRUCITTA;GIORGIO SALADINI;DARIO CASARA;GIOVANNI SCARZELLO;CARMELO BENGALA;FILIPPO LONGO;GELSOMINA MANSUETO;UMBERTO BASSO;P. C. MUZZIO;DOMENICO RUBELLO;CINZIA ORLANDINI;SARA DONATI;VALENTINA GUARNERI;ELISABETTA LANDUCCI;ALESSANDRA GENNARI;B. SALVADORI;L. CORTI","0.93;0.6;0.5;0.5;0.48;0.48;0.46;0.44;0.33;0.33;0.33;0.33;0.33;0.29;0.24;0.24;0.24;0.24;0.24;0.23","PIERFRANCO CONTÉ;L. RICCARDI;GIOVANNI SCARZELLO;VALENTINA GUARNERI;GIORGIO SALADINI;L. CORTI;SEVERINO MONTEMURRO;VITTORINA ZAGONEL;GIUSEPPE OPOCHER;ENZO MARIA RUGGERI;SARA LONARDI;SCISCIO;LUIGI PESCARINI;ANTONIO ROSATO;E. CRUCITTA;N TEIXTEIRA;GISELLA GENNARO;GIORGIO BATTAGLIA;MARIA LUISA FRISO;UMBERTO BASSO","7;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","PIERFRANCO CONTÉ;E. CRUCITTA;GIORGIO SALADINI;GIOVANNI SCARZELLO;UMBERTO BASSO;VALENTINA GUARNERI;L. CORTI;SEVERINO MONTEMURRO;ENZO MARIA RUGGERI;SARA LONARDI;SCISCIO;MARIA LUISA FRISO;A. RUCCI;GIUSEPPE OPOCHER;LUIGI PESCARINI;GISELLA GENNARO;GIORGIO BATTAGLIA;SILVIA TOGNAZZO;ANTONIO ROSATO;VITTORINA ZAGONEL","0.93;0.5;0.48;0.46;0.33;0.24;0.23;0.2;0.2;0.2;0.2;0.2;0.2;0.17;0.17;0.17;0.17;0.17;0.14;0.11","PIERFRANCO CONTÉ;ALBERTO BURLINA;ANITA DE ROSSI;ANTONIA DE ROMEO;CARLO GIAQUINTO;EZIA RUGA;MIRIAM STURKENBOOM;OSVALDA RAMPON;R D’ELIA;VANIA GIACOMET;ALFREDO FALCONE;ANTONELLO DI PAOLO;E. PFANNER;GIACOMO ALLEGRINI;GIANLUCA MASI;MARIO DEL TACCA;MONICA LENCIONI;ROMANO DANESI;SILVIA COMIS;L. CORTI","104;55;55;55;55;55;55;55;55;55;54;54;54;54;54;54;54;54;54;40","PIERFRANCO CONTÉ;ANITA DE ROSSI;L. CORTI;ANTONIO ROSATO;GIORGIO SALADINI;GIORGIO BATTAGLIA;A. RUCCI;ENZO MARIA RUGGERI;SCISCIO;SEVERINO MONTEMURRO;SILVIA TOGNAZZO;VALENTINA GUARNERI;GISELLA GENNARO;LUIGI PESCARINI;E. CRUCITTA;GIOVANNI SCARZELLO;GIUSEPPE OPOCHER;L. RICCARDI;MARIA LUISA FRISO;N TEIXTEIRA","96;55;40;31;29;23;15;15;15;15;11;8;4;4;0;0;0;0;0;0","PIERFRANCO CONTÉ;GIORGIO SALADINI;L. CORTI;VALENTINA GUARNERI;A. RUCCI;ANITA DE ROSSI;ANTONIO ROSATO;ENZO MARIA RUGGERI;GIORGIO BATTAGLIA;GISELLA GENNARO;LUIGI PESCARINI;SCISCIO;SEVERINO MONTEMURRO;SILVIA TOGNAZZO;E. CRUCITTA;GIOVANNI SCARZELLO;GIUSEPPE OPOCHER;L. RICCARDI;MARIA LUISA FRISO;N TEIXTEIRA","5;2;2;2;1;1;1;1;1;1;1;1;1;1;0;0;0;0;0;0","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;ENGINEERING;GEOGRAPHY;SOCIOLOGY","25;6;4;3;1;1;1;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;GASTROENTEROLOGY;GENETICS;IMMUNOLOGY;MEDICAL PHYSICS;NUCLEAR PHYSICS;ORGANIC CHEMISTRY;PATHOLOGY;BIOCHEMISTRY;CANCER RESEARCH;ENVIRONMENTAL HEALTH;METEOROLOGY;PHARMACOLOGY;RADIOLOGY;UROLOGY;ANDROLOGY;CARDIOLOGY;DEMOGRAPHY;ENDOCRINOLOGY;ENGINEERING ETHICS;ENGINEERING MANAGEMENT;MEDICAL EDUCATION;MOLECULAR BIOLOGY;NUCLEAR MEDICINE;OPTOMETRY;PALEONTOLOGY;PEDIATRICS;PHOTOCHEMISTRY;VIROLOGY","22;6;5;4;3;3;3;3;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;CHEMOTHERAPY;RADIATION THERAPY;DISEASE;ADVERSE EFFECT;GENE;IMMUNOHISTOCHEMISTRY;PHOTODYNAMIC THERAPY;POPULATION;REGIMEN;TRAINING (METEOROLOGY);ABDOMINAL SURGERY;ADJUVANT;ANASTOMOSIS;ANTIBODY;APOPTOSIS;ASYMPTOMATIC;BACTERIA;BELLA;BONE MARROW;CAMPTOTHECIN;CARCINOMA;COMPLICATION;CREATININE;DEHISCENCE;DIABETES MELLITUS;DIALYSIS;DYSPLASIA;ESOPHAGUS;GLYCOPROTEIN;HELICOBACTER PYLORI;HISTOLOGY;HUMAN IMMUNODEFICIENCY VIRUS (HIV);HYPERPARATHYROIDISM;IRRADIATION;KIDNEY;LACTIC ACIDOSIS;LESION;MEDICAL RADIATION;MEMBRANE;METAPLASIA;OBSERVATIONAL STUDY;OVERALL SURVIVAL;PHARMACOKINETICS;PHOTOSENSITIZER;PLATELET;PRIMARY HYPERPARATHYROIDISM;PROSPECTIVE COHORT STUDY;PROTEIN C;RADIATION;RECTUM;RENAL FUNCTION;SCINTIGRAPHY;STAGE (STRATIGRAPHY);STEM CELL;SUBCLINICAL INFECTION;THERAPEUTIC EFFECT;THROMBOSIS;THYROID;TOXICITY;TRANSPLANTATION;VIRUS","12;6;5;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;COLORECTAL CANCER;PACLITAXEL;CISPLATIN;DOCETAXEL;TOLERABILITY;ADENOCARCINOMA;ANTIPHOSPHOLIPID SYNDROME;AUTOANTIBODY;AUTOIMMUNE DISEASE;CARDIOTOXICITY;CD34;CHILDHOOD CANCER;COLORECTAL SURGERY;COMPLEMENT SYSTEM;DEEP VEIN;DIABETIC NEPHROPATHY;DOXORUBICIN;FACTOR V;FLUOROURACIL;GEMCITABINE;IMMUNOSTAINING;INTESTINAL METAPLASIA;IONIZING RADIATION;LACTIC ACID;MITOCHONDRIAL DNA;MITOCHONDRIAL TOXICITY;MUTATION;NEPHROPATHY;OVARIAN CANCER;PHOSPHOLIPID;PLATELET TRANSFUSION;POLYMERASE CHAIN REACTION;PROGENITOR CELL;RADIOSENSITIZER;RENAL BLOOD FLOW;SYSTEMIC LUPUS ERYTHEMATOSUS;THROMBOPHILIA;TITER;VENOUS THROMBOSIS;VIRAL DISEASE;VIRAL LOAD;VON HIPPEL–LINDAU DISEASE","4;4;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","METASTATIC BREAST CANCER;ANTHRACYCLINE;EPIRUBICIN;TAXANE;ANTIRETROVIRAL THERAPY;CAPECITABINE;CARBOPLATIN;CARDIOLIPIN;EFFECTIVE RENAL PLASMA FLOW;FACTOR V LEIDEN;GENE MUTATION;HYPERTENSIVE NEPHROPATHY;IRINOTECAN;MAMMOGRAPHY;MEGAKARYOCYTE;OXALIPLATIN;RECTAL CARCINOMA;REVERSE TRANSCRIPTASE;TOTAL MESORECTAL EXCISION;ZIDOVUDINE","3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MIDDLE AGED;;MALE;ADULT;AGED;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ESOPHAGEAL NEOPLASMS;PACLITAXEL;ANTINEOPLASTIC AGENTS, PHYTOGENIC;CARCINOMA, SQUAMOUS CELL;ANTI-HIV AGENTS;ANTINEOPLASTIC AGENTS;BREAST NEOPLASMS;CAMPTOTHECIN;ITALY;LAMIVUDINE;OVARIAN NEOPLASMS;ZIDOVUDINE","18;14;10;9;9;8;8;8;8;8;7;6;5;5;5;5;5;5;5;5","CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;EXPANDING ACCESS TO RADIOTHERAPY GLOBALLY;GLIOMAS;PHOTODYNAMIC THERAPY IN ONCOLOGY AND MICROBIOLOGY;CHRONIC KIDNEY DISEASE AND DIALYSIS TREATMENT;COLORECTAL CANCER RESEARCH AND TREATMENT;DIAGNOSIS AND TREATMENT OF RENAL ARTERY STENOSIS;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;EMERGING ANIMAL PATHOGENS AND DISEASES;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;GLOBAL CANCER INCIDENCE AND MORTALITY PATTERNS;HELICOBACTER PYLORI INFECTION AND GASTRIC CANCER;IMPACT OF HIV INFECTION ON CARDIOVASCULAR HEALTH;METABOLIC REPROGRAMMING IN CANCER BIOLOGY;MINERAL METABOLISM IN CHRONIC KIDNEY DISEASE;PEDIATRIC CANCER AND QUALITY OF LIFE;PLATELET DISORDERS AND THROMBOSIS MECHANISMS;SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTIPHOSPHOLIPID SYNDROME;THROMBOSIS AND COAGULATION DISORDERS","4;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","RADIOTHERAPY;EPIRUBICIN;MEDICAL EDUCATION;MEDICAL RADIATION;METASTATIC BREAST CANCER;PHOTODYNAMIC THERAPY;PHOTOTHERMAL THERAPY;REGIMEN;REVERSE-TRANSCRIPTASE INHIBITOR;TAXANE;TOLERABILITY;ABACAVIR;ADOLESCENT AND YOUNG ADULT ONCOLOGY;ANASTOMOTIC LEAKAGE;ANTIPHOSPHOLIPID SYNDROME;ANTIRETROVIRAL THERAPY;AUTOANTIBODIES;BELLA;BRAIN TUMOR EPIDEMIOLOGY;BREAST CANCER","3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","BREAST CANCER;MEDICAL RADIATION;RADIATION PHYSICS;ABACAVIRLAMIVUDINE ZIDOVUDINELAMIVUDINE;ACID LEVELS;ADVANCED BREAST;ADVANCED OVARIAN;ADVANCEDMETASTATIC BREAST;ANASTOMOTIC DEHISCENCE;ANTIPHOSPHOLIPID SYNDROME;ANTIRETROVIRAL AGENTS;ANTIRETROVIRAL PHENOTYPIC;ANTIRETROVIRAL-NAIVE HIV--INFECTED;AUTOLOGOUS PERIPHERAL;AZIENDA OSPEDALIERA;BCL- INVOLVEMENT;BELLA POLYCHEMOTHERAPY;BLOOD PROGENITOR;BRAIN TUMORS;CANCER CLINICAL;CANCER EXPERIENCE;CANCER PATIENTS;CANCER TREATED;CARCINOMA PRELIMINARY;CARDIOLIPIN-BINDING PROTEINS;CD CELL;CELL SUBSETS;CELL SUPPORT;CHEMOTHERAPY-NAIVE METASTATIC;CHILDHOOD INTRACRANIAL","3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","LA LEVELS;FV GA;FII GA;PLASMA LA;GA SUBSTITUTION;HIV- RNA;MITOCHONDRIAL DYSFUNCTION;TUMOR TREATMENT;ANDOR ABC;ANTIRETROVIRAL AGENTS;DETECTABLE HIV-;GA MUTATION;HIV-INFECTED CHILDREN;INHIBITOR-CONTAINING REGIMENS;IONIZING IRRADIATION;LA LEVEL;LACTIC ACID;MOTHER-TO-CHILD TRANSMISSION;MUTATIONS CONFERRING;PERINATAL EXPOSURE;PHENOTYPIC SUSCEPTIBILITY;PHOTOFRIN II;PLASMA LEVELS;PROTEASE INHIBITOR-CONTAINING;RADIATION THERAPY;REDUCED PHENOTYPIC;TCABC ARM;VIRTUAL PHENOTYPE;ZDV-RESISTANT VIRUS;ABACAVIR ABC","8;5;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_IOV",2002,11,8.72727272727273,1.27272727272727,0.785714285714286,0.181818181818182,0.272727272727273,0.0909090909090909,0.0909090909090909,1,4,2,0,5,0.36,0.18,0,0.45,110.82,2.00871437415533,0.0909090909090909,0.818181818181818,NA,0.532586036490183,0.1,0.266666666666667,0,"PIERFRANCO CONTÉ;DIANA M. GIBB;ANITA DE ROSSI;MARCO FORMICHI;A. SARAH WALKER;LUCIO TARGA;DANIELA MOLENA;ANTONELLO DI PAOLO;DAVID DUNN;MP ALBERGONI;CRISTIANO LANZA;SIMONA NEGRI;FLORA GIOIA;GIOVANNI SCARZELLO;PATRIZIA BOCCAGNI;LUCIA FRATINO;ALFREDO FALCONE;STEFANO PARODI;LOREDANA NICOLETTI;S. MONFARDINI","3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","PIERFRANCO CONTÉ;DIANA M. GIBB;ANITA DE ROSSI;A. SARAH WALKER;DAVIDE DE FORNI;SIMONA NEGRI;CLAUDIA CIANCI;ANGIOLO GADDUCCI;ANDREA RICCARDO GENAZZANI;PATRIZIA BOCCAGNI;MARIO ERMANI;FRANCO LUMACHI;S.M.M. BASSO;UMBERTO BASSO;ALBA A. BRANDES;MARCO FORMICHI;LUCIO TARGA;F CORBARA;A. BANZATO;EDOARDO GAGLIONE","1.3;0.34;0.34;0.25;0.25;0.2;0.2;0.2;0.2;0.17;0.17;0.17;0.17;0.17;0.17;0.14;0.14;0.14;0.14;0.14","PIERFRANCO CONTÉ;ANITA DE ROSSI;GIOVANNI SCARZELLO;VANNA CHIARION‐SILENI;VITTORINA ZAGONEL;VALERIA TOSELLO;GIOVANNI ESPOSITO;A. BANZATO;GIORGIO BATTAGLIA;ERICH PIOVAN;UMBERTO BASSO;ALBERTO AMADORI","3;2;1;1;1;1;1;1;1;1;1;1","PIERFRANCO CONTÉ;ANITA DE ROSSI;UMBERTO BASSO;A. BANZATO;VANNA CHIARION‐SILENI;VALERIA TOSELLO;GIOVANNI ESPOSITO;GIORGIO BATTAGLIA;ERICH PIOVAN;ALBERTO AMADORI;VITTORINA ZAGONEL;GIOVANNI SCARZELLO","1.3;0.34;0.17;0.14;0.09;0.09;0.09;0.09;0.09;0.09;0.08;0.06","ANTONELLA VENTURINO;DENISE DAL LAGO;DIEGO SERRAINO;FLORA GIOIA;LAZZARO REPETTO;LUCIA FRATINO;MARINA VERCELLI;MATTI AAPRO;RICCARDO A. AUDISIO;S. MONFARDINI;STEFANO PARODI;VITTORINA ZAGONEL;WALTER GIANNI;PIERFRANCO CONTÉ;ALFREDO FALCONE;ANTONELLO DI PAOLO;E. PFANNER;GIACOMO ALLEGRINI;GIANLUCA MASI;I. BRUNETTI","781;781;781;781;781;781;781;781;781;781;781;781;781;175;156;156;156;156;156;156","VITTORINA ZAGONEL;PIERFRANCO CONTÉ;VANNA CHIARION‐SILENI;ALBERTO AMADORI;ERICH PIOVAN;GIOVANNI ESPOSITO;VALERIA TOSELLO;ANITA DE ROSSI;GIORGIO BATTAGLIA;UMBERTO BASSO;A. BANZATO;GIOVANNI SCARZELLO","781;175;124;60;60;60;60;46;32;26;2;2","PIERFRANCO CONTÉ;ANITA DE ROSSI;A. BANZATO;ALBERTO AMADORI;ERICH PIOVAN;GIORGIO BATTAGLIA;GIOVANNI ESPOSITO;GIOVANNI SCARZELLO;UMBERTO BASSO;VALERIA TOSELLO;VANNA CHIARION‐SILENI;VITTORINA ZAGONEL","3;2;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;MATHEMATICS;PHYSICS","10;5;1;1","INTERNAL MEDICINE;ONCOLOGY;GASTROENTEROLOGY;GENETICS;SURGERY;VIROLOGY;CANCER RESEARCH;ASTROBIOLOGY;BIOCHEMISTRY;CARDIOLOGY;ECOLOGY;ENVIRONMENTAL HEALTH;GERONTOLOGY;GYNECOLOGY;IMMUNOLOGY;MOLECULAR BIOLOGY;PHYSICAL THERAPY;PSYCHIATRY;RADIOLOGY;STATISTICS","10;5;3;3;3;3;2;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;CHEMOTHERAPY;CLINICAL TRIAL;GENE;LOGISTIC REGRESSION;MULTIVARIATE ANALYSIS;REGIMEN;VIRUS;ACTIVITIES OF DAILY LIVING;ANEURYSM;ASYMPTOMATIC;BILE ACID;CELL CULTURE;CLINICAL HISTORY;COMORBIDITY;CONCOMITANT;DISEASE;DRUG RESISTANCE;GERIATRICS;GRADING (ENGINEERING);HUMAN IMMUNODEFICIENCY VIRUS (HIV);IN VITRO;IN VIVO;INTERQUARTILE RANGE;LEUKEMIA;LYMPH NODE;MELANOMA;METAPLASIA;MULTIVARIATE STATISTICS;MYOCARDIAL INFARCTION;PHARMACOKINETICS;POPULATION;POSTERIOR WALL;PRESENTATION (OBSTETRICS);PULMONARY EMBOLISM;RANDOMIZED CONTROLLED TRIAL;REFRACTORY (PLANETARY SCIENCE);SINGLE CENTER;STEM CELL;STOMACH;TOXICITY;TRANSPLANTATION;VENTRICLE","8;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;HEPATITIS B VIRUS;OVARIAN CANCER;VIRAL DISEASE;VIRAL LOAD;ADENOCARCINOMA;CISPLATIN;COLORECTAL CANCER;CYCLOPHOSPHAMIDE;DACARBAZINE;EX VIVO;FLUOROURACIL;GENETIC ENHANCEMENT;GERIATRIC ONCOLOGY;GREEN FLUORESCENT PROTEIN;HAEMATOPOIESIS;HEMATOPOIETIC STEM CELL TRANSPLANTATION;IMMUNOTHERAPY;INTESTINAL METAPLASIA;LYMPHOBLASTIC LEUKEMIA;MULTICENTER STUDY;NEUTROPENIA;PACLITAXEL;PERFORMANCE STATUS;PERIPHERAL BLOOD MONONUCLEAR CELL;PHASES OF CLINICAL RESEARCH;PSEUDOANEURYSM;RECOMBINANT DNA;REFLUX;RNA;SALVAGE THERAPY;TRANSGENE;UNIVARIATE;UNIVARIATE ANALYSIS","2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ANTIRETROVIRAL THERAPY;LAMIVUDINE;SIDA;ZIDOVUDINE;BARRETT'S OESOPHAGUS;BILE REFLUX;CARBOPLATIN;CARMUSTINE;FEBRILE NEUTROPENIA;HEMATOPOIETIC CELL;INTERFERON ALFA;IRINOTECAN;LENTIVIRUS;MULTICENTER TRIAL;OXALIPLATIN;REVERSE TRANSCRIPTASE;SAVIOR SIBLING;VIRAL VECTOR","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;OVARIAN NEOPLASMS;NEOPLASM RECURRENCE, LOCAL;CAMPTOTHECIN;FEMALE;AGED;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;BREAST NEOPLASMS;FLUOROURACIL;HIV-1;LEUCOVORIN;ORGANOPLATINUM COMPOUNDS;PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;;ADULT;ANEURYSM, FALSE;BARRETT ESOPHAGUS;COLORECTAL NEOPLASMS;GASTROESOPHAGEAL REFLUX;GENETIC VECTORS","8;8;7;5;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3","ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH;EPIDEMIOLOGY AND TREATMENT OF CHILDHOOD LEUKEMIA;FRAILTY IN OLDER ADULTS AND GERIATRIC CARE;GENE THERAPY TECHNIQUES AND APPLICATIONS;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;IMMUNOBIOLOGY OF DENDRITIC CELLS;MECHANISMS OF ESTROGEN RECEPTOR SIGNALING;PREOPERATIVE CHEMORADIOTHERAPY FOR ESOPHAGEAL CANCER;SURGICAL VENTRICULAR RECONSTRUCTION IN MYOCARDIAL INFARCTION","1;1;1;1;1;1;1;1;1;1;1","REGIMEN;ABACAVIR;ACUTE LYMPHOBLASTIC LEUKEMIA;AGING;ANTIRETROVIRAL THERAPY;BARRETT'S ESOPHAGUS;BARRETT'S OESOPHAGUS;BIFUNCTIONAL AGENTS;BILE REFLUX;BISPHOSPHONATES;BREAST CANCER;CANCER IMMUNOEDITING;CANCER IMMUNOTHERAPY;CANCER IN OLDER ADULTS;CANCER THERAPY;CANCER TREATMENT;CARBOPLATIN;CARMUSTINE;CLINICAL HISTORY;COMPREHENSIVE GERIATRIC ASSESSMENT","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","OVARIAN CANCER;ACUTE LYMPHOBLASTIC;ADDS INFORMATION;ADVANCED MELANOMA;ANTIRETROVIRAL THERAPY;ASSESSMENT ADDS;BILE REFLUX;BIPHASIC DECAY;BIWEEKLY CHEMOTHERAPY;BREAST CANCER;CANCER CELLS;CANCER PATIENTS;CANCER RECURRENCES;CELL TRANSPLANTATION;CELL-ASSOCIATED HIV-;CENTER EXPERIENCE;CISPLATIN DACARBAZINE;CLINICAL TRIAL;COLORECTAL CANCER;COMPREHENSIVE GERIATRIC;COOPERATIVE ONCOLOGY;DISTAL OESOPHAGUS;EASTERN COOPERATIVE;ELDERLY CANCER;GENE TRANSFER;GERIATRIC ASSESSMENT;GERIATRIC ONCOLOGY;HEMATOPOIETIC STEM;HIV- DNA;HIV--INFECTED CHILDREN","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CD CELLS;HIV- DNA;PLASMA HIV--RNA;HIV--RNA LEVELS;LOG COPIES;CD CELL;HIV- RNA;HIV--DNA LEVEL;HIV--RNA LEVEL;HIV--DNA COPIES;CELL-ASSOCIATED HIV-;HIV--DNA LEVELS;LOG HIV--DNA;PENTA TRIAL;PLASMA HIV-;ANTIRETROVIRAL THERAPY;BASELINE CD;BASELINE HIV--DNA;BASELINE PLASMA;CELLS PBMC;HIV--RNA COPIES;PERIPHERAL BLOOD;ABSOLUTE LOG;BASELINE HIV--RNA;BLOOD MONONUCLEAR;CELL COUNTS;CELL PERCENTAGE;CENTRES PARTICIPATING;CONFIDENCE INTERVAL;DNA DECAY","15;13;9;8;8;7;6;6;6;5;4;4;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2",1,0.09,3,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,27,27,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_IOV",2003,24,8.20833333333333,1.25,0.8,0.0416666666666667,0.291666666666667,0,0.0416666666666667,0,1,2,2,15,0.04,0.08,0.08,0.62,20.62,0.389681044066803,0.333333333333333,0.958333333333333,NA,0.315075664855758,0,0.285714285714286,0,"CARLO RICCARDO ROSSI;FRANCO LUMACHI;M ANZÀ;FRANCO MANTERO;DAVIDE PASTORELLI;CLAUDIO BOTTI;PASQUALE PERRI;CESARE RUFFOLO;DI FILIPPO F;GIUSEPPE OPOCHER;MARIO ERMANI;PIERLUIGI PILATI;SARA LONARDI;R GARINEI;S.M.M. BASSO;MIRTO FOLETTO;FRANCESCO CAVALIERE;IMERIO ANGRIMAN;ALBA A. BRANDES;DI FILIPPO S","4;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","FRANCO MANTERO;GIUSEPPE OPOCHER;CARLO RICCARDO ROSSI;FRANCO LUMACHI;OLIVER BEDENDO;WANDA ACAMPA;ALBERTO CUOCOLO;LAURA EVANGELISTA;MARIO ERMANI;PIERLUIGI PILATI;SARA LONARDI;S.M.M. BASSO;MIRTO FOLETTO;ALBA A. BRANDES;DAVIDE PASTORELLI;CESARE RUFFOLO;IMERIO ANGRIMAN;SEIYA SAITO;ROMANO SCALERTA;F. CORBARA","0.48;0.48;0.47;0.45;0.33;0.33;0.33;0.33;0.31;0.31;0.31;0.31;0.31;0.31;0.28;0.24;0.24;0.17;0.17;0.17","CARLO RICCARDO ROSSI;DAVIDE PASTORELLI;GIUSEPPE OPOCHER;SARA LONARDI;EROS FERRAZZÍ;PAOLA ZANOVELLO;SILVIA DALLA SANTA;STEFANO INDRACCOLO;FABLE ZUSTOVICH;PIERFRANCO CONTÉ;L CAMPANA;VALERIA TOSELLO;MARCO SCARPA;RUGGERO DE MARIA;HARUYUKI ANZAI;ANTONIO SOMMARIVA;ANGELO VERONESE;A. BANZATO;ANNAROSA DEL MISTRO;FERNANDO A. BOZZA","4;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","GIUSEPPE OPOCHER;CARLO RICCARDO ROSSI;LAURA EVANGELISTA;SARA LONARDI;DAVIDE PASTORELLI;HARUYUKI ANZAI;A. BANZATO;EROS FERRAZZÍ;PIERFRANCO CONTÉ;L CAMPANA;STEFANO INDRACCOLO;MARCO SCARPA;FERNANDO A. BOZZA;FABLE ZUSTOVICH;ANTONIO SOMMARIVA;ANNAROSA DEL MISTRO;ANITA DE ROSSI;M D'APRILE;PAOLA ZANOVELLO;SILVIA DALLA SANTA","0.48;0.47;0.33;0.31;0.28;0.17;0.17;0.16;0.14;0.14;0.12;0.12;0.12;0.11;0.11;0.11;0.11;0.11;0.09;0.09","BORIS ENGELS;CHRISTOPHER BAUM;HAKAN ÇAM;MONIKA GLADOW;STEFANO INDRACCOLO;THOMAS BLANKENSTEIN;THOMAS SCHÜLER;WOLFGANG UCKERT;EROS FERRAZZÍ;ADRIANA ERAMO;ANN ZEUNER;C PESCHLE;ELVIRA PELOSI;EMAD S. ALNEMRI;GIANLUIGI CONDORELLI;GIULIANO MARIANI;NADIA FELLI;RUGGERO DE MARIA;SRINIVASA M. SRINIVASULA;UGO TESTA","191;191;191;191;191;191;191;191;54;47;47;47;47;47;47;47;47;47;47;47","STEFANO INDRACCOLO;RUGGERO DE MARIA;CARLO RICCARDO ROSSI;PAOLA ZANOVELLO;SILVIA DALLA SANTA;VALERIA TOSELLO;ANGELO VERONESE;HARUYUKI ANZAI;GIUSEPPE OPOCHER;MARCO SCARPA;BARBARA CASTAGNARI;EROS FERRAZZÍ;M D'APRILE;DAVIDE PASTORELLI;SARA LONARDI;ANTONIO SOMMARIVA;FABLE ZUSTOVICH;PIERFRANCO CONTÉ;L CAMPANA;ANITA DE ROSSI","191;47;41;40;40;40;37;33;20;18;17;17;13;10;10;9;8;7;3;1","CARLO RICCARDO ROSSI;DAVIDE PASTORELLI;GIUSEPPE OPOCHER;SARA LONARDI;ANGELO VERONESE;ANITA DE ROSSI;ANNAROSA DEL MISTRO;ANTONIO SOMMARIVA;BARBARA CASTAGNARI;EROS FERRAZZÍ;FABLE ZUSTOVICH;FERNANDO A. BOZZA;HARUYUKI ANZAI;L CAMPANA;M D'APRILE;MARCO SCARPA;PAOLA ZANOVELLO;PIERFRANCO CONTÉ;RUGGERO DE MARIA;SILVIA DALLA SANTA","4;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;CHEMISTRY;ECONOMICS;HISTORY;MATERIALS SCIENCE;PHILOSOPHY","22;10;3;1;1;1;1","INTERNAL MEDICINE;CANCER RESEARCH;SURGERY;GENETICS;GASTROENTEROLOGY;ENVIRONMENTAL HEALTH;IMMUNOLOGY;ONCOLOGY;PATHOLOGY;BIOCHEMISTRY;MOLECULAR BIOLOGY;NUCLEAR MEDICINE;PALEONTOLOGY;VIROLOGY;CARDIOLOGY;CELL BIOLOGY;ENDOCRINOLOGY;GENERAL SURGERY;GYNECOLOGY;OBSTETRICS;PHARMACOLOGY;RADIOLOGY;UROLOGY","17;8;8;7;5;4;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2","CANCER;CHEMOTHERAPY;PERFUSION;GENE;POPULATION;IMMUNE SYSTEM;TOXICITY;APOPTOSIS;COLITIS;CONFIDENCE INTERVAL;DISEASE;DOSE;HORMONE;HYPERTHERMIA;IN VITRO;MELANOMA;STAGE (STRATIGRAPHY);STEM CELL;TUMOR NECROSIS FACTOR ALPHA;ALBUMIN;ALDOSTERONE;ANASTOMOSIS;ANEMIA;ANTIGEN;BLOOD FLOW;BLOOD PRESSURE;BLUNT;BODY WEIGHT;BONE MARROW;BOWEL RESECTION;CLINICAL TRIAL;COMPLICATION;CONGENITAL ADRENAL HYPERPLASIA;CORD BLOOD;CRYPT;ENZYME;EPITHELIUM;ERECTILE DYSFUNCTION;ERYTHROPOIETIN;FRACTURE (GEOLOGY);GASTROINTESTINAL TRACT;GLUCOCORTICOID;GROUP B;HEAD AND NECK;HEMOGLOBIN;HOMING (BIOLOGY);HUMAN SERUM ALBUMIN;ILEOSTOMY;LAPAROTOMY;LEAKAGE (ECONOMICS);LEUKEMIA;LYMPHOMA;MOBILIZATION;NONSTEROIDAL;NOONAN SYNDROME;ODDS RATIO;PANCREAS;PATHOGENESIS;PERITONITIS;POSITRON EMISSION TOMOGRAPHY;PREGNANCY;PROSTAGLANDIN;PROSTAGLANDIN E2;PUNCHING;RADIATION THERAPY;RANDOMIZED CONTROLLED TRIAL;REGIMEN;RESECTION;RISK FACTOR;SARCOMA;SOFT TISSUE;STROMAL CELL;TECHNETIUM;THALLIUM;URINARY SYSTEM;VIRUS","7;5;5;4;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;COLORECTAL CANCER;CROHN'S DISEASE;CYTOTOXIC T CELL;ENDOCRINE SYSTEM;GENE EXPRESSION;HAEMATOPOIESIS;21-HYDROXYLASE;ADENOCARCINOMA;BLADDER CANCER;CARCINOGENESIS;CD34;CD8;CHEMOKINE;CISPLATIN;CLEAVAGE (GEOLOGY);CORONARY CIRCULATION;CYCLOOXYGENASE;CYSTOSCOPY;DOXORUBICIN;EPITOPE;ERYTHROPOIESIS;ESSENTIAL HYPERTENSION;FERTILITY;GENETIC ENHANCEMENT;HEPATITIS B VIRUS;HYPERALDOSTERONISM;IMMUNOTHERAPY;INFERTILITY;INFLAMMATORY BOWEL DISEASE;LAMINA PROPRIA;LIMB PERFUSION;MELPHALAN;METHYLATION;MULTIPLICITY OF INFECTION;MURINE LEUKEMIA VIRUS;MYOCARDIAL PERFUSION IMAGING;NEUTROPENIA;PANCREATECTOMY;PANCREATIC CANCER;PANCREATIC HEAD;PERFORATION;PRIMARY ALDOSTERONISM;PROGENITOR CELL;PROGRAMMED CELL DEATH;PROGRESSIVE DISEASE;RECOMBINANT DNA;SECONDARY HYPERTENSION;SOFT TISSUE SARCOMA;SULINDAC;T CELL;T-CELL LEUKEMIA;TRANSCRIPTION FACTOR;TRANSFECTION;TRANSGENE;TUMOR MARKER;TUMOR PROGRESSION;ULCERATIVE COLITIS","4;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ADULT T-CELL LEUKEMIA/LYMPHOMA;AZOXYMETHANE;BLADDER TUMOR;BREAST DISEASE;BREAST PAIN;CASPASE;CASPASE 3;CD28;CD40;COLONIC DISEASE;CXCR4;DNA METHYLATION;ENHANCER;EXPRESSION VECTOR;FAMILIAL ADENOMATOUS POLYPOSIS;GASTROINTESTINAL CANCER;GATA1;HEPADNAVIRIDAE;IFOSFAMIDE;MAMMARY TUMOR;MAMMOGRAPHY;METHYLTRANSFERASE;NEOADJUVANT THERAPY;TUMOR ANTIGEN;TUMOR M2-PK;VECTOR (MOLECULAR BIOLOGY);VEDOLIZUMAB;VIRAL VECTOR","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MIDDLE AGED;TUMOR NECROSIS FACTOR-ALPHA;ADULT;AGED;MELANOMA;MALE;ADENOCARCINOMA;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;CHEMOTHERAPY, CANCER, REGIONAL PERFUSION;EXTREMITIES;SARCOMA;BREAST NEOPLASMS;SKIN NEOPLASMS;ANTINEOPLASTIC AGENTS, ALKYLATING;CARCINOMA;COLONIC NEOPLASMS;EXTRAVASATION OF DIAGNOSTIC AND THERAPEUTIC MATERIALS;LUMINESCENT PROTEINS","21;11;11;10;9;9;9;8;7;7;7;7;7;6;6;5;5;5;5;5","GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;CYCLOOXYGENASE-2 INHIBITORS IN INFLAMMATION AND CANCER;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;EPIGENETIC MODIFICATIONS AND THEIR FUNCTIONAL IMPLICATIONS;FOCUSED ULTRASOUND TECHNOLOGY AND APPLICATIONS;GENE THERAPY TECHNIQUES AND APPLICATIONS;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;HUMAN T-CELL LEUKEMIA VIRUS TYPE 1 INFECTION;IMMUNOBIOLOGY OF DENDRITIC CELLS;MANAGEMENT OF PERITONEAL CARCINOMATOSIS FROM DIGESTIVE TRACT;MECHANISMS AND RENOPROTECTIVE STRATEGIES FOR CISPLATIN NEPHROTOXICITY;MELANOMA;MOLECULAR BIOLOGY OF STEROIDOGENESIS AND DISORDERS;NEUROBLASTOMA RESEARCH AND TREATMENT;NON-CONTACT PHYSIOLOGICAL MONITORING TECHNOLOGY;PANCREATIC CANCER RESEARCH AND TREATMENT;POSITRON EMISSION TOMOGRAPHY IMAGING IN ONCOLOGY;PROTEIN TYROSINE PHOSPHATASES IN HUMAN HEALTH AND DISEASE","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;CANCER RISK;CANCER SUSCEPTIBILITY;DOSE;MELANOMA;PANCREATIC NEUROENDOCRINE TUMORS;21-HYDROXYLASE;ABERRANT CRYPT FOCI;ADULT T-CELL LEUKEMIA/LYMPHOMA;ANDROGEN DEFICIENCY;BIOMARKERS FOR IMMUNOTHERAPY;BLADDER CANCER;BLADDER TUMOR;BOWEL RESECTION;BREAST CANCER SCREENING;BREAST DISEASE;BREAST PAIN;CANCER EPIGENETICS;CANCER INCIDENCE;CARDIAC IMAGING","2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","LIMB PERFUSION;BREAST CANCER;ADRENAL TUMOR;ADVANCED LIMB;ANTIBLASTIC PERFUSION;BLADDER TUMORS;BONE MARROW;BOWEL DISEASES;BREAST COMPLAINTS;BREAST EXAMINATION;CANCER RISK;CASPASE-MEDIATED CLEAVAGE;CDSUPSUPCELLS PRIOR;CELL LEUKEMIA;CELL PRODUCTION;CHRONIC COLITIS;CHRONIC TWO-WEEK;CLINICAL BREAST;COLORECTAL TUMORIGENESIS;COMPLAINTS RETROSPECTIVE;COMPLETE RESPONSE;CONTINUOUS INFUSION;CROHNS DISEASES;CT CYSTOSCOPY;CUTANEOUS MELANOMA;CXCR- EXPRESSION;CYTOTOXIC T-LYMPHOCYTE;DEFICIENCY EFFECTS;DISEASES FREE;DOSE FINDING","3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CASPASE ACTIVATION;ACTIVATION GATA-;CASPASE-RESISTANT SCLTAL-;ERYTHROID CELLS;EXPRESSING CASPASE-RESISTANT;GATA- DEGRADATION;IMPAIRED ERYTHROPOIESIS;TRANSCRIPTION FACTOR;ABNORMAL EXPRESSION;ACUTE LYMPHOBLASTIC;BLOOD CELL;CASPASE CASCADE;CASPASE-MEDIATED CLEAVAGE;CASPASE-RESISTANT GATA-;CELL DEVELOPMENT;CELLS EXPRESSING;DEATH RECEPTOR;DEGRADATION OCCURRED;DEVELOPING ERYTHROBLASTS;ERYTHROBLASTS EXPRESSING;ERYTHROBLASTS SCLTAL-;ERYTHROID PROGENITORS;ERYTHROID TRANSCRIPTION;ERYTHROPOIESIS INDUCED;ERYTHROPOIETIN CELLS;FACTOR DEPRIVATION;FACTOR GATA-;FACTOR REQUIRED;GATA- EXPRESSION;GROWTH FACTOR","3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",1,0.04,6,9,0,0,0,0,7,0,0,9,0,0,0,0,2,0,0,0,0,0,0,16,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_IOV",2004,25,9.32,1.36,0.735294117647059,0.08,0.2,0.04,0.2,0,8,5,6,3,0.32,0.2,0.24,0.12,32.16,0.683475676211235,0.32,0.96,NA,0.330976526433499,0.166666666666667,0.228571428571429,0,"CARLO RICCARDO ROSSI;S. MONFARDINI;SIMONE MOCELLIN;ALBA A. BRANDES;MARIO LISE;ROMANO SCALERTA;DONATO NITTI;CESARE RUFFOLO;VANNA CHIARION‐SILENI;MICHELA BAROLLO;MARCO SCARPA;PIERLUIGI PILATI;SARA LONARDI;GIULIANO MARIANI;ANGELO VERONESE;DARIO CASARA;A LIBONI;LINDA NICOLARDI;MASSIMO NEGRINI;EROS FERRAZZÍ","3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ALBA A. BRANDES;SARA LONARDI;CARLO RICCARDO ROSSI;SIMONE MOCELLIN;LINDA NICOLARDI;MARIO LISE;S. MONFARDINI;ALICIA TOSONI;P. BERTOLI;MARCO TARANTELLO;C. VELLER FORNASA;GIULIANO MARIANI;MARIA CRISTINA MONTESCO;DOMENICO RUBELLO;ROMANO SCALERTA;DONATO NITTI;PIERLUIGI PILATI;CESARE RUFFOLO;MICHELA BAROLLO;MARCO SCARPA","0.48;0.45;0.44;0.44;0.39;0.37;0.37;0.34;0.25;0.25;0.25;0.25;0.25;0.25;0.24;0.24;0.24;0.24;0.24;0.24","CARLO RICCARDO ROSSI;VANNA CHIARION‐SILENI;MARCO SCARPA;SARA LONARDI;ANGELO VERONESE;EROS FERRAZZÍ;DOMENICO RUBELLO;VINCENZO CIMINALE;GINO CRIVELLARI;GIAN LUCA DE SALVO;PIERFRANCO CONTÉ;L CAMPANA;GIORGIO SALADINI;RUGGERO DE MARIA;ELISABETTA ROSSI;L. CORTI;MARIA CRISTINA MONTESCO;ADOLFO FAVARETTO;ANTONIO ROSATO;FRANCO BERTI","3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","SARA LONARDI;CARLO RICCARDO ROSSI;MARIA CRISTINA MONTESCO;DOMENICO RUBELLO;MARCO SCARPA;L CAMPANA;L. CORTI;ANGELO VERONESE;EROS FERRAZZÍ;VANNA CHIARION‐SILENI;FRANCO BERTI;ANITA DE ROSSI;GIAN LUCA DE SALVO;GIORGIO SALADINI;FERNANDO A. BOZZA;PIERFRANCO CONTÉ;RUGGERO DE MARIA;UMBERTO BASSO;ALBERTO AMADORI;ELENA MIOTTO","0.45;0.44;0.25;0.25;0.24;0.2;0.2;0.19;0.19;0.18;0.14;0.14;0.12;0.12;0.12;0.1;0.09;0.09;0.09;0.08","ALBA A. BRANDES;A LIBONI;ANGELO VERONESE;EROS FERRAZZÍ;MASSIMO NEGRINI;LINDA NICOLARDI;A. TOSONI;D. GROSSO;FRANCO BERTI;M. ERMANI;PIETRO AMISTÀ;S. MONFARDINI;ALICIA TOSONI;ANDRÉS J.M. FERRERI;FRANCESCA VASTOLA;GIOVANNA CAVALLO;L. SCOPECE;MARIA GRAZIA PANUCCI;MARIO ERMANI;MICHELE RENI","235;138;133;133;133;131;130;130;130;130;130;119;105;104;104;104;104;104;104;104","ANGELO VERONESE;FRANCO BERTI;UMBERTO BASSO;RUGGERO DE MARIA;ELENA MIOTTO;ANTONIO ROSATO;ELISABETTA ROSSI;VINCENZO CIMINALE;ALBERTO AMADORI;SILVIA TOGNAZZO;L. CORTI;EROS FERRAZZÍ;VANNA CHIARION‐SILENI;F MARZULLO;GIOVANNI DE SIMONE;CARLO RICCARDO ROSSI;FERNANDO A. BOZZA;GIAN LUCA DE SALVO;GIORGIO SALADINI;ADOLFO FAVARETTO","133;130;104;99;97;71;71;71;52;41;37;36;31;22;22;19;14;14;14;13","ANGELO VERONESE;CARLO RICCARDO ROSSI;MARCO SCARPA;SARA LONARDI;VANNA CHIARION‐SILENI;ADOLFO FAVARETTO;ALBERTO AMADORI;ANITA DE ROSSI;ANTONIO ROSATO;DOMENICO RUBELLO;ELENA MIOTTO;ELISABETTA ROSSI;EROS FERRAZZÍ;F MARZULLO;FERNANDO A. BOZZA;FRANCO BERTI;GIAN LUCA DE SALVO;GINO CRIVELLARI;GIORGIO SALADINI;GIOVANNI DE SIMONE","2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;ENGINEERING;MATERIALS SCIENCE;MATHEMATICS;PSYCHOLOGY","18;11;5;2;1;1;1;1;1","INTERNAL MEDICINE;SURGERY;CANCER RESEARCH;BIOCHEMISTRY;IMMUNOLOGY;ONCOLOGY;GENETICS;RADIOLOGY;MOLECULAR BIOLOGY;CELL BIOLOGY;GASTROENTEROLOGY;NUCLEAR MEDICINE;PATHOLOGY;VIROLOGY;DERMATOLOGY;OPTICS;PALEONTOLOGY;ACOUSTICS;ANDROLOGY;ASTROBIOLOGY;BIOPHYSICS;ECOLOGY;ELECTRICAL ENGINEERING;ENDOCRINOLOGY;GENERAL SURGERY;GEOMETRY;NUCLEAR PHYSICS;NURSING;OPTOELECTRONICS;ORGANIC CHEMISTRY;PROGRAMMING LANGUAGE;PSYCHOANALYSIS;QUANTUM MECHANICS;STATISTICS;UROLOGY","17;12;8;6;6;6;5;5;4;3;3;3;3;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;CHEMOTHERAPY;GENE;MELANOMA;RADIATION THERAPY;REGIMEN;DISEASE;IN VITRO;TOXICITY;CELL CULTURE;IMMUNE SYSTEM;STAGE (STRATIGRAPHY);ANEMIA;ANTIBODY;APOPTOSIS;ASYMPTOMATIC;BIOPSY;BOLUS (DIGESTION);BONE MARROW;CALCIUM;CELL;CELL GROWTH;CHARGE CARRIER;CLINICAL TRIAL;COHEN'S KAPPA;COMPENSATION (PSYCHOLOGY);CYTOKINE;DETECTOR;ENDOTHELIUM;ENZYME;EXTRACELLULAR MATRIX;FILTER (SIGNAL PROCESSING);HEMODYNAMICS;HUMAN IMMUNODEFICIENCY VIRUS (HIV);HUMAN PAPILLOMAVIRUS;HYPERPARATHYROIDISM;IMMUNOPATHOLOGY;INTERFERON;INTRADERMAL INJECTION;IRRADIATION;KAPPA;LAPAROSCOPY;LASER;LUNG;LUNG CANCER;LYMPH NODE;MATRIX METALLOPROTEINASE;MITOCHONDRION;MODULATION (MUSIC);NITRIC OXIDE;PALLIATIVE CARE;PATIENT SATISFACTION;PERCUTANEOUS;PERFUSION;PHARMACOKINETICS;POLYMER;PRIMARY HYPERPARATHYROIDISM;PROSPECTIVE COHORT STUDY;RECEPTOR;RECTUM;REFRACTORY (PLANETARY SCIENCE);REPRODUCIBILITY;SCINTIGRAPHY;SIGNAL (PROGRAMMING LANGUAGE);SIGNAL TRANSDUCTION;STAINING;STENOSIS;STENT;STOMATITIS;THYROID;TRANSPLANTATION;TUMOR NECROSIS FACTOR ALPHA;TYPE (BIOLOGY);URETER;URINARY SYSTEM;VIRUS;VOLTAGE","8;8;4;4;4;4;3;3;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;TEMOZOLOMIDE;CARCINOGENESIS;CHEMOTHERAPY REGIMEN;CISPLATIN;CYCLOPHOSPHAMIDE;PHASES OF CLINICAL RESEARCH;PROGRESSION-FREE SURVIVAL;PROGRESSIVE DISEASE;ALPHA INTERFERON;B CELL;CERVICAL CANCER;CHARGE SHARING;CLINICAL ENDPOINT;COLLAGENASE;COLORECTAL CANCER;CONSTRUCT VALIDITY;COPOLYMER;CROHN'S DISEASE;CYTOTOXICITY;DACARBAZINE;ENDOTHELIAL STEM CELL;EXON;FIBROBLAST;FLUOROURACIL;GELATINASE;GENE EXPRESSION;GENE SILENCING;GENOME;HYDRONEPHROSIS;INTERNALIZATION;LASER THERAPY;LIMB PERFUSION;LIPID RAFT;MELPHALAN;METASTASIS;METASTATIC MELANOMA;METHYLATION;MYELODYSPLASTIC SYNDROMES;NEPHROSTOMY;NEUTROPENIA;NITRIC OXIDE SYNTHASE;NITROSOUREA;PARATHYROID ADENOMA;PARATHYROID HORMONE;PARTICLE DETECTOR;PERCUTANEOUS NEPHROSTOMY;PHENOTYPE;SEMICONDUCTOR DETECTOR;T CELL;TECHNETIUM (99MTC) SESTAMIBI;TECHNETIUM TC 99M SESTAMIBI;THYROID DISEASE;TRANSCRIPTION FACTOR;TRANSFECTION;TRYPAN BLUE;VIRAL DISEASE;VIRAL LOAD","5;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","SENTINEL LYMPH NODE;SENTINEL NODE;TUMOR SUPPRESSOR GENE;ALPHA (FINANCE);ANTIRETROVIRAL THERAPY;AXILLA;CARMUSTINE;CERVICAL INTRAEPITHELIAL NEOPLASIA;CREB;DNA METHYLATION;ENOS;EPIRUBICIN;FEBRILE NEUTROPENIA;JURKAT CELLS;LENTIVIRUS;LOW LEVEL LASER THERAPY;MICROBIAL COLLAGENASE;PARATHYROID NEOPLASM;PARATHYROIDECTOMY;PRIMARY TUMOR;PROMOTER;RAFT;REFRACTORY ANEMIA;VINCRISTINE;VIRAL EVOLUTION","3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MELANOMA;FEMALE;MIDDLE AGED;AGED;DACARBAZINE;MALE;ADULT;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;SKIN NEOPLASMS;TREATMENT OUTCOME;BRAIN NEOPLASMS;BREAST NEOPLASMS;GLIOBLASTOMA;NEOPLASM RECURRENCE, LOCAL;T-LYMPHOCYTES;CELL CYCLE;CISPLATIN;FOLLOW-UP STUDIES;HIV INFECTIONS","21;13;10;10;8;8;8;7;7;6;6;5;5;5;5;5;4;4;4;4","GLIOMAS;BLOOD RHEOLOGY AND COAGULATION MECHANISMS;EPIDEMIOLOGY AND PATHOBIOLOGY OF MONKEYPOX VIRUS INFECTION;EPIGENETIC MODIFICATIONS AND THEIR FUNCTIONAL IMPLICATIONS;GASTRIC CANCER RESEARCH AND TREATMENT;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;HER2 SIGNALING IN BREAST CANCER TREATMENT;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;HUMAN T-CELL LEUKEMIA VIRUS TYPE 1 INFECTION;IMMUNOTOXIN THERAPY FOR CANCER TREATMENT;INFRARED DETECTOR TECHNOLOGIES;LIPID RAFTS AND MEMBRANE DYNAMICS;LOW-LEVEL LASER THERAPY IN BIOMEDICAL APPLICATIONS;LYMPHOID NEOPLASMS;MAMMALIAN MAP KINASE SIGNALING PATHWAYS;MANAGEMENT OF BRAIN METASTASES IN CANCER PATIENTS;MELANOMA;MINERAL METABOLISM IN CHRONIC KIDNEY DISEASE;MOLECULAR RESEARCH ON BREAST CANCER;PROVISION AND ASSESSMENT OF NUTRITION SUPPORT THERAPY","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","REGIMEN;TEMOZOLOMIDE;CHEMOTHERAPY REGIMEN;GAMMA PROBE;GLIOBLASTOMA;MELANOMA;PROGRESSION-FREE SURVIVAL;ALPHA (FINANCE);ALTERNATIVE SPLICING;ANTIRETROVIRAL THERAPY;AXILLA;B-CELL RECEPTOR SIGNALING;BLOOD-BRAIN BARRIER;BOLUS (DIGESTION);BRAIN METASTASES;BREAST CANCER;CANCER CELL METABOLISM;CARMUSTINE;CDZNTE;CELL DEATH","4;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;II STUDY;PHASE II;RECURRENT GLIOBLASTOMA;SENTINEL NODE;ABERRANT METHYLATION;ADULT REFRACTORY;ADVANCED-STAGE HODGKINS;AFFECTING SENTINEL;ANTIBLASTIC STOP-FLOW;ANTIRETROVIRAL THERAPIES;BOWEL CROSS;BRAIN METASTASES;CD DEATHINDUCING;CDZNTE SIGNALS;CELL GROWTH;CELL LEUKEMIA;CELL MALIGNANCIES;CELL PROLIFERATION;CELLS IRRADIATEDIIN;CHIMERIC TRANSCRIPTS;CLINICAL OUTCOME;CLINICAL VARIABLES;COMMON MANAGEMENT;COMPLEX FORMATION;CONSOLIDATIVE RADIOTHERAPY;COOPERATIVO DI;CROHNS DISEASE;CROSS TRANSPLANTATION;CRYPTIC INSERTION","3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CELL LINES;MEDIAN KW;MEMBRANE STAINING;CDH METHYLATION;IL-RΒ GENE;INTEROBSERVER REPRODUCIBILITY;KW RANGE;HUMAN CANCER;TUMOR SUPPRESSOR;CDH GENE;CELL GROWTH;CELL SUBSETS;CELLS MEDIAN;CHEMOTHERAPY-NAIVE PATIENTS;CLASSIFICATION CRITERIA;CPG ISLAND;GENE EXPRESSION;HER-NEU EXPRESSION;II CELL;IMMUNOSTAINED CELLS;INTERMEDIATE CATEGORIES;PERIPHERAL BLOOD;PROMOTER METHYLATION;REDUCED PROLIFERATION;REFERENCE VALUES;SATISFACTORY LEVEL;STAINING MEDIAN;ABSTRACT GENE;ACCEPTABLE TOXICITY;ACCESSORY PROTEIN","7;6;5;4;4;4;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1",3,0.12,5,3,0,0,0,0,1.75,1,0,6.5,0,0,0,0,2,0,0,0,0,0,0.5,38.5,38.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_IOV",2005,31,13.9032258064516,3.03225806451613,0.329787234042553,0.354838709677419,0.290322580645161,0.0967741935483871,0.354838709677419,1,15,5,4,5,0.48,0.16,0.13,0.16,47.74,0.90174864359761,0.32258064516129,0.903225806451613,NA,0.413402479006444,0.261904761904762,0.215909090909091,0.333333333333333,"DIANA M. GIBB;S. MONFARDINI;NIGEL KLEIN;LIVIO TRENTIN;J DARBYSHIRE;J-P ABOULKER;GIANPIETRO SEMENZATO;ANITA DE ROSSI;ABDEL BABIKER;MARIANNE DEBRÉ;MARTA MIORIN;PAOLA ZANOVELLO;CARLO AGOSTINI;LUIGI CHIECO‐BIANCHI;STEFANO INDRACCOLO;GIAN LUCA DE SALVO;VALERIA TOSELLO;OTELLO NIBALE;MONICA FACCO;CARLO GIAQUINTO","6;5;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","S. MONFARDINI;SIMONE MOCELLIN;ANTONIO JIRILLO;L CAMPANA;CRISTINA FALCI;PAOLA ZANOVELLO;LIVIO TRENTIN;GIANPIETRO SEMENZATO;SUSANNA MANDRUZZATO;VINCENZO BRONTE;GIUSEPPE OPOCHER;STEFANO INDRACCOLO;VALERIA TOSELLO;ALBERTO AMADORI;ALBERTO STAFFIERI;GINO MARIONI;MATTEO LODO;ANNA MARIA ZANGAGLIA;G. CARTEI;MARTA MIORIN","1.37;0.75;0.6;0.5;0.5;0.38;0.32;0.32;0.25;0.25;0.23;0.22;0.22;0.22;0.2;0.2;0.2;0.2;0.2;0.19","S. MONFARDINI;LIVIO TRENTIN;GIANPIETRO SEMENZATO;ANITA DE ROSSI;MARTA MIORIN;PAOLA ZANOVELLO;CARLO AGOSTINI;STEFANO INDRACCOLO;GIAN LUCA DE SALVO;VALERIA TOSELLO;MONICA FACCO;GIUSEPPE OPOCHER;RENATO ZAMBELLO;SIMONE MOCELLIN;ANTONIO JIRILLO;UMBERTO BASSO;GUIDO SOTTI;ALBERTO AMADORI;DOMENICO RUBELLO;ERMANNO ANCONA","5;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","S. MONFARDINI;SIMONE MOCELLIN;ANTONIO JIRILLO;L CAMPANA;CRISTINA FALCI;PAOLA ZANOVELLO;LIVIO TRENTIN;GIANPIETRO SEMENZATO;SUSANNA MANDRUZZATO;VINCENZO BRONTE;GIUSEPPE OPOCHER;STEFANO INDRACCOLO;VALERIA TOSELLO;ALBERTO AMADORI;G. CARTEI;MARTA MIORIN;CARLO AGOSTINI;MONICA FACCO;RENATO ZAMBELLO;UMBERTO BASSO","1.37;0.75;0.6;0.5;0.5;0.38;0.32;0.32;0.25;0.25;0.23;0.22;0.22;0.22;0.2;0.19;0.19;0.19;0.19;0.18","GUIDO SOTTI;ADRIAN MATTKE;ANDREA FERRARI;E. KOSCIELNIAK;GIANNI BISOGNO;GIOVANNI CECCHETTO;ILARIA ZANETTI;J. TREUNER;LUIGI DE SIO;MICHELA CASANOVA;MODESTO CARLI;RITA ALAGGIO;S. MONFARDINI;M. LISE;FRANCESCA SENIC-MATUGLIA;MICHAEL E. HODSDON;PIER PAOLO DI FIORE;PIETRO DE CAMILLI;SIMONA POLO;YUXIN MAO","474;333;333;333;333;333;333;333;333;333;333;333;304;200;157;157;157;157;157;157","ADRIAN MATTKE;ANDREA FERRARI;E. KOSCIELNIAK;GIANNI BISOGNO;GIOVANNI CECCHETTO;GUIDO SOTTI;ILARIA ZANETTI;J. TREUNER;LUIGI DE SIO;MICHELA CASANOVA;MODESTO CARLI;RITA ALAGGIO;PIER PAOLO DI FIORE;SIMONA POLO;MARIA LUISA FRISO;GIUSEPPE OPOCHER;ANITA DE ROSSI;DOMENICO RUBELLO;UMBERTO BASSO;GIAN LUCA DE SALVO","333;333;333;333;333;333;333;333;333;333;333;333;157;157;141;108;104;101;95;93","ANITA DE ROSSI;CARLO AGOSTINI;DOMENICO RUBELLO;ERMANNO ANCONA;GIAN LUCA DE SALVO;GIANPIETRO SEMENZATO;GIUSEPPE OPOCHER;LIVIO TRENTIN;MONICA FACCO;PAOLA ZANOVELLO;RENATO ZAMBELLO;STEFANO INDRACCOLO;UMBERTO BASSO;ADRIAN MATTKE;AGOSTINO TAFURI;ALBERTO AMADORI;ALBERTO RUOL;ANDREA FERRARI;ANN ZEUNER;ANTONIO ROSATO","3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;MATHEMATICS","26;15;2;1;1","INTERNAL MEDICINE;CANCER RESEARCH;IMMUNOLOGY;GENETICS;SURGERY;ONCOLOGY;PATHOLOGY;GASTROENTEROLOGY;BIOCHEMISTRY;CELL BIOLOGY;RADIOLOGY;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;GENERAL SURGERY;MEDICAL PHYSICS;PALEONTOLOGY;ANATOMY;AUDIOLOGY;BIOTECHNOLOGY;GERONTOLOGY;INTENSIVE CARE MEDICINE;MICROBIOLOGY;MOLECULAR BIOLOGY;NUCLEAR MEDICINE;PHARMACOLOGY;STATISTICS;UROLOGY;VIROLOGY;WORLD WIDE WEB","22;9;9;8;8;6;6;5;4;4;4;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;CHEMOTHERAPY;GENE;ADVERSE EFFECT;BIOPSY;IMMUNE SYSTEM;IN VITRO;RECEPTOR;ALTERNATIVE MEDICINE;ANTIGEN;CELL CULTURE;CLINICAL TRIAL;CYTOKINE;HUMAN IMMUNODEFICIENCY VIRUS (HIV);POLYCYTHEMIA VERA;POPULATION;RADIATION THERAPY;REGIMEN;SARCOMA;STAGE (STRATIGRAPHY)","17;8;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","BREAST CANCER;FLUOROURACIL;CELL CYCLE;COLORECTAL CANCER;CYCLOPHOSPHAMIDE;DOXORUBICIN;IMMUNOTHERAPY;MUTATION;NEUTROPENIA;OVARIAN CANCER;PERIPHERAL BLOOD MONONUCLEAR CELL;TRANSFECTION;VIRAL LOAD;ACTIVE METABOLITE;ADRENAL ADENOMA;B CELL;BIOTRANSFORMATION;BONE DENSITY;BONE MINERAL;BREAKPOINT CLUSTER REGION;CALCITRIOL RECEPTOR;CANCER CELL;CANCER THERAPY;CD8;CHRONIC LYMPHOCYTIC LEUKEMIA;CISPLATIN;COMPLEMENTARY THERAPY;CYTOCHROME P450;CYTOTOXICITY;DENDRITIC CELL;DOCETAXEL;ENDOCRINE SYSTEM;ERYTHROPOIESIS;ERYTHROPOIETIN RECEPTOR;FLUORODEOXYGLUCOSE;GENETIC ENHANCEMENT;GENOTYPE;GERIATRIC ONCOLOGY;GROWTH FACTOR;HAEMATOPOIESIS;HAZARD RATIO;HUMAN HERPESVIRUS;HUMAN LEUKOCYTE ANTIGEN;IMMUNE ESCAPE;IMMUNE SURVEILLANCE;IMMUNITY;INTERLEUKIN;KETOCONAZOLE;KIDNEY TRANSPLANTATION;MALIGNANT PERIPHERAL NERVE SHEATH TUMOR;METASTASIS;MICROSOME;MUTANT;OCCULT;PANCREATIC CANCER;PARATHYROID HORMONE;PEPTIDE SEQUENCE;PET-CT;PHASES OF CLINICAL RESEARCH;PITUITARY ADENOMA;POLYCYTHEMIA RUBRA VERA;PROGRAMMED CELL DEATH;RECOMBINANT DNA;RELAXATION THERAPY;RHABDOMYOSARCOMA;SENSORINEURAL HEARING LOSS;SOFT TISSUE SARCOMA;SPINOCEREBELLAR ATAXIA;TOLERABILITY;UBIQUITIN;ULCERATIVE COLITIS;UNIVARIATE ANALYSIS;VIRAL DISEASE;VIRAL REPLICATION","8;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ANTHRACYCLINE;ANTIRETROVIRAL THERAPY;SENTINEL LYMPH NODE;TRASTUZUMAB;AXILLA;AXILLARY LYMPH NODES;B-CELL RECEPTOR;BREAST CARCINOMA;CANCER IMMUNOTHERAPY;CD3;CYP3A;CYP3A4;DEUBIQUITINATING ENZYME;ERYTHROBLAST;FAS RECEPTOR;FEBRILE NEUTROPENIA;GOSERELIN;HAPLOTYPE;HER2/NEU;HUNTINGTIN;KAPOSI'S SARCOMA;LENTIVIRUS;METASTATIC BREAST CANCER;MOLECULAR MEDICINE;ONCOGENE;OVARIAN TUMOR;OXALIPLATIN;PRIMARY TUMOR;SECONDARY HYPERPARATHYROIDISM;SENTINEL NODE;TAMOXIFEN;TAXANE;TOXIC MEGACOLON;TUMOR IMMUNOLOGY;VINORELBINE;VIRAL VECTOR","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;MIDDLE AGED;ADULT;AGED;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;BREAST NEOPLASMS;AGED, 80 AND OVER;ANTINEOPLASTIC AGENTS;DOXORUBICIN;HIV-1;T-LYMPHOCYTES;VINBLASTINE;;FLUOROURACIL;HIV INFECTIONS;INTERFERON-ALPHA;NERVE SHEATH NEOPLASMS;ADOLESCENT","26;19;14;13;12;11;11;11;7;7;6;6;6;6;5;5;5;5;5;4","MOLECULAR RESEARCH ON BREAST CANCER;NATURAL KILLER CELLS IN IMMUNITY;COLORECTAL CANCER RESEARCH AND TREATMENT;HER2 SIGNALING IN BREAST CANCER TREATMENT;ACUTE MYELOID LEUKEMIA;CANCER IMMUNOTHERAPY;CANCER OF UNKNOWN PRIMARY SITE;DIAGNOSIS AND MANAGEMENT OF GASTROESOPHAGEAL REFLUX DISEASE;DNA TOPOISOMERASES: STRUCTURE, FUNCTION, AND INHIBITION;EXPANDING ACCESS TO RADIOTHERAPY GLOBALLY;GENE THERAPY TECHNIQUES AND APPLICATIONS;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;HERBAL MEDICINE USE AND SAFETY MONITORING;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;LYMPHOID NEOPLASMS;MANAGEMENT OF BRAIN METASTASES IN CANCER PATIENTS;MANAGEMENT OF PRIMARY ALDOSTERONISM;MELANOMA;MINERAL METABOLISM IN CHRONIC KIDNEY DISEASE","3;3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;CANCER IMMUNOTHERAPY;CANCER THERAPY;KAPOSI'S SARCOMA;METASTATIC BREAST CANCER;REGIMEN;TRASTUZUMAB;ACTIVE METABOLITE;ADRENAL ADENOMA;ADRENAL INCIDENTALOMA;ADRENAL VEIN SAMPLING;ALTERNATIVE MEDICINE;ANTIRETROVIRAL THERAPY;AXILLA;AXILLARY LYMPH NODES;B CELL ABNORMALITIES;B-CELL RECEPTOR SIGNALING;BARRETT'S ESOPHAGUS;BIOTRANSFORMATION;BRCA1","5;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;ADJUVANT TREATMENT;ANTIRETROVIRAL THERAPY;CANCER CELLS;ELDERLY PATIENTS;GRANULAR LYMPHOCYTES;HUMAN BREAST;LYMPHOCYTES LDGL;LYMPHOPROLIFERATIVE DISEASE;ACTIVE ANTIRETROVIRAL;ADJUVANT CHEMOTHERAPY;ADRENAL ADENOMA;ADVANCED RECTAL;AIDS-RELATED KAPOSIS;ALTERNATIVE ORAL;ANGIOGENESIS INHIBITION;ANTIREFLUX SURGERY;ANTITUMOR ACTIVITY;ATAXIN- INSIGHTS;AXILLARY DISSECTION;AXILLARY RECURRENCE;BARRETTS EPITHELIUM;BCELL CHRONIC;BCELL RECEPTOR;BCLL CELLS;BCLLDERIVED CELL;BILATERAL SENSORINEURAL;BONE DENSITY;BRCA-MUTATED HCC;CANCER ADMINISTERED","7;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HIV- DNA;ELDERLY PATIENTS;PANCREATIC CANCER;ADJUVANT CHEMOTHERAPY;CELL LINES;MATRIGEL INVASION;BCLL CELLS;CD- GLS;EXTRACELLULAR MATRIX;HIV- RNA;HR CI;PHASE II;PV ERYTHROBLASTS;ADDING GT;ANALYSIS IDENTIFIED;BCR COMPONENTS;BM BIOPSIES;CANCER CELL;CANCER CELLS;CD GLS;CDB EXPRESSION;CELL LINE;CMF --;CONTROL CELLS;DISEASE-FREE SURVIVAL;DNA DECLINE;DOSE-LIMITING TOXICITIES;ERYTHROID CELLS;FRAIL ELDERLY;FRAIL PATIENTS","9;6;5;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2",3,0.1,3,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,78,78,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_IOV",2006,106,9.36792452830189,2.97169811320755,0.336507936507937,0.405660377358491,0.452830188679245,0.113207547169811,0.367924528301887,2,72,9,10,10,0.68,0.08,0.09,0.09,71.86,1.40683266960036,0.216981132075472,0.89622641509434,NA,0.484570492923623,0.451155115511551,0.410144927536232,0.380630630630631,"DOMENICO RUBELLO;GIAN LUCA DE SALVO;LARA MARIA PASETTO;S. MONFARDINI;ANDREA PIOTTO;MARIA ROSA PELIZZO;MASSIMO RUGGE;DONATO NITTI;ANTONIO TONIATO;LUIGI CHIECO‐BIANCHI;ALBERTO RUOL;LUCIA RAMPIN;ANTONIO ROSATO;UMBERTO BASSO;ERMANNO ANCONA;PAOLA ZANOVELLO;SALVATORE PUCCIARELLI;VANNA CHIARION‐SILENI;GIULIANO MARIANI;CRISTINA NANNI","16;9;8;8;8;8;7;7;6;6;6;6;6;6;6;5;5;5;5;5","DOMENICO RUBELLO;ALBA A. BRANDES;MARIA ROSA PELIZZO;S. MONFARDINI;ANDREA PIOTTO;PASETTO LM;LARA MARIA PASETTO;PAOLA DEL BIANCO;GIAN LUCA DE SALVO;ERMANNO ANCONA;ALBERTO RUOL;MASSIMO RUGGE;LUCIA RAMPIN;SABRINA RAMPADO;ANTONIO TONIATO;UMBERTO BASSO;ANTONIO ROSATO;LUIGI CHIECO‐BIANCHI;DONATO NITTI;G. CARTEI","2.52;1.36;1.33;1.13;1.12;1;0.99;0.95;0.93;0.93;0.88;0.79;0.71;0.71;0.7;0.68;0.66;0.66;0.65;0.61","DOMENICO RUBELLO;GIAN LUCA DE SALVO;LARA MARIA PASETTO;S. MONFARDINI;ANDREA PIOTTO;MASSIMO RUGGE;DONATO NITTI;ANTONIO TONIATO;LUIGI CHIECO‐BIANCHI;ALBERTO RUOL;LUCIA RAMPIN;ANTONIO ROSATO;UMBERTO BASSO;ERMANNO ANCONA;PAOLA ZANOVELLO;SALVATORE PUCCIARELLI;VANNA CHIARION‐SILENI;PAOLA DEL BIANCO;ALBA A. BRANDES;G. CARTEI","16;9;8;8;8;7;7;6;6;6;6;6;6;6;5;5;5;5;5;5","DOMENICO RUBELLO;ALBA A. BRANDES;S. MONFARDINI;ANDREA PIOTTO;PASETTO LM;LARA MARIA PASETTO;PAOLA DEL BIANCO;GIAN LUCA DE SALVO;ERMANNO ANCONA;ALBERTO RUOL;MASSIMO RUGGE;LUCIA RAMPIN;ANTONIO TONIATO;UMBERTO BASSO;ANTONIO ROSATO;LUIGI CHIECO‐BIANCHI;DONATO NITTI;G. CARTEI;MARIAROSA PELIZZO;PIERFRANCO CONTÉ","2.52;1.36;1.13;1.12;1;0.99;0.95;0.93;0.93;0.88;0.79;0.71;0.7;0.68;0.66;0.66;0.65;0.61;0.58;0.57","IVAN BORRELLO;LUIGI DOLCETTI;PAOLO SERAFINI;VINCENZO BRONTE;ALBA A. BRANDES;PAOLA ZANOVELLO;SILVIO BICCIATO;MARTIN J. VAN DEN BENT;MARTIN TAPHOORN;MATHILDE C.M. KOUWENHOVEN;CARMELA DE SANTO;FRANK BROMBACHER;GIOVANNA GALLINA;GIUSEPPE BASSO;ILARIA MARIGO;MARIO P. COLOMBO;ALAIN CARPENTIER;ANOUK ALLGEIER;CEES C. TIJSSEN;CHARLES J. VECHT","1508;1508;1508;1508;1341;1073;901;849;849;849;791;791;791;791;791;791;733;733;733;733","LUIGI DOLCETTI;VINCENZO BRONTE;ALBA A. BRANDES;CARMELA DE SANTO;GIOVANNA GALLINA;ILARIA MARIGO;MARC FRÉNAY;THIERRY GORLIA;DOMENICO RUBELLO;ROBERTA BERTORELLE;MASSIMO RUGGE;V. BLATT;DARIO MARINO;LARA MARIA PASETTO;LUCIA RAMPIN;GIAN LUCA DE SALVO;MANUEL ZORZI;ANGELA BUONADONNA;ANTONIO RUSSO;D. ERRANTE","1508;1508;1114;791;791;791;733;733;581;562;540;416;396;393;388;367;343;328;328;328","DOMENICO RUBELLO;GIAN LUCA DE SALVO;LARA MARIA PASETTO;MASSIMO RUGGE;S. MONFARDINI;UMBERTO BASSO;LUCIA RAMPIN;ERMANNO ANCONA;G. CARTEI;PAOLA DEL BIANCO;ANTONIO ROSATO;PIERFRANCO CONTÉ;ROBERTA BERTORELLE;SERGIO PEDRAZZOLI;ALBA A. BRANDES;ANTONELLA BRUNELLO;VANNA CHIARION‐SILENI;ADOLFO FAVARETTO;ALBERTO AMADORI;CRISTINA FALCI","16;9;7;7;7;6;6;5;5;5;5;4;4;4;4;4;4;3;3;3","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;ENGINEERING;COMPUTER SCIENCE;SOCIOLOGY;MATERIALS SCIENCE;MATHEMATICS;PSYCHOLOGY","95;44;9;7;4;2;2;1;1;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;CANCER RESEARCH;PATHOLOGY;GENETICS;RADIOLOGY;GASTROENTEROLOGY;BIOCHEMISTRY;IMMUNOLOGY;NUCLEAR MEDICINE;PALEONTOLOGY;PHARMACOLOGY;ENVIRONMENTAL HEALTH;VIROLOGY;CELL BIOLOGY;GENERAL SURGERY;GYNECOLOGY;MOLECULAR BIOLOGY;OPTICS","81;36;32;22;21;18;18;16;14;13;13;13;7;5;5;4;4;4;4;4","CANCER;CHEMOTHERAPY;GENE;STAGE (STRATIGRAPHY);IN VITRO;LYMPH NODE;THYROID;RANDOMIZED CONTROLLED TRIAL;BIOPSY;DISEASE;ESOPHAGUS;RADIATION THERAPY;REGIMEN;TOXICITY;CARCINOMA;CONFIDENCE INTERVAL;IMMUNE SYSTEM;MULTIVARIATE ANALYSIS;SCINTIGRAPHY;ADVERSE EFFECT;CALCIUM;CYTOKINE;DISSECTION (MEDICAL);GLIOMA;IN VIVO;LUNG CANCER;LYMPH;MELANOMA;POPULATION","57;23;15;11;9;9;8;7;6;6;6;6;6;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4","BREAST CANCER;COLORECTAL CANCER;ADENOCARCINOMA;ESOPHAGEAL CANCER;GEMCITABINE;THYROID CANCER;METASTASIS;TEMOZOLOMIDE;THYROID CARCINOMA;ASTROCYTOMA;CYCLOPHOSPHAMIDE;CYTOTOXIC T CELL;GENOTYPE;NEUTROPENIA;OVARIAN CANCER;PARATHYROID HORMONE;CD8;CERVICAL CANCER;CHEMORADIOTHERAPY;DACARBAZINE;FLUOROURACIL;GENE EXPRESSION;GERIATRIC ONCOLOGY;MUTATION;PARATHYROID ADENOMA;PERFORMANCE STATUS;PHASES OF CLINICAL RESEARCH;TECHNETIUM TC 99M SESTAMIBI;THYROIDECTOMY;TOLERABILITY;UNIVARIATE ANALYSIS;VIRAL LOAD","18;13;7;6;6;6;5;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","SENTINEL LYMPH NODE;OXALIPLATIN;SINGLE-NUCLEOTIDE POLYMORPHISM;VINCRISTINE;ESOPHAGECTOMY;METASTATIC BREAST CANCER;NEOADJUVANT THERAPY;OLIGODENDROGLIOMA;PAPILLARY THYROID CANCER;PARATHYROIDECTOMY;SENTINEL NODE;ANTIRETROVIRAL THERAPY;D-LOOP;GERMLINE MUTATION;IRINOTECAN;MICROMETASTASIS;AMSACRINE;ANAPLASTIC ASTROCYTOMA;ANTHRACYCLINE;APHIDICOLIN;ARGINASE;ASCUS (BRYOZOA);ATROPHIC GASTRITIS;BARRETT'S ESOPHAGUS;BARRETT'S OESOPHAGUS;CD3;CERVICAL INTRAEPITHELIAL NEOPLASIA;CERVICAL LYMPH NODES;CERVICAL SCREENING;CETUXIMAB;COLPOSCOPY;COMPUTED RADIOGRAPHY;CREB;CTL*;DETECTIVE QUANTUM EFFICIENCY;DNA METHYLATION;DNA MICROARRAY;ELISPOT;EPIRUBICIN;EPITHELIAL OVARIAN CANCER;FEBRILE NEUTROPENIA;FILGRASTIM;GEFITINIB;GENE EXPRESSION PROFILING;GENE SIGNATURE;HEART RATE VARIABILITY;HOUSEKEEPING GENE;HPV INFECTION;LNCAP;MAMMOGRAPHY;MASTECTOMY;MEDULLARY THYROID CANCER;METHYLTRANSFERASE;MHC CLASS I;MICROARRAY;MICROARRAY ANALYSIS TECHNIQUES;MYELOID-DERIVED SUPPRESSOR CELL;NATURAL KILLER CELL;OSTEOPENIA;PAPILLARY CARCINOMA;PARATHYROID NEOPLASM;PHARMACOGENETICS;POINT MUTATION;PROBAND;SECONDARY HYPERPARATHYROIDISM;SEROPREVALENCE;TAMOXIFEN;TAXANE;THYMIDYLATE SYNTHASE;TOPOISOMERASE INHIBITOR;TOTAL MESORECTAL EXCISION;VINORELBINE;VIRAL VECTOR","6;5;4;4;3;3;3;3;3;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ADENOCARCINOMA;ESOPHAGEAL NEOPLASMS;NEOPLASMS;;BREAST NEOPLASMS;THYROID NEOPLASMS;BRAIN NEOPLASMS;COLORECTAL NEOPLASMS;FLUOROURACIL;DACARBAZINE;STOMACH NEOPLASMS;ADOLESCENT;AGED, 80 AND OVER","78;63;50;50;46;43;33;28;28;24;22;20;18;17;17;17;16;16;15;15","MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;PREOPERATIVE CHEMORADIOTHERAPY FOR ESOPHAGEAL CANCER;COLORECTAL CANCER RESEARCH AND TREATMENT;GLIOMAS;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;IMMUNOBIOLOGY OF DENDRITIC CELLS;COMPLICATIONS AND TECHNIQUES IN THYROID SURGERY;DNA TOPOISOMERASES: STRUCTURE, FUNCTION, AND INHIBITION;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH;DEVELOPMENT AND APPLICATIONS OF RADIOPHARMACEUTICALS;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;GLOBAL CANCER INCIDENCE AND MORTALITY PATTERNS;HEPATOCELLULAR CARCINOMA;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;MELANOMA;MINERAL METABOLISM IN CHRONIC KIDNEY DISEASE;NATURAL KILLER CELLS IN IMMUNITY","8;6;5;5;4;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2","THYROID NODULES;REGIMEN;GAMMA PROBE;PARATHYROID HORMONE;TEMOZOLOMIDE;CANCER GENOMICS;HYPOPARATHYROIDISM;MEDULLARY THYROID CANCER;NEOADJUVANT THERAPY;THYROID CARCINOMA;ALPHA PARTICLE THERAPY;BREAST CANCER;CANCER CELL METABOLISM;CANCER TREATMENT;CHEMORADIOTHERAPY;DACARBAZINE;ESOPHAGEAL PERFORATION;ESOPHAGECTOMY;GERIATRIC ONCOLOGY;GRADING (ENGINEERING)","7;6;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3","BREAST CANCER;COLORECTAL CANCER;CANCER PATIENTS;II STUDY;PHASE II;THYROID CANCER;RECTAL CANCER;CELL CARCINOMA;ESOPHAGEAL CANCER;LOCALLY ADVANCED;LONG-TERM RESULTS;METASTATIC BREAST;MINIMALLY INVASIVE;PAPILLARY THYROID;PRELIMINARY RESULTS;ANOREXIA NERVOSA;CELL LINES;CLINICAL PRACTICE;CONTROLLED TRIAL;DNA D-LOOP;ELDERLY CANCER;EMISSION TOMOGRAPHY;GENE EXPRESSION;HEPATOCELLULAR CARCINOMA;HUMAN HERPESVIRUS;HUMAN IMMUNODEFICIENCY;HUMAN PAPILLOMAVIRUS;LYMPH NODE;METASTATIC MELANOMA;MITOCHONDRIAL DNA","7;6;5;5;5;5;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","LYMPH NODES;BREAST CANCER;PROGRESSION-FREE SURVIVAL;TA TA;COLORECTAL CANCER;CONTROL SUBJECTS;ESOPHAGEAL CANCER;MAINTENANCE PACLITAXEL;MTDNA D-LOOP;RESPONSE RATE;SOMATIC MUTATIONS;TISSUE SAMPLES;CANCER PATIENTS;P-TNM STAGE;UGTA POLYMORPHISM;ADJUVANT TREATMENT;BLOOD DNA;CANCER RISK;CONSECUTIVE PATIENTS;D-LOOP REGION;D-LOOP SOMATIC;HDI ARM;HIV- RNA;MBQ MCI;MCI MTC-SESTAMIBI;MEDIAN AGE;MTC-SESTAMIBI DOSE;SNP CORRELATED;SQUAMOUS CELL;STAGE III","10;9;7;7;6;6;6;6;6;6;6;6;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4",23,0.22,6,2,0,1,0,1,4,0,1,3,0,0,7,1,1.75,0,3,4.75,0,0,0,80.5,81,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_IOV",2007,135,9.85925925925926,2.65925925925926,0.376044568245125,0.377777777777778,0.392592592592593,0.118518518518519,0.318518518518519,2,70,21,18,17,0.52,0.16,0.13,0.13,45.11,0.85476578094794,0.281481481481481,0.925925925925926,NA,0.500302771414608,0.426428571428571,0.454958183990442,0.423076923076923,"S. MONFARDINI;UMBERTO CILLO;ERMANNO ANCONA;UMBERTO BASSO;DOMENICO RUBELLO;DAVIDE D’AMICO;ENRICO GRINGERI;GIUSEPPE PORTALE;MASSIMO RUGGE;ALBERTO RUOL;AMEDEO CARRARO;F. D’AMICO;MICHELE VALMASONI;ALESSANDRO VITALE;LARA MARIA PASETTO;GIACOMO ZANUS;SABRINA RAMPADO;ALBERTO BROLESE;CRISTINA GHIOTTO;GIAN LUCA DE SALVO","14;13;13;11;11;10;9;9;8;8;8;8;8;8;7;7;7;7;6;6","S. MONFARDINI;UMBERTO BASSO;DOMENICO RUBELLO;ERMANNO ANCONA;ANITA DE ROSSI;GIUSEPPE PORTALE;UMBERTO CILLO;ANNAROSA DEL MISTRO;CRISTINA GHIOTTO;MASSIMO RUGGE;ALBERTO RUOL;SABRINA RAMPADO;SARA LONARDI;LUCIA RAMPIN;CARLO CASTORO;GIORGIO BATTAGLIA;DAVIDE D’AMICO;STEFANO INDRACCOLO;LARA MARIA PASETTO;ENRICO GRINGERI","2.29;1.96;1.74;1.62;1.42;1.17;1.11;1.06;1.06;1.04;0.96;0.88;0.86;0.86;0.83;0.82;0.81;0.78;0.73;0.7","S. MONFARDINI;UMBERTO CILLO;ERMANNO ANCONA;UMBERTO BASSO;DOMENICO RUBELLO;DAVIDE D’AMICO;ENRICO GRINGERI;GIUSEPPE PORTALE;MASSIMO RUGGE;ALESSANDRO VITALE;LARA MARIA PASETTO;SABRINA RAMPADO;CRISTINA GHIOTTO;GIAN LUCA DE SALVO;ROBERTA BERTORELLE;CARLO CASTORO;GUIDO SOTTI;CARLO RICCARDO ROSSI;MANUEL ZORZI;DONATO NITTI","14;13;13;11;11;10;9;9;8;8;7;7;6;6;6;6;6;5;5;5","S. MONFARDINI;UMBERTO BASSO;DOMENICO RUBELLO;ERMANNO ANCONA;ANITA DE ROSSI;GIUSEPPE PORTALE;UMBERTO CILLO;ANNAROSA DEL MISTRO;CRISTINA GHIOTTO;MASSIMO RUGGE;SABRINA RAMPADO;SARA LONARDI;LUCIA RAMPIN;CARLO CASTORO;GIORGIO BATTAGLIA;DAVIDE D’AMICO;STEFANO INDRACCOLO;LARA MARIA PASETTO;ENRICO GRINGERI;ELENA BANTI","2.29;1.96;1.74;1.62;1.42;1.17;1.11;1.06;1.06;1.04;0.88;0.86;0.86;0.83;0.82;0.81;0.78;0.73;0.7;0.69","ANGELO VERONESE;CARLO M. CROCE;CATIA GIOVANNINI;CHANG‐GONG LIU;EROS FERRAZZÍ;FRANCESCA FORNARI;GEORGE A. CALIN;GIAN LUCA GRAZI;LAURA GRAMANTIERI;LUIGI BOLONDI;MANUELA FERRACIN;MASSIMO NEGRINI;SILVIA SABBIONI;DOMENICO RUBELLO;ERMANNO ANCONA;GIUSEPPE PORTALE;ALBERTO RUOL;UMBERTO CILLO;MANUEL ZORZI;CARLO NALDONI","800;800;800;800;800;800;800;800;800;800;800;800;800;540;487;436;434;392;384;376","ANGELO VERONESE;EROS FERRAZZÍ;DOMENICO RUBELLO;ERMANNO ANCONA;MANUEL ZORZI;GIAN LUCA DE SALVO;ALBERTO AMADORI;ADOLFO FAVARETTO;VANNA CHIARION‐SILENI;PIERFRANCO CONTÉ;GIUSEPPE PORTALE;VALENTINA GUARNERI;PAOLA DEL BIANCO;CARLO CASTORO;PIER CARLO MUZZIO;GIORGIO BATTAGLIA;STEFANO INDRACCOLO;GIOVANNI ESPOSITO;ALBA A. BRANDES;SARA LONARDI","800;800;482;411;384;354;347;314;296;293;289;288;268;263;256;246;244;238;223;218","S. MONFARDINI;UMBERTO BASSO;ALESSANDRO VITALE;ERMANNO ANCONA;DOMENICO RUBELLO;LARA MARIA PASETTO;CARLO CASTORO;CRISTINA GHIOTTO;GIAN LUCA DE SALVO;ROBERTA BERTORELLE;GIUSEPPE PORTALE;GUIDO SOTTI;MANUEL ZORZI;GIORGIO BATTAGLIA;ADOLFO FAVARETTO;ANITA DE ROSSI;CARLO RICCARDO ROSSI;GRAZIA ARTIOLI;MARIA ORNELLA NICOLETTO;MARTIN DONACH","11;10;8;7;7;7;6;6;6;6;5;5;5;4;4;4;4;4;4;4","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;MATHEMATICS;PHYSICS;ENGINEERING;SOCIOLOGY;ECONOMICS;ENVIRONMENTAL SCIENCE;MATERIALS SCIENCE;PHILOSOPHY;POLITICAL SCIENCE;PSYCHOLOGY","125;45;13;8;6;6;5;5;1;1;1;1;1;1","INTERNAL MEDICINE;SURGERY;PATHOLOGY;ONCOLOGY;RADIOLOGY;GASTROENTEROLOGY;CANCER RESEARCH;BIOCHEMISTRY;GENETICS;NUCLEAR MEDICINE;IMMUNOLOGY;ENVIRONMENTAL HEALTH;GENERAL SURGERY;GYNECOLOGY;ORGANIC CHEMISTRY;PALEONTOLOGY;UROLOGY;CELL BIOLOGY;VIROLOGY;BIOTECHNOLOGY;DEMOGRAPHY;ENDOCRINOLOGY;MOLECULAR BIOLOGY","105;60;38;35;30;28;23;16;16;15;14;12;8;8;8;7;7;5;5;4;4;4;4","CANCER;CHEMOTHERAPY;GENE;RADIATION THERAPY;TRANSPLANTATION;POPULATION;BIOPSY;ESOPHAGUS;LUNG CANCER;THYROID;CLINICAL TRIAL;IMMUNOHISTOCHEMISTRY;CARCINOMA;MALIGNANCY;STAGE (STRATIGRAPHY);TOXICITY;HEPATOCELLULAR CARCINOMA;LYMPH NODE;POSITRON EMISSION TOMOGRAPHY;VIRUS","71;32;16;15;13;12;9;9;9;9;8;8;7;7;7;7;6;6;6;6","BREAST CANCER;COLORECTAL CANCER;LIVER TRANSPLANTATION;CISPLATIN;ADENOCARCINOMA;GEMCITABINE;OVARIAN CANCER;PHASES OF CLINICAL RESEARCH;THYROID CANCER;THYROID CARCINOMA;CERVICAL CANCER;ESOPHAGEAL CANCER;GERIATRIC ONCOLOGY;MUCOSITIS;MUTATION;CHEMORADIOTHERAPY;CLINICAL ENDPOINT;METASTASIS;PROSTATE CANCER;BRACHYTHERAPY;CANCER REGISTRY;CARCINOGENESIS;CELL CYCLE;CHEMOKINE;CYCLOPHOSPHAMIDE;DOCETAXEL;EPIDERMAL GROWTH FACTOR RECEPTOR;ESOPHAGEAL DISEASE;ETOPOSIDE;FLUOROURACIL;GENE EXPRESSION;NEUTROPENIA;PACLITAXEL;PROSTATE;VIRAL DISEASE","20;16;10;9;7;7;6;6;6;6;5;5;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","OXALIPLATIN;SENTINEL LYMPH NODE;CARBOPLATIN;ESOPHAGECTOMY;AXILLA;CERVICAL CANCER SCREENING;COLPOSCOPY;MAMMOGRAPHY;MASTECTOMY;METASTATIC BREAST CANCER;ASCUS (BRYOZOA);BRCA MUTATION;CERVICAL INTRAEPITHELIAL NEOPLASIA;CERVICAL SCREENING;CHEMOKINE RECEPTOR;CHROMOSOME 7 (HUMAN);CXCR4;ERLOTINIB;ESOPHAGOGASTRIC JUNCTION;GASTROESOPHAGEAL JUNCTION;GEFITINIB;HERPESVIRIDAE;KARYOTYPE;LIQUID-BASED CYTOLOGY;MILAN CRITERIA;MODEL FOR END-STAGE LIVER DISEASE;ONCOGENE;PEMETREXED;PROSTATE-SPECIFIC ANTIGEN;TRASTUZUMAB;VINORELBINE","7;7;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;MIDDLE AGED;MALE;AGED;ADULT;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;THYROID NEOPLASMS;ADENOCARCINOMA;BREAST NEOPLASMS;ESOPHAGEAL NEOPLASMS;;LIVER NEOPLASMS;TREATMENT OUTCOME;LIVER TRANSPLANTATION;NEOPLASM RECURRENCE, LOCAL;RETROSPECTIVE STUDIES;AGED, 80 AND OVER;ANTINEOPLASTIC AGENTS;CARCINOMA, SQUAMOUS CELL","105;72;60;56;50;46;37;32;31;29;28;25;22;22;20;20;20;19;19;19","MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;HEPATOCELLULAR CARCINOMA;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;PREOPERATIVE CHEMORADIOTHERAPY FOR ESOPHAGEAL CANCER;COLORECTAL CANCER RESEARCH AND TREATMENT;GLIOMAS;GLOBAL CANCER INCIDENCE AND MORTALITY PATTERNS;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;ESOPHAGEAL INTERVENTION TECHNIQUES;FRAILTY IN OLDER ADULTS AND GERIATRIC CARE;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;LIVER CIRRHOSIS AND ASSOCIATED COMPLICATIONS;LIVER TRANSPLANTATION AND GRAFT SURVIVAL ANALYSIS;MOLECULAR RESEARCH ON BREAST CANCER;ADVANCEMENTS IN LUNG CANCER RESEARCH;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;DIAGNOSIS AND TREATMENT OF GASTROINTESTINAL STROMAL TUMORS;DISEASES RELATED TO BLOOD GROUP VARIANTS;GENE THERAPY TECHNIQUES AND APPLICATIONS;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK","9;7;5;5;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2","BREAST CANCER;ESOPHAGEAL PERFORATION;MEDULLARY THYROID CANCER;BREAST CANCER SCREENING;DIFFERENTIATED THYROID CANCER;THYROID NODULES;TREATMENT;CYTOLOGY SCREENING;GERIATRIC ONCOLOGY;HEPATOCELLULAR CARCINOMA;LIVER DISEASE;LIVER TRANSPLANTATION;LIVING DONOR LIVER TRANSPLANTATION;MUCOSITIS;REGIMEN;THYROID CARCINOMA;CANCER INCIDENCE;CARBOPLATIN;CHEMORADIOTHERAPY;CLINICAL ENDPOINT","8;8;8;7;6;6;6;5;5;5;5;5;5;5;5;5;4;4;4;4","BREAST CANCER;LIVER TRANSPLANTATION;LYMPH NODE;ELDERLY PATIENTS;CANCER PATIENTS;CANCER SCREENING;CELL CARCINOMA;CERVICAL CANCER;COLORECTAL CANCER;OVARIAN CANCER;PHASE II;CONTROLLED TRIAL;ESOPHAGEAL CANCER;GERIATRIC ONCOLOGY;HEPATOCELLULAR CARCINOMA;METASTATIC BREAST;PATIENTS RESULTS;PHASE III;RANDOMISED CONTROLLED;RECTAL CANCER;SENTINEL LYMPH;SQUAMOUS CELL;THYROID CANCER;THYROID CARCINOMA;ADJUVANT CHEMOTHERAPY;ADVANCED EPITHELIAL;AXILLARY LYMPH;BILIARY TRACT;CANCER INCIDENCE;CLINICAL TRIAL","8;8;6;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2","PUBMED SCOPUS;CROSSREF PUBMED;RECTAL CANCER;MED -CROSSREF;CANCERN ENGL;RECTAL CANCERN;CLIN ONCOL;ONCOL -CROSSREF;LOCAL CONTROL;RESECTABLE RECTAL;ADJUVANT THERAPY;BREAST CANCER;EGFR MUTATIONS;F-FDG PETCT;CARCINOMAN ENGL;ELDERLY PATIENTS;GUNDERSON LL;MAGNETIC RESONANCE;MEDIAN SURVIVAL;RECTAL CARCINOMAN;ADJUVANT CHEMOTHERAPY;BASED CYTOLOGY;CANCER PATIENTS;CONFIDENCE INTERVAL;INCIDENCE RATES;LIQUID BASED;LOCAL RECURRENCES;LOCALLY ADVANCED;MOERTEL CG;POST-OPERATIVE RADIATION","59;47;34;26;19;18;15;10;9;9;8;8;8;8;7;7;7;7;7;7;6;6;6;6;6;6;6;6;6;6",24,0.18,6.25,4.25,3,2,0,30.25,5,0,1,4.75,0,1,10,2,1.75,0,1,12,1,0,0,66.25,67,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_IOV",2008,152,9.8421052631579,2.23684210526316,0.447058823529412,0.368421052631579,0.243421052631579,0.105263157894737,0.302631578947368,4,69,45,19,14,0.45,0.3,0.12,0.09,47.74,0.86996928493165,0.296052631578947,0.960526315789474,NA,0.477008036936227,0.396761133603239,0.364298724954463,0.290674603174603,"DONATO NITTI;DOMENICO RUBELLO;MASSIMO RUGGE;LARA MARIA PASETTO;S. MONFARDINI;UMBERTO BASSO;GIACOMO NOVARA;ERMANNO ANCONA;WALTER ARTIBANI;SALVATORE PUCCIARELLI;ALBERTO RUOL;MANUEL ZORZI;ANTONIO GALFANO;ANTONIO TONIATO;ISABELLA MERANTE BOSCHIN;ANTONIO JIRILLO;CRISTINA FALCI;GIAN LUCA DE SALVO;VANNA CHIARION‐SILENI;VINCENZO DE LISI","13;12;10;10;10;10;9;9;8;8;8;7;7;7;7;6;6;5;5;5","DOMENICO RUBELLO;MASSIMO RUGGE;ALESSANDRA BERNARDI;DARIO CASARA;GIACOMO NOVARA;UMBERTO BASSO;S. MONFARDINI;DONATO NITTI;ANTONIO TONIATO;ISABELLA MERANTE BOSCHIN;LARA MARIA PASETTO;MASSIMO RUGGE;ERMANNO ANCONA;GIOVANNI ZANINOTTO;VINCENZO FICARRA;WALTER ARTIBANI;ANTONIO JIRILLO;CHRISTIAN RIZZETTO;ANTONIO GALFANO;SALVATORE PUCCIARELLI","2.13;1.83;1.5;1.46;1.42;1.32;1.32;1.22;1.04;1.04;1.04;1;0.98;0.93;0.92;0.92;0.91;0.85;0.82;0.8","DOMENICO RUBELLO;MASSIMO RUGGE;LARA MARIA PASETTO;S. MONFARDINI;UMBERTO BASSO;GIACOMO NOVARA;ERMANNO ANCONA;WALTER ARTIBANI;MANUEL ZORZI;ANTONIO GALFANO;ANTONIO TONIATO;ISABELLA MERANTE BOSCHIN;ANTONIO JIRILLO;CRISTINA FALCI;GIAN LUCA DE SALVO;VANNA CHIARION‐SILENI;RENZO MAZZAROTTO;ANTONELLA BRUNELLO;ALBERTO AMADORI;VINCENZO FICARRA","12;10;10;10;10;9;9;8;7;7;7;7;6;6;5;5;5;5;5;5","DOMENICO RUBELLO;MASSIMO RUGGE;ALESSANDRA BERNARDI;DARIO CASARA;GIACOMO NOVARA;UMBERTO BASSO;S. MONFARDINI;ANTONIO TONIATO;ISABELLA MERANTE BOSCHIN;LARA MARIA PASETTO;MASSIMO RUGGE;ERMANNO ANCONA;VINCENZO FICARRA;WALTER ARTIBANI;ANTONIO JIRILLO;CHRISTIAN RIZZETTO;ANTONIO GALFANO;GAIA GRASSETTO;ANTONELLA BRUNELLO;SARA LONARDI","2.13;1.83;1.5;1.46;1.42;1.32;1.32;1.04;1.04;1.04;1;0.98;0.92;0.92;0.91;0.85;0.82;0.77;0.77;0.76","MASSIMO RUGGE;ALBERTO RUOL;DONATO NITTI;ERMANNO ANCONA;FABIO FARINATI;A. SÉRGIO;STEFANO INDRACCOLO;GIUSEPPE PORTALE;FRANCESCO CAVALLIN;GIORGIO BATTAGLIA;PATRIZIA BURRA;A. BALDAN;ANNA GIACOMIN;CHIARA CRISTOFORI;G PIVETTA;LISA GIRARDI;ROBERTO RAGAZZI;ROMILDA CARDIN;UMBERTO CILLO;GIOVANNI ZANINOTTO","771;684;684;671;544;535;527;507;506;506;480;469;469;469;469;469;469;469;469;442","MASSIMO RUGGE;A. SÉRGIO;STEFANO INDRACCOLO;FRANCESCO CAVALLIN;GIORGIO BATTAGLIA;GIACOMO NOVARA;GIANMARIA PENNELLI;ERMANNO ANCONA;GIAN LUCA DE SALVO;DOMENICO RUBELLO;VANNA CHIARION‐SILENI;MARIA ROSA PELIZZO;ANNAROSA DEL MISTRO;P ZAMBON;L. CORTI;ANTONELLA VECCHIATO;CATERINA MIAN;MICHELA BASSO;ANITA DE ROSSI;CARLO CASTORO","688;535;527;506;506;423;383;381;377;362;347;337;333;322;302;278;278;278;268;267","DOMENICO RUBELLO;GIACOMO NOVARA;LARA MARIA PASETTO;UMBERTO BASSO;MASSIMO RUGGE;MANUEL ZORZI;ANTONELLA BRUNELLO;ANTONIO JIRILLO;ERMANNO ANCONA;RENZO MAZZAROTTO;VANNA CHIARION‐SILENI;ALBERTO AMADORI;ANTONIO ROSATO;ANTONIO TONIATO;CRISTINA FALCI;DARIO CASARA;GIAN LUCA DE SALVO;ISABELLA MERANTE BOSCHIN;MARIA LUISA FRISO;MARIA ROSA PELIZZO","10;9;9;9;8;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;SOCIOLOGY;MATHEMATICS;ENGINEERING;GEOGRAPHY;PHILOSOPHY;POLITICAL SCIENCE;BUSINESS;ECONOMICS;HISTORY;MATERIALS SCIENCE;PSYCHOLOGY","135;58;15;14;7;7;5;3;3;3;3;1;1;1;1;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;PATHOLOGY;GASTROENTEROLOGY;GENETICS;RADIOLOGY;CANCER RESEARCH;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;IMMUNOLOGY;PALEONTOLOGY;GYNECOLOGY;CELL BIOLOGY;ENDOCRINOLOGY;NURSING;GENERAL SURGERY;NUCLEAR MEDICINE;UROLOGY;OPTICS;ORGANIC CHEMISTRY","107;50;44;33;30;30;25;22;18;18;18;13;10;9;9;9;8;8;8;7;7","CANCER;CHEMOTHERAPY;GENE;POPULATION;RADIATION THERAPY;DISEASE;CARCINOMA;STAGE (STRATIGRAPHY);THYROID;LYMPH NODE;BIOPSY;MULTIVARIATE ANALYSIS;SURGICAL ONCOLOGY;CONFIDENCE INTERVAL;ESOPHAGUS;INCIDENCE (GEOMETRY);LYMPH;MELANOMA;TOXICITY;APOPTOSIS;ASYMPTOMATIC;CLINICAL TRIAL;HEPATOCELLULAR CARCINOMA;IMMUNE SYSTEM;PATHOLOGICAL;PREGNANCY;PROSPECTIVE COHORT STUDY;QUALITY OF LIFE (HEALTHCARE)","70;27;27;18;16;11;10;10;10;9;7;7;7;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5","COLORECTAL CANCER;BREAST CANCER;METASTASIS;GENOTYPE;CHEMORADIOTHERAPY;GASTRITIS;MUTATION;PROSTATE CANCER;THYROID CANCER;THYROID CARCINOMA;UNIVARIATE ANALYSIS;ALLELE;MUCOSITIS;PROSTATE;ACHALASIA;ADENOCARCINOMA;CHROMOSOME;CISPLATIN;ESOPHAGEAL CANCER;EXON;FLUOROURACIL;HAZARD RATIO;INTESTINAL METAPLASIA;OVARIAN CANCER;PROGRESSIVE DISEASE;ULCERATIVE COLITIS","18;16;7;6;5;5;5;5;5;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3","SINGLE-NUCLEOTIDE POLYMORPHISM;ATROPHIC GASTRITIS;CARBOPLATIN;HAPLOTYPE;MAMMOGRAPHY;SENTINEL LYMPH NODE;SENTINEL NODE;ADJUVANT CHEMOTHERAPY;BREAST CARCINOMA;CAGA;ESOPHAGEAL ADENOCARCINOMA;ESOPHAGECTOMY;ESTROGEN RECEPTOR;GERMLINE MUTATION;LYMPH NODE METASTASIS;MYOTOMY;OXALIPLATIN;PROBAND;PROCTOCOLECTOMY;T-CELL RECEPTOR;TELOMERASE REVERSE TRANSCRIPTASE;TRANSITIONAL CELL CARCINOMA;VARICOCELE;VINORELBINE","4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;ADENOCARCINOMA;CARCINOMA, SQUAMOUS CELL;BREAST NEOPLASMS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;AGED, 80 AND OVER;ITALY;ESOPHAGEAL NEOPLASMS;RETROSPECTIVE STUDIES;THYROID NEOPLASMS;NEOPLASM STAGING;;NEOPLASM RECURRENCE, LOCAL;NEOPLASMS;FLUOROURACIL","127;92;86;74;72;57;37;37;34;31;28;28;25;23;23;22;21;20;20;19","COLORECTAL CANCER RESEARCH AND TREATMENT;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;HELICOBACTER PYLORI INFECTION AND GASTRIC CANCER;MELANOMA;PREOPERATIVE CHEMORADIOTHERAPY FOR ESOPHAGEAL CANCER;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;MOLECULAR CHARACTERIZATION OF COLORECTAL CANCER;DIAGNOSIS AND MANAGEMENT OF GASTROESOPHAGEAL REFLUX DISEASE;GLIOMAS;GLOBAL CANCER INCIDENCE AND MORTALITY PATTERNS;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;RENAL CELL CARCINOMA;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;BREAST MAGNETIC RESONANCE IMAGING IN ONCOLOGY;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;EPIDEMIOLOGY AND MANAGEMENT OF CYTOMEGALOVIRUS INFECTION;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;FRAILTY IN OLDER ADULTS AND GERIATRIC CARE;GLOBAL TRENDS IN COLORECTAL CANCER RESEARCH","7;7;5;5;5;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2","TREATMENT;SURGICAL ONCOLOGY;MELANOMA;THYROID NODULES;BREAST CANCER;CHEMORADIOTHERAPY;DIFFERENTIATED THYROID CANCER;MEDULLARY THYROID CANCER;NEOADJUVANT THERAPY;THYROID CARCINOMA;UNIVARIATE ANALYSIS;ADJUVANT CHEMOTHERAPY;BREAST CANCER SCREENING;CANCER INCIDENCE;MUCOSITIS;REGIMEN;ATROPHIC GASTRITIS;CANCER IN OLDER ADULTS;CARBOPLATIN;GASTRIC CANCER","10;7;6;6;5;5;5;5;5;5;5;4;4;4;4;4;3;3;3;3","LYMPH NODE;CELL CARCINOMA;ELDERLY PATIENTS;PHASE II;BREAST CANCER;COLON CANCER;COLORECTAL CANCER;THYROID CARCINOMA;SQUAMOUS CELL;GASTRIC CANCER;HEPATOCELLULAR CARCINOMA;LOCALLY ADVANCED;LONG-TERM OUTCOME;PROSTATE CANCER;RECTAL CANCER;RENAL CELL;ADVANCED HEAD;AIEOP SOFT;CANCER PATIENTS;CANCER SCREENING;CELL DEATH;CERVICAL CANCER;CLINICAL OUTCOME;ESOPHAGEAL CANCER;HEALTH-RELATED QUALITY;HUMAN HERPESVIRUS;II STUDY;II TRIAL;IMMUNE COMPLEXES;INDEPENDENT PREDICTORS","8;7;6;6;5;5;5;5;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","BREAST CANCER;OVARIAN CANCER;CANCER CELLS;SPERM COUNT;STATISTICALLY SIGNIFICANTLY;SUBOPTIMAL LIVERS;VARICOCELE PATIENTS;AFFECTED INDIVIDUALS;ANTEGRADE SCROTAL;CANCER MORTALITY;ESOPHAGEAL CANCER;HPV TESTING;IFN DC;OHDG LEVELS;PERIPHERAL BLOOD;RELATIVE SENSITIVITY;RESIDUAL TUMOR;SCROTAL SCLEROTHERAPY;SIGNIFICANTLY IMPROVED;BRCA MUTATION;CAGA STATUS;CERVICAL CANCER;CONVENTIONAL CYTOLOGY;COUNT MOTILITY;ESOPHAGEAL ADENOCARCINOMA;ESOPHAGEAL STRICTURES;EXCESS MORTALITY;HHV- INFECTION;HPV DNA;IL DC","18;7;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4",27,0.18,6.58,3,1,1,0,3.5,3,0,2,3,0,1,1,0,1.5,0,1,1,0,0,0,71,71.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_IOV",2009,147,10.891156462585,2.7687074829932,0.361179361179361,0.306122448979592,0.326530612244898,0.136054421768707,0.346938775510204,2,63,34,24,18,0.43,0.23,0.16,0.12,43.99,0.951055752279413,0.346938775510204,0.952380952380952,NA,0.482746990327876,0.44071261682243,0.435185185185185,0.380537400145243,"UMBERTO CILLO;ALESSANDRO VITALE;PATRIZIA BURRA;MASSIMO RUGGE;FABLE ZUSTOVICH;F. D’AMICO;MASSIMO GION;GIUSEPPE LOMBARDI;PATRIZIA PONTISSO;N. TONO;DONATO NITTI;DAVIDE PASTORELLI;GIACOMO ZANUS;ENRICO GRINGERI;GIORGIO FASSINA;CARLO RICCARDO ROSSI;PAOLA ZANOVELLO;SALVATORE PUCCIARELLI;STEFANO INDRACCOLO;GIAN LUCA DE SALVO","17;13;12;10;10;9;8;8;7;7;7;7;7;7;7;6;6;6;6;6","UMBERTO CILLO;FABLE ZUSTOVICH;ALESSANDRO VITALE;GIUSEPPE LOMBARDI;PAOLA ZANOVELLO;S. MONFARDINI;DAVIDE PASTORELLI;MASSIMO RUGGE;PATRIZIA BURRA;MASSIMO GION;F. D’AMICO;DONATO NITTI;CESARE RUFFOLO;IMERIO ANGRIMAN;MARCO SCARPA;ANTONIO ROSATO;MARIA ROSA PELIZZO;SARA LONARDI;PATRIZIA PONTISSO;N. TONO","2.01;1.64;1.59;1.47;1.45;1.43;1.38;1.16;1.12;1.04;0.79;0.78;0.76;0.76;0.74;0.73;0.67;0.66;0.6;0.6","UMBERTO CILLO;ALESSANDRO VITALE;PATRIZIA BURRA;MASSIMO RUGGE;FABLE ZUSTOVICH;MASSIMO GION;GIUSEPPE LOMBARDI;N. TONO;DONATO NITTI;DAVIDE PASTORELLI;GIACOMO ZANUS;ENRICO GRINGERI;CARLO RICCARDO ROSSI;PAOLA ZANOVELLO;SALVATORE PUCCIARELLI;STEFANO INDRACCOLO;GIAN LUCA DE SALVO;GIUSEPPE OPOCHER;SARA LONARDI;MICHELE VALMASONI","17;13;12;10;10;8;8;7;7;7;7;7;6;6;6;6;6;6;6;6","UMBERTO CILLO;FABLE ZUSTOVICH;ALESSANDRO VITALE;GIUSEPPE LOMBARDI;PAOLA ZANOVELLO;S. MONFARDINI;DAVIDE PASTORELLI;MASSIMO RUGGE;PATRIZIA BURRA;MASSIMO GION;DONATO NITTI;MARCO SCARPA;ANTONIO ROSATO;MARIA ROSA PELIZZO;SARA LONARDI;N. TONO;GIAN LUCA DE SALVO;SALVATORE PUCCIARELLI;STEFANO INDRACCOLO;ENRICO GRINGERI","2.01;1.64;1.59;1.47;1.45;1.43;1.38;1.16;1.12;1.04;0.78;0.74;0.73;0.67;0.66;0.6;0.58;0.55;0.55;0.55","VINCENZO BRONTE;GIUSEPPE OPOCHER;FRANCESCA SCHIAVI;ANTONIO ROSATO;MARIA RONDINA;SARA BOBISSE;A. PARENTI;ALDO SOLARI;ALLAN BALMAIN;BYRON HANN;CHRISTINE WONG;MADDALENA ADORNO;MARCO MONTAGNER;MICHELANGELO CORDENONSI;SILVIO BICCIATO;SIRIO DUPONT;STEFANO PICCOLO;VINCENZA GUZZARDO;STEFANO UGEL;ILARIA MARIGO","958;880;867;857;856;802;741;741;741;741;741;741;741;741;741;741;741;741;629;597","VINCENZO BRONTE;GIUSEPPE OPOCHER;FRANCESCA SCHIAVI;ANTONIO ROSATO;MARIA RONDINA;SARA BOBISSE;SILVIO BICCIATO;ILARIA MARIGO;STEFANO UGEL;ELISA PERANZONI;LUIGI DOLCETTI;PAOLA ZANOVELLO;ALESSANDRO VITALE;SUSANNA MANDRUZZATO;GIAN LUCA DE SALVO;SARA LONARDI;VANNA CHIARION‐SILENI;VIVIANA PIGNATARO;AIDA TOFFOLI;ALESSANDRO PROIETTI","958;880;859;857;802;802;741;597;597;570;538;473;386;360;359;354;326;292;258;258","ALESSANDRO VITALE;FABLE ZUSTOVICH;GIUSEPPE LOMBARDI;N. TONO;DAVIDE PASTORELLI;ANTONIO ROSATO;GIAN LUCA DE SALVO;GIUSEPPE OPOCHER;SARA LONARDI;PAOLA ZANOVELLO;STEFANO INDRACCOLO;MARCO SCARPA;MASSIMO RUGGE;VINCENZO BRONTE;VANNA CHIARION‐SILENI;AMEDEO CARRARO;CARLO RICCARDO ROSSI;FRANCESCA SCHIAVI;MARCO MONTAGNA;PAOLA DEL BIANCO","13;10;7;7;6;6;6;6;6;6;6;5;5;5;5;4;4;4;4;4","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;ECONOMICS;MATHEMATICS;POLITICAL SCIENCE;ENGINEERING;PSYCHOLOGY;SOCIOLOGY;BUSINESS;COMPUTER SCIENCE;HISTORY;MATERIALS SCIENCE;PHILOSOPHY","129;57;17;13;5;3;3;2;2;2;1;1;1;1;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;GASTROENTEROLOGY;CANCER RESEARCH;GENETICS;PATHOLOGY;BIOCHEMISTRY;IMMUNOLOGY;ENVIRONMENTAL HEALTH;NURSING;OPTICS;RADIOLOGY;UROLOGY;CELL BIOLOGY;ENDOCRINOLOGY;NUCLEAR MEDICINE;PHYSICAL THERAPY;INTENSIVE CARE MEDICINE;PALEONTOLOGY","111;46;40;34;33;33;29;26;24;11;9;9;9;8;7;7;7;7;6;6","CANCER;GENE;CHEMOTHERAPY;HEPATOCELLULAR CARCINOMA;DISEASE;TRANSPLANTATION;MELANOMA;CARCINOMA;CIRRHOSIS;POPULATION;IMMUNE SYSTEM;IN VITRO;INCIDENCE (GEOMETRY);QUALITY OF LIFE (HEALTHCARE);ANTIBODY;RADIATION THERAPY;SARCOMA;STAGE (STRATIGRAPHY);RANDOMIZED CONTROLLED TRIAL;THYROID;TOXICITY","64;31;25;20;16;14;12;10;10;10;8;8;8;8;7;6;6;6;5;5;5","BREAST CANCER;COLORECTAL CANCER;LIVER TRANSPLANTATION;CISPLATIN;FLUOROURACIL;MUTATION;GENOTYPE;IMMUNOTHERAPY;CARCINOGENESIS;CHEMORADIOTHERAPY;LIVER CANCER;METASTASIS;T CELL;ALLELE;DOCETAXEL;ESOPHAGEAL CANCER;GEMCITABINE;INFLAMMATORY BOWEL DISEASE;PACLITAXEL;PHENOTYPE;ULCERATIVE COLITIS","16;16;14;8;7;7;6;6;5;5;5;5;5;4;4;4;4;4;4;4;4","ADOPTIVE CELL TRANSFER;MILAN CRITERIA;OXALIPLATIN;CARBOPLATIN;GERMLINE MUTATION;SINGLE-NUCLEOTIDE POLYMORPHISM;IMMUNOGLOBULIN M;MAMMOGRAPHY;PRENATAL DIAGNOSIS;PROCTOCOLECTOMY;ADOPTIVE IMMUNOTHERAPY;ANTHRACYCLINE;CANCER IMMUNOTHERAPY;ESOPHAGECTOMY;HAPLOTYPE;IRINOTECAN;LOSS OF HETEROZYGOSITY;MYELOID-DERIVED SUPPRESSOR CELL;PENETRANCE;SENTINEL LYMPH NODE;SENTINEL NODE;TUMOR SUPPRESSOR GENE;VINCRISTINE;VINORELBINE;VIRAL VECTOR","5;5;5;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;MALE;AGED;MIDDLE AGED;;ADULT;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;MELANOMA;ITALY;BREAST NEOPLASMS;YOUNG ADULT;ADOLESCENT;SKIN NEOPLASMS;LUNG NEOPLASMS;TREATMENT OUTCOME;AGED, 80 AND OVER;CARCINOMA, HEPATOCELLULAR;NEOPLASMS;PROGNOSIS","92;74;58;51;50;46;45;30;28;25;24;23;21;21;19;19;18;18;18;17","COLORECTAL CANCER RESEARCH AND TREATMENT;HEPATOCELLULAR CARCINOMA;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;LIVER TRANSPLANTATION AND GRAFT SURVIVAL ANALYSIS;MELANOMA;ADVANCEMENTS IN LUNG CANCER RESEARCH;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;IMMUNOBIOLOGY OF DENDRITIC CELLS;LIVER CIRRHOSIS AND ASSOCIATED COMPLICATIONS;PANCREATIC CANCER RESEARCH AND TREATMENT;PHEOCHROMOCYTOMA AND PARAGANGLIOMA;SARCOMA RESEARCH AND TREATMENT;THERAPEUTIC ANTIBODIES: DEVELOPMENT, ENGINEERING, AND APPLICATIONS;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;DIAGNOSIS AND TREATMENT OF GASTROINTESTINAL STROMAL TUMORS;GLIOMAS","9;8;7;4;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2","HEPATOCELLULAR CARCINOMA;LIVING DONOR LIVER TRANSPLANTATION;LIVER CANCER;LIVER TRANSPLANTATION;MELANOMA;CHEMORADIOTHERAPY;ADOPTIVE CELL TRANSFER;MILAN CRITERIA;BREAST CANCER;CANCER INCIDENCE;CARBOPLATIN;LIVER DISEASE;METASTATIC COLORECTAL CANCER;ADJUVANT CHEMOTHERAPY;CELL-FREE DNA;CELL-FREE FETAL DNA;CONCOMITANT;IMMUNOGLOBULIN M;NEOADJUVANT THERAPY;NUTRITIONAL STATUS","9;9;8;8;7;6;5;5;4;4;4;4;4;3;3;3;3;3;3;3","HEPATOCELLULAR CARCINOMA;LIVER TRANSPLANTATION;CANCER PATIENTS;BREAST CANCER;RECTAL CANCER;COLORECTAL CANCER;LOCALLY ADVANCED;PHASE II;ADIUVANTE RETTO;ADVANCED RECTAL;BOWEL DISEASE;CANCER PATHOLOGIC;CANCER REGISTRIES;FLUOROURACIL FU-BASED;FU-BASED CHEMORADIATION;III TRIAL;INFLAMMATORY BOWEL;LIPOSOMAL DOXORUBICIN;OVARIAN CANCER;PATHOLOGIC RESPONSE;PHASE III;PREOPERATIVE FLUOROURACIL;RANDOMIZED PHASE;RESPONSE ANALYSIS;RESTORATIVE PROCTOCOLECTOMY;RETTO STAR-;STAR- RANDOMIZED;STUDIO TERAPIA;TERAPIA ADIUVANTE;WEEKLY OXALIPLATIN","12;11;10;7;7;5;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","CDB GR;IMMUNE COMPLEXES;LIVER TRANSPLANTATION;UP-TO- CRITERIA;AGE SD;CARCINOMA HCC;DIAGNOSTIC ACCURACY;HEPATOCELLULAR CARCINOMA;SERUM LEVELS;CELL CARCINOMA;HIV- INFECTION;LIVER CANCER;SCCA-IGM REACTIVITY;SQUAMOUS CELL;BREAST CANCER;CANCER DETECTION;FAMILY HISTORY;GG GENOTYPE;LOGISTIC REGRESSION;MOUSE MONOCLONAL;SCCA-IGM IMMUNE;STATISTICALLY SIGNIFICANT;VIRAL LOAD;BONE METASTASIS;BREAST MILK;CANCER PATIENTS;CANCER RES;CANCER SUSCEPTIBILITY;DEFB GENE;ENDOMETRIAL CANCER","13;10;9;8;7;7;7;7;7;6;6;6;6;6;5;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4",27,0.18,6,3.5,1,0,0,0,7,1,1,6,0,1,1.5,0,3,1,0,2,0,0,0,102,102,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_IOV",2010,133,12.0526315789474,2.27067669172932,0.440397350993377,0.300751879699248,0.270676691729323,0.172932330827068,0.383458646616541,4,73,24,16,11,0.55,0.18,0.12,0.08,62.56,1.38427902715271,0.278195488721804,0.954887218045113,NA,0.498662185052251,0.31960631960632,0.377747252747253,0.248803827751196,"ERMANNO ANCONA;MASSIMO RUGGE;LUCIANO GIACOMELLI;STEFANO INDRACCOLO;FABLE ZUSTOVICH;MARCO SCARPA;GIUSEPPE OPOCHER;MATTEO FASSAN;VINCENZO BRONTE;MANUEL ZORZI;DAVIDE PASTORELLI;ALBERTO RUOL;GIUSEPPE LOMBARDI;DONATO NITTI;SALVATORE PUCCIARELLI;CHRISTIAN RIZZETTO;MATTEO CAGOL;FIORELLA CALABRESE;ANTONIO ROSATO;GIOVANNI ZANINOTTO","10;9;7;7;7;7;7;7;7;6;6;6;6;5;5;5;5;5;5;5","VINCENZO BRONTE;STEFANO INDRACCOLO;IMERIO ANGRIMAN;ANGELO CLAUDIO PALOZZO;MASSIMO RUGGE;ERMANNO ANCONA;MATTEO FASSAN;MANUEL ZORZI;FABLE ZUSTOVICH;LUCIANO GIACOMELLI;MARCO SCARPA;UMBERTO BASSO;GIUSEPPE LOMBARDI;ALBERTO RUOL;FRANCO LUMACHI;ANTONELLA BRUNELLO;LUIGI DALL’OLMO;ANTONIO ROSATO;ADOLFO FAVARETTO;MATTEO CAGOL","1.89;1.68;1.38;1.12;1.12;1.06;0.93;0.91;0.91;0.83;0.79;0.69;0.66;0.65;0.63;0.62;0.6;0.57;0.55;0.55","ERMANNO ANCONA;MASSIMO RUGGE;STEFANO INDRACCOLO;FABLE ZUSTOVICH;MARCO SCARPA;GIUSEPPE OPOCHER;VINCENZO BRONTE;MANUEL ZORZI;DAVIDE PASTORELLI;ALBERTO RUOL;GIUSEPPE LOMBARDI;SALVATORE PUCCIARELLI;CHRISTIAN RIZZETTO;MATTEO CAGOL;ANTONIO ROSATO;UMBERTO BASSO;IMERIO ANGRIMAN;GIANMARIA PENNELLI;ALESSANDRO VITALE;PAOLA ZANOVELLO","10;9;7;7;7;7;7;6;6;6;6;5;5;5;5;5;5;5;5;4","VINCENZO BRONTE;STEFANO INDRACCOLO;IMERIO ANGRIMAN;ANGELO CLAUDIO PALOZZO;MASSIMO RUGGE;ERMANNO ANCONA;MANUEL ZORZI;FABLE ZUSTOVICH;MARCO SCARPA;UMBERTO BASSO;GIUSEPPE LOMBARDI;ALBERTO RUOL;ANTONELLA BRUNELLO;LUIGI DALL’OLMO;ANTONIO ROSATO;ADOLFO FAVARETTO;MATTEO CAGOL;LUIGI DOLCETTI;GIUSEPPE OPOCHER;DAVIDE PASTORELLI","1.89;1.68;1.38;1.12;1.12;1.06;0.91;0.91;0.79;0.69;0.66;0.65;0.62;0.6;0.57;0.55;0.55;0.52;0.51;0.5","SILVIO BICCIATO;MANUEL ZORZI;FIORELLA CALABRESE;VINCENZO BRONTE;MARCO ZAPPA;GIUSEPPE OPOCHER;ANNAROSA DEL MISTRO;ANNA GILLIO‐TOS;BRUNO GHIRINGHELLO;CARLO NALDONI;FRANCESCA CAROZZI;GUGLIELMO RONCO;JACK CUZICK;LAURA DE MARCO;MASSIMO CONFORTINI;NEREO SEGNAN;PAOLA PIEROTTI;PAOLO DALLA PALMA;PAOLO GIORGI ROSSI;PATRIZIA SCHINCAGLIA","1447;1056;967;950;943;919;896;880;880;880;880;880;880;880;880;880;880;880;880;880","MANUEL ZORZI;VINCENZO BRONTE;GIUSEPPE OPOCHER;ANNAROSA DEL MISTRO;PAOLA ZANOVELLO;SUSANNA MANDRUZZATO;ANTONIO ROSATO;FRANCESCA SCHIAVI;VANNA CHIARION‐SILENI;FRANCESCA BOARETTO;BERNARDO BONANNI;C. DI MAGGIO;DANIELA TURCHETTI;FRANCESCO CAVALLIN;SIRANOUSH MANOUKIAN;MASSIMO RUGGE;STEFANO INDRACCOLO;ALESSANDRO VITALE;PAOLA DEL BIANCO;MARCO MONTAGNA","1056;950;919;896;848;798;794;595;570;381;318;318;318;318;318;302;260;242;240;220","FABLE ZUSTOVICH;VINCENZO BRONTE;GIUSEPPE OPOCHER;MARCO SCARPA;MANUEL ZORZI;STEFANO INDRACCOLO;GIUSEPPE LOMBARDI;ERMANNO ANCONA;MASSIMO RUGGE;MATTEO CAGOL;ANTONIO ROSATO;UMBERTO BASSO;ALESSANDRO VITALE;DAVIDE PASTORELLI;MARCO MONTAGNA;PAOLA DEL BIANCO;GIORGIO BATTAGLIA;PAOLA ZANOVELLO;ALBERTO AMADORI;ANTONELLA BRUNELLO","7;7;7;7;6;6;6;5;5;5;5;5;4;4;4;4;4;3;3;3","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;MATHEMATICS;SOCIOLOGY;COMPUTER SCIENCE;MATERIALS SCIENCE;BUSINESS;ECONOMICS;ENGINEERING;POLITICAL SCIENCE;HISTORY;PSYCHOLOGY","113;57;19;8;5;5;4;4;2;2;2;2;1;1","INTERNAL MEDICINE;SURGERY;CANCER RESEARCH;ONCOLOGY;GENETICS;PATHOLOGY;BIOCHEMISTRY;IMMUNOLOGY;RADIOLOGY;GASTROENTEROLOGY;CELL BIOLOGY;PALEONTOLOGY;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;GYNECOLOGY;MOLECULAR BIOLOGY;OPTICS;PSYCHIATRY;NUCLEAR MEDICINE;ASTROBIOLOGY;BIOTECHNOLOGY;DEMOGRAPHY;NURSING;QUANTUM MECHANICS;UROLOGY;VIROLOGY","92;38;35;31;30;29;21;21;21;20;12;12;10;10;8;8;7;7;6;4;4;4;4;4;4;4","CANCER;GENE;CHEMOTHERAPY;IMMUNE SYSTEM;DISEASE;CONFIDENCE INTERVAL;POPULATION;RADIATION THERAPY;STAGE (STRATIGRAPHY);MULTIVARIATE ANALYSIS;CARCINOMA;IMMUNOHISTOCHEMISTRY;IN VITRO;IN VIVO;RECEPTOR;BIOPSY;MELANOMA;REGIMEN;THYROID;TOXICITY;TRANSPLANTATION","62;26;15;13;11;10;10;10;9;8;7;7;7;7;7;6;6;6;6;6;6","BREAST CANCER;COLORECTAL CANCER;METASTASIS;CARCINOGENESIS;MUTATION;T CELL;ADENOCARCINOMA;CD8;ALLELE;HAZARD RATIO;LIVER TRANSPLANTATION;SUPPRESSOR;CHEMORADIOTHERAPY;CISPLATIN;CYTOTOXIC T CELL;ESOPHAGEAL CANCER;GEMCITABINE;GENE EXPRESSION;GENOTYPE;GERMLINE;IMMUNOSTAINING;INTESTINAL METAPLASIA;PHENOTYPE;ULCERATIVE COLITIS;UNIVARIATE ANALYSIS","22;12;9;8;8;7;6;6;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4","GERMLINE MUTATION;ADOPTIVE CELL TRANSFER;MYELOID-DERIVED SUPPRESSOR CELL;NEOADJUVANT THERAPY;CTL*;PENETRANCE;IRINOTECAN;MAMMOGRAPHY;OXALIPLATIN;CARBOPLATIN;EPITHELIAL–MESENCHYMAL TRANSITION;ESOPHAGECTOMY;GENE EXPRESSION PROFILING;MICROARRAY ANALYSIS TECHNIQUES;MICROSATELLITE;OSTEOCALCIN;PAPILLARY THYROID CANCER;PEMETREXED;SENTINEL LYMPH NODE;SINGLE-NUCLEOTIDE POLYMORPHISM;SOMATOSTATIN RECEPTOR 2","7;5;5;5;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;MIDDLE AGED;MALE;ADULT;AGED;BREAST NEOPLASMS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ADENOCARCINOMA;ESOPHAGEAL NEOPLASMS;ITALY;AGED, 80 AND OVER;TREATMENT OUTCOME;;THYROID NEOPLASMS;ANTINEOPLASTIC AGENTS;LIVER NEOPLASMS;NEOPLASM STAGING;RETROSPECTIVE STUDIES;CARCINOMA, SQUAMOUS CELL","108;75;72;61;58;57;35;27;23;23;23;22;22;20;19;15;15;15;15;14","PREOPERATIVE CHEMORADIOTHERAPY FOR ESOPHAGEAL CANCER;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;MACROPHAGE ACTIVATION AND POLARIZATION;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;HEPATOCELLULAR CARCINOMA;MELANOMA;ANORECTAL SURGICAL PROCEDURES;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;GLIOMAS;GLOBAL CANCER INCIDENCE AND MORTALITY PATTERNS;GLOBAL TRENDS IN COLORECTAL CANCER RESEARCH;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;HUMAN T-CELL LEUKEMIA VIRUS TYPE 1 INFECTION;IMPACT OF OBESITY ON CANCER RISK AND PROGNOSIS;LIVER CIRRHOSIS AND ASSOCIATED COMPLICATIONS;MALIGNANT PLEURAL MESOTHELIOMA RESEARCH","8;6;5;5;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","BREAST CANCER;CANCER RISK;NEOADJUVANT THERAPY;REGIMEN;ADOPTIVE CELL TRANSFER;MYELOID-DERIVED SUPPRESSOR CELL;MYELOID-DERIVED SUPPRESSOR CELLS;BARRETT'S ESOPHAGUS;BRCA1;CANCER INCIDENCE;CANCER SUSCEPTIBILITY;CHEMORADIOTHERAPY;CTL*;HEPATOCELLULAR CARCINOMA;IMMUNOSTAINING;INTESTINAL METAPLASIA;MELANOMA;PENETRANCE;REFRACTORY (PLANETARY SCIENCE);THYROID NODULES","9;7;6;6;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4","BREAST CANCER;HEPATOCELLULAR CARCINOMA;BARRETTS CARCINOGENESIS;BRCA-ASSOCIATED BREAST;CANCER RISK;COMMON GENETIC;ENDOCRINE NEOPLASIA;FINE NEEDLE;GENETIC VARIANTS;LIVER TRANSPLANTATION;LONG-TERM RESULTS;MULTIPLE ENDOCRINE;NEEDLE ASPIRATION;OESOPHAGEAL CANCER;OVARIAN CANCER;PAPILLARY THYROID;VIRUS TYPE;ACROMEGALIC PATIENTS;ADVANCED STAGE;ALKALINE PHOSPHATASE;ASPIRATION BIOPSY;CANCER PATIENTS;CANCER SCREENING;CELL DEATH;CLINICAL RISK;CORRECTION COMMON;DIFFERENTIAL DIAGNOSIS;EPSTEINBARR VIRUS;ESOPHAGEAL CANCER;GLIOBLASTOMA MULTIFORME","14;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","BREAST CANCER;CANCER RISK;PROTEIN EXPRESSION;TACROLIMUS QD;ALLELE HR;ANALYSIS REVEALED;ATR PROTEIN;BRCA MUTATION;CI -P;GERMLINE MUTATIONS;HCC CANDIDATES;PATIENTS UNDERWENT;PRIMARY TRANSPLANTATION;RESECTED PATIENTS;TELOMERE LENGTH;BRAF VE;BRAFVE MUTATION;CDA ACTIVITY;CELL DEATH;COMPLETION RATE;DEEP SEDATION;ESOPHAGEAL CANCER;GENETIC VARIANTS;MIR- EXPRESSION;RET MUTATIONS;SCREENING PROGRAMMES;TAK LPC-KO;TUMOR SUPPRESSOR;CANCER RISKS;CELLULAR PROLIFERATION","23;10;8;7;6;6;6;6;6;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5;5;5;4;4",31,0.23,7.5,3,1,1,1,22,8.5,1,3.25,3.5,0,1,2.5,0,2,0,1,3,1,0,0,72.5,73,3,0,0,4,0,0,0,0,0,0,0,0,4,0,0,8,3.75,4.98,5.5,1,4,1,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"VIOLA ANTONELLA;BRONTE ENZO;BRONTE VINCENZO;CROSETTI MARCO;FRUTTERO ROBERTA;GASCO ALBERTO;LAZZARATO LORETTA","3;2;2;2;2;2;2","HUMANITAS MIRASOLE SPA;VIOLA ANTONELLA;BRONTE ENZO;BRONTE VINCENZO;CROSETTI MARCO;FRUTTERO ROBERTA;GASCO ALBERTO;ISTITUTO ONCOLOGICO VENETO;ISTITUTO ONCOLOGICO VENETO IRC;LAZZARATO LORETTA","3;3;2;2;2;2;2;2;2;2","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3204 IMMUNOLOGY;34 CHEMICAL SCIENCES;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY","6;2;1;1;1;1","HEMATOLOGY","1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","1","A61K31/4245;A61P35/00;A61P35/04;C07D271/10;C07D498/04;A61K35/28;A61K38/00;A61P37/06;C07K14/52;C07K16/24","2;2;2;2;2;1;1;1;1;1","A61P29/00;A61P31/00;A61P35/00;A61P35/04;A61P37/04;C07D271/10;C07D498/04;A61K35/28;A61P37/06;C07K14/521","2;2;2;2;2;2;2;1;1;1",5,4.75,1107,3.42,0,0,26.2,0,0,2,0,2,0,0,1,0,5,0,0,0,0,0,0,0,4,1,0,4,0,0,1,0,0,0,0,0,0,"Italy","3","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;4206 PUBLIC HEALTH","5;4;3;1;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DIGESTIVE DISEASES;COLO-RECTAL CANCER;RARE DISEASES;AGING;LUNG;PREVENTION","5;5;5;3;2;2;1;1;1","CANCER","5","6.1 PHARMACEUTICALS","4","COLON AND RECTAL CANCER;LUNG CANCER;SARCOMA;STOMACH CANCER","2;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING","3;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,6,"PUBLIC LIBRARY OF SCIENCE","6","31 BIOLOGICAL SCIENCES;3105 GENETICS;32 BIOMEDICAL AND CLINICAL SCIENCES;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;42 HEALTH SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;4203 HEALTH SERVICES AND SYSTEMS","11;4;4;3;3;2;1","GENETICS;BREAST CANCER;CANCER;PREVENTION;CLINICAL RESEARCH;DIABETES;HUMAN GENOME","4;2;2;2;1;1;1","CANCER","2","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.6 RESOURCES AND INFRASTRUCTURE (AETIOLOGY)","1;1",NA,NA,"CLINICAL MEDICINE AND SCIENCE","2","BREAST CANCER","2",NA,NA
"IRCCS_IOV",2011,140,11.1714285714286,2.77857142857143,0.359897172236504,0.385714285714286,0.357142857142857,0.192857142857143,0.385714285714286,2,76,31,14,11,0.54,0.22,0.1,0.08,55.33,1.30079931648485,0.328571428571429,0.95,NA,0.46584643544277,0.359453781512605,0.418992718446602,0.375352112676056,"MARCO SCARPA;MASSIMO RUGGE;CESARE RUFFOLO;GIUSEPPE OPOCHER;VINCENZO BRONTE;GIORGIO BATTAGLIA;IMERIO ANGRIMAN;ERMANNO ANCONA;PAOLA ZANOVELLO;CATERINA MIAN;STEFANO INDRACCOLO;CLAUDIA MESCOLI;ANTONIO JIRILLO;MARIA ROSA PELIZZO;PATRIZIA PONTISSO;ANGELO GATTA;VINCENZO CIMINALE;VITTORINA ZAGONEL;ALBERTO RUOL;MARCO MONTAGNA","12;11;9;8;7;7;7;7;6;6;6;6;6;6;5;5;5;5;5;5","ANGELO CLAUDIO PALOZZO;LAURA EVANGELISTA;MARCO SCARPA;ANTONIO JIRILLO;MASSIMO RUGGE;GIORGIO BATTAGLIA;ROBERTA DI TURI;CESARE RUFFOLO;GIUSEPPE OPOCHER;IMERIO ANGRIMAN;ERMANNO ANCONA;GIUSEPPE LOMBARDI;VINCENZO BRONTE;ANTONELLA BRUNELLO;PAOLA ZANOVELLO;MARIA ROSA PELIZZO;STEFANO REALDON;GUIDO SOTTI;MATTEO FASSAN;FABLE ZUSTOVICH","2.25;1.47;1.33;1.24;1.22;1.03;1;0.96;0.81;0.73;0.68;0.67;0.67;0.66;0.65;0.65;0.62;0.62;0.62;0.62","MARCO SCARPA;MASSIMO RUGGE;GIUSEPPE OPOCHER;VINCENZO BRONTE;GIORGIO BATTAGLIA;ERMANNO ANCONA;PAOLA ZANOVELLO;STEFANO INDRACCOLO;ANTONIO JIRILLO;VINCENZO CIMINALE;VITTORINA ZAGONEL;MARCO MONTAGNA;RAFAEL MORALES;CRISTIAN TURATO;FABLE ZUSTOVICH;LIDIA MOSERLE;MATTEO CAGOL;STEFANO REALDON;ADOLFO FAVARETTO;FEDERICA VIANELLO","12;11;8;7;7;7;6;6;6;5;5;5;4;4;4;4;4;4;4;4","ANGELO CLAUDIO PALOZZO;LAURA EVANGELISTA;MARCO SCARPA;ANTONIO JIRILLO;MASSIMO RUGGE;GIORGIO BATTAGLIA;GIUSEPPE OPOCHER;ERMANNO ANCONA;GIUSEPPE LOMBARDI;VINCENZO BRONTE;ANTONELLA BRUNELLO;PAOLA ZANOVELLO;STEFANO REALDON;GUIDO SOTTI;FABLE ZUSTOVICH;VINCENZO CIMINALE;VITTORINA ZAGONEL;ANITA DE ROSSI;CHIARA TRENTIN;G. DIAMANTIS","2.25;1.47;1.33;1.24;1.22;1.03;0.81;0.68;0.67;0.67;0.66;0.65;0.62;0.62;0.62;0.61;0.61;0.51;0.5;0.5","ANTONIO ROSATO;GIUSEPPE BASSO;CHIARA FRASSON;A. PARENTI;ALESSANDRO POLETTI;FRANCESCA ZANCONATO;LUCA AZZOLIN;MARCO MONTAGNER;MARIA GRAZIA DAIDONE;MASAFUMI INUI;MATTIA FORCATO;MICHELANGELO CORDENONSI;SILVIO BICCIATO;SIRIO DUPONT;STEFANO PICCOLO;VINCENZO BRONTE;GIUSEPPE OPOCHER;SARA LONARDI;ANDREA BONETTI;A. TAGLIAGAMBE","1833;1810;1439;1219;1219;1219;1219;1219;1219;1219;1219;1219;1219;1219;1219;1185;1136;875;747;723","ANTONIO ROSATO;VINCENZO BRONTE;GIUSEPPE OPOCHER;SARA LONARDI;A. TAGLIAGAMBE;ANDREA BONETTI;ANNA MARIA BOCHICCHIO;C. ASCHELE;CARMINE PINTO;DOMENICO CORSI;GABRIELE LUPPI;GERARDO ROSATI;GERMANA CHIAULON;GIOVANNI AMBROSINI;GIOVANNI SILVANO;L. CIONINI;LUCA BONI;MARIA CHIARA TRONCONI;MARIA EMANUELA NEGRU;MAURIZIO GALLO","1833;1185;1136;875;723;723;723;723;723;723;723;723;723;723;723;723;723;723;723;723","MARCO SCARPA;GIUSEPPE OPOCHER;VINCENZO BRONTE;PAOLA ZANOVELLO;STEFANO INDRACCOLO;ANTONIO JIRILLO;MARCO MONTAGNA;VINCENZO CIMINALE;VITTORINA ZAGONEL;GIORGIO BATTAGLIA;ADOLFO FAVARETTO;ANGELO CLAUDIO PALOZZO;ANITA DE ROSSI;ANTONELLA BRUNELLO;ANTONIO ROSATO;CARLO CASTORO;CRISTIAN TURATO;FABLE ZUSTOVICH;FEDERICA VIANELLO;GIUSEPPE LOMBARDI","12;8;7;6;6;6;5;5;5;5;4;4;4;4;4;4;4;4;4;4","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;PSYCHOLOGY;ECONOMICS;ENGINEERING;PHILOSOPHY;BUSINESS;ENVIRONMENTAL SCIENCE;MATHEMATICS;POLITICAL SCIENCE;SOCIOLOGY","116;51;11;10;7;6;3;2;2;1;1;1;1;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;GENETICS;CANCER RESEARCH;PATHOLOGY;GASTROENTEROLOGY;BIOCHEMISTRY;IMMUNOLOGY;RADIOLOGY;CELL BIOLOGY;ENDOCRINOLOGY;VIROLOGY;ENVIRONMENTAL HEALTH;NUCLEAR MEDICINE;CLINICAL PSYCHOLOGY;FAMILY MEDICINE;PALEONTOLOGY;PHYSICAL THERAPY;UROLOGY","97;40;37;35;34;30;28;20;20;17;16;10;9;8;6;5;5;5;5;5","CANCER;GENE;DISEASE;CHEMOTHERAPY;IMMUNE SYSTEM;HEPATOCELLULAR CARCINOMA;IMMUNOHISTOCHEMISTRY;POPULATION;VIRUS;CARCINOMA;RADIATION THERAPY;THYROID;ESOPHAGUS;BIOPSY;CLINICAL TRIAL;COHORT;IN VITRO;LUNG CANCER;POSITRON EMISSION TOMOGRAPHY;RECEPTOR","63;30;21;16;10;9;9;9;9;8;8;8;7;6;6;6;6;6;6;6","BREAST CANCER;COLORECTAL CANCER;MUTATION;ADENOCARCINOMA;ALLELE;CARCINOGENESIS;THYROID CARCINOMA;ULCERATIVE COLITIS;CD8;ESOPHAGEAL CANCER;GENE EXPRESSION;INFLAMMATORY BOWEL DISEASE;THYROID CANCER;INTESTINAL METAPLASIA;OVARIAN CANCER;PHENOTYPE;RNA;SORAFENIB;CHEMORADIOTHERAPY;CISPLATIN;CLINICAL ENDPOINT;DOWNREGULATION AND UPREGULATION;EPIDERMAL GROWTH FACTOR RECEPTOR;FLUORODEOXYGLUCOSE;GEMCITABINE;GERMLINE;IMMUNOTHERAPY;LIVER TRANSPLANTATION;MESSENGER RNA;MICRORNA;PET-CT;PHASES OF CLINICAL RESEARCH;REFLUX;TRANSFECTION","19;11;10;7;6;6;6;6;5;5;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","GERMLINE MUTATION;BARRETT'S ESOPHAGUS;GERD;MICROARRAY ANALYSIS TECHNIQUES;MICROSATELLITE;POUCHITIS;PROCTOCOLECTOMY;RNA SPLICING;CARBOPLATIN;CTL*;ESOPHAGECTOMY;ESOPHAGITIS;ESTROGEN RECEPTOR;HAPLOTYPE;MEDULLARY CARCINOMA;MEDULLARY THYROID CANCER;MICROARRAY;MODEL FOR END-STAGE LIVER DISEASE;MYELOID-DERIVED SUPPRESSOR CELL;NEOADJUVANT THERAPY;OXALIPLATIN;PAPILLARY THYROID CANCER","6;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;MALE;AGED;MIDDLE AGED;ADULT;BREAST NEOPLASMS;;THYROID NEOPLASMS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ADENOCARCINOMA;CARCINOMA, SQUAMOUS CELL;AGED, 80 AND OVER;RNA, MESSENGER;BIOMARKERS, TUMOR;LIVER NEOPLASMS;RETROSPECTIVE STUDIES;COLORECTAL NEOPLASMS;ITALY;NEOPLASMS","99;70;62;53;52;43;39;38;33;32;31;25;23;22;21;19;19;17;17;16","HUMAN T-CELL LEUKEMIA VIRUS TYPE 1 INFECTION;PREOPERATIVE CHEMORADIOTHERAPY FOR ESOPHAGEAL CANCER;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;ADVANCEMENTS IN LUNG CANCER RESEARCH;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;MACROPHAGE ACTIVATION AND POLARIZATION;METABOLIC REPROGRAMMING IN CANCER BIOLOGY;PHEOCHROMOCYTOMA AND PARAGANGLIOMA;POSITRON EMISSION TOMOGRAPHY IMAGING IN ONCOLOGY;BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH;COLORECTAL CANCER RESEARCH AND TREATMENT;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;HEPATOCELLULAR CARCINOMA;SARCOMA RESEARCH AND TREATMENT;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;ESOPHAGEAL INTERVENTION TECHNIQUES;FRAILTY IN OLDER ADULTS AND GERIATRIC CARE;GLIOMAS;HELICOBACTER PYLORI INFECTION AND GASTRIC CANCER;LIVER CIRRHOSIS AND ASSOCIATED COMPLICATIONS","6;6;5;4;4;4;4;4;4;3;3;3;3;3;2;2;2;2;2;2","BARRETT'S ESOPHAGUS;BREAST CANCER;PET IMAGING;CANCER RISK;HEPATOCELLULAR CARCINOMA;HTLV-1;MEDULLARY THYROID CANCER;INTESTINAL METAPLASIA;METAPLASIA;SURGICAL ONCOLOGY;TREATMENT;CANCER CELL METABOLISM;CANCER SUSCEPTIBILITY;CHEMORADIOTHERAPY;CLINICAL ENDPOINT;FLUORODEOXYGLUCOSE;METASTATIC COLORECTAL CANCER;MYELOID-DERIVED SUPPRESSOR CELLS;NEOADJUVANT THERAPY;PET-CT","7;6;6;5;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3","BREAST CANCER;CANCER PATIENTS;THYROID CARCINOMA;HEPATOCELLULAR CARCINOMA;CELL CARCINOMA;LUNG CANCER;MEDULLARY THYROID;PHASE II;RECTAL CANCER;LIVER TRANSPLANTATION;MICRORNA EXPRESSION;RENAL CELL;SQUAMOUS CELL;SUPPRESSOR CELLS;BARRETTS ESOPHAGUS;BRCA MUTATION;CELL CANCER;CELL LUNG;CHRONICRELAPSING POUCHITIS;CLINICAL SETTINGS;CONGENITAL ESOPHAGEAL;DIMENSIONAL EUS;ELDERLY PATIENTS;ENTERAL NUTRITION;ESOPHAGEAL ADENOCARCINOMA;ESOPHAGEAL STENOSIS;FOLLICULAR THYROID;HUMAN IMMUNODEFICIENCY;HUMAN T-CELL;II STUDY","14;10;6;5;4;4;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","BREAST CANCER;ANTIVIRAL TREATMENT;ELDERLY PATIENTS;HAFS CELLS;AFP MRNA;CANCER PATIENTS;HCC LESIONS;LESIONS MM;MULTIVARIATE ANALYSIS;NEGATIVE PROGNOSTIC;PROGNOSTIC FACTORS;DISEASE PROGRESSION;GROWTH FACTOR;RECTAL CANCER;TTP IPI;ANTI-VEGF THERAPY;AURORA KINASES;CCA CELLS;CELL LINES;CIRRHOTIC RATS;DSS SUBCUTANEOUS;FACTOR RECEPTOR;HOME CARE;IKRASI MUTATION;IMMUNE ACTIVATION;LATE EVENTS;MBC PATIENTS;MICRORNA EXPRESSION;PARATHYROID CANCER;POOR PROGNOSIS","13;8;7;7;6;6;6;6;6;6;6;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4",29,0.21,6,3,2,1,0,1.75,4.5,1,1,4,0,1,3,0,2.5,1.75,1,2,2,0,0,129,129,2,0,1,1,0,0,0,0,0,0,0,0,2,0,0,5,6,3.08,5,0,2,2,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"BRONTE ENZO;CROSETTI MARCO;FRUTTERO ROBERTA;GASCO ALBERTO;LAZZARATO LORETTA;VIOLA ANTONELLA","2;2;2;2;2;2","HUMANITAS MIRASOLE SPA;ISTITUTO ONCOLOGICO VENETO IRCCS;BRONTE ENZO;CROSETTI MARCO;FRUTTERO ROBERTA;GASCO ALBERTO;LAZZARATO LORETTA;VIOLA ANTONELLA","2;2;1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS","4;2","VACCINE RELATED","1","5.1 PHARMACEUTICALS","1","A61K31/4245;A61P29/00;A61P35/00;C07D271/08","2;1;1;1","A61K31/4245;A61P29/00;A61P31/00;A61P35/00;C07D271/08;C07D271/10;C07D498/04","1;1;1;1;1;1;1",12,8.67,929.55,5.74,2,0.17,33.42,0,0,5,0,4,0,0,3,0,8,3,0,0,0,0,0,0,11,1,0,10,1,0,0,0,0,0,0,1,0,"Italy","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;4205 NURSING","12;11;4;2;1;1","CANCER;CLINICAL RESEARCH;RARE DISEASES;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;ORPHAN DRUG;DIGESTIVE DISEASES;HEMATOLOGY;LUNG;LUNG CANCER;LYMPHOMA;AGING;BIOTECHNOLOGY;CHRONIC LIVER DISEASE AND CIRRHOSIS;COLO-RECTAL CANCER;GENETICS;LIVER CANCER;LIVER DISEASE;OVARIAN CANCER;PATIENT SAFETY","10;10;8;6;4;3;2;2;2;2;1;1;1;1;1;1;1;1;1","CANCER","8","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES","8;1;1;1","LIVER CANCER;LUNG CANCER;NON-HODGKIN'S LYMPHOMA;COLON AND RECTAL CANCER;EAR CANCER;GALLBLADDER CANCER;HEAD AND NECK CANCER;LARYNGEAL CANCER;MELANOMA;NASAL CAVITY AND PARANASAL SINUS CANCER;ORAL CAVITY AND LIP CANCER;OVARIAN CANCER;PHARYNGEAL CANCER;SALIVARY GLAND CANCER;SARCOMA","2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING","7;1;1",1,477625,68232.14,4,7,2,1,44,17058.0357142857,8.2072755823083,"IMPERIAL COLLEGE LONDON;ISTITUTO ONCOLOGICO VENETO;KING'S COLLEGE LONDON;MERCK (UNITED KINGDOM);ROYAL VETERINARY COLLEGE;UNIVERSITY COLLEGE LONDON;UNIVERSITY OF PADUA","1;1;1;1;1;1;1","BIOTECHNOLOGY AND BIOLOGICAL SCIENCES RESEARCH COUNCIL","1","COALITION S;ICRP - INTERNATIONAL CANCER RESEARCH PARTNERSHIP;UKRI - UK RESEARCH AND INNOVATION","1;1;1","RESEARCH GRANT (PROJECT CATEGORY)","1","31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY","1;1",NA,NA,"GENERIC HEALTH RELEVANCE","1","1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","1;1","NOT SITE-SPECIFIC CANCER","1","1.1 NORMAL FUNCTIONING;1.3 CANCER INITIATION: ONCOGENES AND TUMOR SUPPRESSOR GENES;1.4 CANCER PROGRESSION AND METASTASIS","1;1;1","A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY","1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_IOV",2012,184,12,2.76086956521739,0.362204724409449,0.315217391304348,0.33695652173913,0.157608695652174,0.483695652173913,3,117,33,19,6,0.64,0.18,0.1,0.03,45.5,1.08934196656207,0.385869565217391,0.956521739130435,6.4490106544901,0.540988235534008,0.43451536643026,0.485673057101629,0.401086956521739,"MASSIMO RUGGE;VITTORINA ZAGONEL;SARA LONARDI;MATTEO FASSAN;DONATO NITTI;FRANCESCA BERGAMO;VANNA CHIARION‐SILENI;CARLO RICCARDO ROSSI;LAURA EVANGELISTA;ANTONIO JIRILLO;MARCO PIZZI;ALFREDO FALCONE;STEFANO INDRACCOLO;MARTA SCHIRRIPA;FOTIOS LOUPAKIS;FABIO POMERRI;ADOLFO FAVARETTO;UMBERTO BASSO;SALVATORE PUCCIARELLI;UMBERTO CILLO","18;18;16;14;11;10;10;9;9;8;8;7;7;7;7;7;7;7;6;6","LAURA EVANGELISTA;ANTONIO JIRILLO;ANGELO CLAUDIO PALOZZO;VITTORINA ZAGONEL;STEFANO INDRACCOLO;MASSIMO RUGGE;SILVIA IMBEVARO;MATTEO FASSAN;SARA LONARDI;DONATO NITTI;VANNA CHIARION‐SILENI;CARLO RICCARDO ROSSI;MARTA PAULINA TROJNIAK;FABIO POMERRI;P. RESCIGNO;FRANCESCA BERGAMO;CARLO CASTORO;MARCO PIZZI;PIER CARLO MUZZIO;GIORGIO SALADINI","2.1;1.8;1.75;1.75;1.7;1.65;1.42;1.4;1.3;1.16;0.94;0.89;0.85;0.83;0.83;0.8;0.77;0.76;0.74;0.73","MASSIMO RUGGE;VITTORINA ZAGONEL;SARA LONARDI;MATTEO FASSAN;DONATO NITTI;FRANCESCA BERGAMO;VANNA CHIARION‐SILENI;CARLO RICCARDO ROSSI;LAURA EVANGELISTA;ANTONIO JIRILLO;STEFANO INDRACCOLO;FABIO POMERRI;ADOLFO FAVARETTO;UMBERTO BASSO;SALVATORE PUCCIARELLI;L CAMPANA;GIUSEPPE OPOCHER;ANTONIO ROSATO;SILVIA IMBEVARO;CARLO CASTORO","18;18;16;14;11;10;10;9;9;8;7;7;7;7;6;6;6;6;6;6","LAURA EVANGELISTA;ANTONIO JIRILLO;ANGELO CLAUDIO PALOZZO;VITTORINA ZAGONEL;STEFANO INDRACCOLO;MASSIMO RUGGE;SILVIA IMBEVARO;MATTEO FASSAN;SARA LONARDI;DONATO NITTI;VANNA CHIARION‐SILENI;CARLO RICCARDO ROSSI;MARTA PAULINA TROJNIAK;FABIO POMERRI;P. RESCIGNO;FRANCESCA BERGAMO;CARLO CASTORO;PIER CARLO MUZZIO;GIORGIO SALADINI;SARA VALPIONE","2.1;1.8;1.75;1.75;1.7;1.65;1.42;1.4;1.3;1.16;0.94;0.89;0.85;0.83;0.83;0.8;0.77;0.74;0.73;0.7","VANNA CHIARION‐SILENI;PIOTR RUTKOWSKI;ANNE-MARIE MARTIN;AXEL HAUSCHILD;BELOO MIRAKHUR;BOGUSŁAWA KARASZEWSKA;CHRISTIAN U. BLANK;CORNELIA MAUCH;ECKHART KAEMPGEN;JEAN‐JACQUES GROB;LEV DEMIDOV;MARY GUCKERT;MICHAEL MILLWARD;PATRICIA HANEY;PAUL B. CHAPMAN;RALF GUTZMER;S. SWANN;SALVADOR MARTÍN‐ALGARRA;THOMAS JOUARY;VICKI GOODMAN","3073;2888;2839;2839;2839;2839;2839;2839;2839;2839;2839;2839;2839;2839;2839;2839;2839;2839;2839;2839","VANNA CHIARION‐SILENI;MARCO MONTAGNA;SIMONA AGATA;MASSIMO RUGGE;ANTONIO ROSATO;CARLO RICCARDO ROSSI;SARA LONARDI;DAVIDE PASTORELLI;STEFANO INDRACCOLO;FRANCESCA BERGAMO;EMANUELA FADDA;ELISA PERANZONI;MARIACRISTINA CHIODA;STEFANO UGEL;SUSANNA MANDRUZZATO;GAETANO LOMBARDI;VITTORINA ZAGONEL;UMBERTO BASSO;GIUSEPPE OPOCHER;ANNAROSA DEL MISTRO","3073;649;559;438;428;369;363;309;278;274;236;200;200;200;200;198;194;189;185;172","VITTORINA ZAGONEL;SARA LONARDI;MASSIMO RUGGE;VANNA CHIARION‐SILENI;FRANCESCA BERGAMO;ANTONIO JIRILLO;STEFANO INDRACCOLO;CARLO RICCARDO ROSSI;LAURA EVANGELISTA;UMBERTO BASSO;ADOLFO FAVARETTO;PIER CARLO MUZZIO;ANTONIO ROSATO;CARLO CASTORO;FABIO POMERRI;SILVIA IMBEVARO;GIORGIO BATTAGLIA;ANGELO CLAUDIO PALOZZO;ANTONELLA VECCHIATO;MARCO MONTAGNA","17;16;11;10;10;8;7;7;7;7;7;6;6;6;6;6;5;5;5;5","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;MATHEMATICS;PHILOSOPHY;SOCIOLOGY;COMPUTER SCIENCE;ECONOMICS;POLITICAL SCIENCE;PSYCHOLOGY;ENGINEERING;GEOGRAPHY;BUSINESS;MATERIALS SCIENCE;HISTORY","170;76;19;13;6;6;6;5;5;4;4;3;3;2;2;1","INTERNAL MEDICINE;ONCOLOGY;CANCER RESEARCH;SURGERY;PATHOLOGY;GASTROENTEROLOGY;GENETICS;RADIOLOGY;BIOCHEMISTRY;PALEONTOLOGY;IMMUNOLOGY;NUCLEAR MEDICINE;ENVIRONMENTAL HEALTH;OPTICS;ENDOCRINOLOGY;FAMILY MEDICINE;CELL BIOLOGY;GYNECOLOGY;MEDICAL PHYSICS;PHARMACOLOGY","145;73;50;47;44;37;31;20;18;17;15;15;14;13;12;12;9;9;7;7","CANCER;CHEMOTHERAPY;GENE;IMMUNOHISTOCHEMISTRY;DISEASE;MELANOMA;POPULATION;RETROSPECTIVE COHORT STUDY;CONFIDENCE INTERVAL;STAGE (STRATIGRAPHY);CLINICAL TRIAL;INCIDENCE (GEOMETRY);RANDOMIZED CONTROLLED TRIAL;IMMUNE SYSTEM;LUNG CANCER;RADIATION THERAPY;TOXICITY;ADVERSE EFFECT;HEPATOCELLULAR CARCINOMA;SARCOMA;TRANSPLANTATION","107;34;32;15;14;14;14;13;12;12;11;11;11;9;9;9;9;8;7;7;7","COLORECTAL CANCER;BREAST CANCER;CLINICAL ENDPOINT;HAZARD RATIO;MUTATION;OVARIAN CANCER;ADENOCARCINOMA;BEVACIZUMAB;GENE EXPRESSION;METASTASIS;EPIDERMAL GROWTH FACTOR RECEPTOR;IMMUNOTHERAPY;PHASES OF CLINICAL RESEARCH;GENOTYPE;NEUTROPENIA;SORAFENIB;ESOPHAGEAL CANCER;THYROID CARCINOMA;CARCINOGENESIS;LIVER TRANSPLANTATION;PROSTATE CANCER;SOFT TISSUE SARCOMA;SUNITINIB;UNIVARIATE ANALYSIS","29;27;10;9;9;9;8;8;8;8;7;7;7;6;6;6;5;5;4;4;4;4;4;4","OXALIPLATIN;GERMLINE MUTATION;IPILIMUMAB;IRINOTECAN;FEBRILE NEUTROPENIA;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;SINGLE-NUCLEOTIDE POLYMORPHISM;TRASTUZUMAB;BRCA MUTATION;CAPECITABINE;ERLOTINIB;IN SITU HYBRIDIZATION;INTRAEPITHELIAL NEOPLASIA;KRAS;METASTATIC BREAST CANCER;NEOADJUVANT THERAPY;AMPK;BARRETT'S ESOPHAGUS;CIRCULATING TUMOR CELL;COLONOSCOPY;DNA METHYLATION;ELECTROCHEMOTHERAPY;ESOPHAGEAL ADENOCARCINOMA;ESTROGEN RECEPTOR;GATED SPECT;HAPLOTYPE;MEDULLARY CARCINOMA;MODEL FOR END-STAGE LIVER DISEASE;PEMETREXED;PROSTATE DISEASE;SENTINEL NODE","10;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;MALE;;MIDDLE AGED;AGED;ADULT;AGED, 80 AND OVER;ADENOCARCINOMA;BREAST NEOPLASMS;ITALY;ANTINEOPLASTIC AGENTS;ESOPHAGEAL NEOPLASMS;COLORECTAL NEOPLASMS;BIOMARKERS, TUMOR;MELANOMA;NEOPLASM RECURRENCE, LOCAL;NEOPLASM STAGING;NEOPLASMS;STOMACH NEOPLASMS","109;82;75;71;67;63;50;32;30;30;30;29;27;26;22;22;19;19;19;18","ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;SARCOMA RESEARCH AND TREATMENT;ADVANCEMENTS IN LUNG CANCER RESEARCH;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;HER2 SIGNALING IN BREAST CANCER TREATMENT;MELANOMA;POSITRON EMISSION TOMOGRAPHY IMAGING IN ONCOLOGY;COLORECTAL CANCER RESEARCH AND TREATMENT;PREOPERATIVE CHEMORADIOTHERAPY FOR ESOPHAGEAL CANCER;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;CANCER STEM CELLS AND TUMOR METASTASIS;CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY;ECONOMIC BURDEN OF CANCER TREATMENT;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;GLIOMAS;HEALTH ECONOMICS AND QUALITY OF LIFE ASSESSMENT;HEPATOCELLULAR CARCINOMA;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER","8;8;7;7;5;5;5;4;4;3;3;3;3;3;3;3;3;3;3;3","BREAST CANCER;CLINICAL ENDPOINT;MELANOMA;METASTATIC COLORECTAL CANCER;SOFT TISSUE SARCOMA;CANCER SUSCEPTIBILITY;OXALIPLATIN;TREATMENT;CANCER CELL METABOLISM;CANCER RISK;NON-SMALL CELL LUNG CANCER;BARRETT'S ESOPHAGUS;CANCER IMAGING;EXPANDED ACCESS;FOLFIRI;FOLFOX;HER2;NEOADJUVANT THERAPY;PET/CT;REGIMEN","13;10;8;7;7;6;6;6;5;5;5;4;4;4;4;4;4;4;4;4","BREAST CANCER;COLORECTAL CANCER;CANCER PATIENTS;PHASE II;ELDERLY PATIENTS;LUNG CANCER;FIRST-LINE TREATMENT;CELL CARCINOMA;CELL LUNG;METASTATIC COLORECTAL;NON-SMALL CELL;OVARIAN CANCER;PATIENTS PTS;SOFT TISSUE;ACCESS PROGRAMME;ADVANCED MELANOMA;ADVANCED NON-SMALL;ESOPHAGEAL CANCER;EXPANDED ACCESS;LOCALLY ADVANCED;PROGRAMME EAP;RANDOMIZED TRIAL;THYROID CARCINOMA;CANCER NSCLC;EMISSION TOMOGRAPHYCOMPUTED;FACTORIAL PHASE;FIRST-LINE FOLFIRI;GROWTH FACTOR;HEPATOCELLULAR CARCINOMA;II RANDOMIZED","14;14;10;8;7;7;6;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3","BREAST CANCER;BRISTOL-MYERS SQUIBB;ADVERSE EVENTS;MIR- -FOLD;MIR- MIR-;BRCA MUTATIONS;CANCER PATIENTS;CONFIDENCE INTERVAL;CLINICAL PRACTICE;DISEASE CONTROL;MEDIAN FOLLOW-UP;CANCER RISK;MEDIAN OS;MERCK SHARP;MUTATION CARRIERS;OVARIAN CANCER;SHARP DOHME;BRCA MUTATION;COLORECTAL CANCER;COMPLETE RESPONSE;GROWTH FACTOR;RECEIVED HONORARIA;ROCHE GLAXOSMITHKLINE;HR CI;PARTIAL RESPONSE;PATIENTS TREATED;PROGRESSION-FREE SURVIVAL;STABLE DISEASE;ABSTRACT PURPOSE;BRCA CARRIERS","27;17;14;14;14;13;12;12;11;11;11;10;10;10;10;10;10;9;9;9;9;9;9;8;8;8;8;8;7;7",57,0.31,4,4,1,1.75,0,2.25,4,0,2,4,0,1,3,0,1,1,2,2.5,1,0,0,73,73,2,1,1,0,0,0,0,0,1,0,0,0,3,0,0,6,3.33333333333333,1.97,1.33333333333333,0,1,2,0,0,1,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"BRONTE VINCENZO;MANDRUZZATO SUSANNA;BRONTE ENZO;CROSETTI MARCO;FRUTTERO ROBERTA;GASCO ALBERTO;LAZZARATO LORETTA;VIOLA ANTONELLA","2;2;1;1;1;1;1;1","ISTITUTO ONCOLOGICO VENETO IRCCS;HUMANITAS MIRASOLE SPA","3;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS","6;3","HEMATOLOGY;CANCER;VACCINE RELATED","2;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","2","A61K35/28;A61K31/4245;A61K31/4439;A61K35/12;A61K39/39;A61P29/00;A61P31/00;A61P35/00;A61P37/04;A61P37/06","2;1;1;1;1;1;1;1;1;1","A61K35/28;A61P37/06;C12N5/0647;A61P29/00;A61P31/00;A61P35/00;A61P35/04;A61P37/04;C07D271/10;C07D498/04","2;2;2;1;1;1;1;1;1;1",16,7.07,292.79,7.44,5,0.31,43.75,0,0,6,0,5,0,2,3,0,13,1,0,0,0,0,0,0,15,1,0,14,2,0,0,0,0,0,0,0,0,"Italy;Belgium;Germany;United States","3;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","15;14;9;2;1;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;LUNG;PATIENT SAFETY;LUNG CANCER;COLO-RECTAL CANCER;DIGESTIVE DISEASES;GENETICS;AGING;BEHAVIORAL AND SOCIAL SCIENCE;BIOTECHNOLOGY;BREAST CANCER;DENTAL/ORAL AND CRANIOFACIAL DISEASE;HEALTH SERVICES;HUMAN GENOME;NEUROSCIENCES;ORPHAN DRUG;OVARIAN CANCER","14;13;11;7;5;5;4;3;3;3;1;1;1;1;1;1;1;1;1;1","CANCER;ORAL AND GASTROINTESTINAL","14;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.4 SURGERY;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;7.2 END OF LIFE CARE","12;3;1;1;1;1","LUNG CANCER;COLON AND RECTAL CANCER;EAR CANCER;HEAD AND NECK CANCER;LARYNGEAL CANCER;MELANOMA;NASAL CAVITY AND PARANASAL SINUS CANCER;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER;SALIVARY GLAND CANCER;BREAST CANCER;NOT SITE-SPECIFIC CANCER;OVARIAN CANCER;PANCREATIC CANCER;SARCOMA","5;3;2;2;2;2;2;2;2;2;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.6 END-OF-LIFE CARE","11;3;2;2;1;1;1",2,7e+06,619047.62,5.5,11.5,7.5,1,32,245629.464285714,0.749095799785536,"ISTITUTO ONCOLOGICO VENETO;AQUAMARIJN (NETHERLANDS);ASPER BIOTECH (ESTONIA);ATOMIC ENERGY AND ALTERNATIVE ENERGIES COMMISSION;HANNOVER MEDICAL SCHOOL;HEINRICH HEINE UNIVERSITY DÜSSELDORF;INSTITUT GUSTAVE ROUSSY;INSTITUTE FOR RESEARCH IN BIOMEDICINE;LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN;ROCHE (SWITZERLAND);ROYAL MARSDEN HOSPITAL;SANOFI (FRANCE);UNIVERSITY COLLEGE CORK;UNIVERSITY COLLEGE DUBLIN;UNIVERSITY COLLEGE LONDON;UNIVERSITY OF ANGERS;UNIVERSITY OF SANTIAGO DE COMPOSTELA;UNIVERSITY OF TWENTE;UNIVERSITY OF TÜBINGEN;UNIVERSITÉ CATHOLIQUE DE LOUVAIN","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","2","COALITION S;EC & ERC - EUROPEAN UNION","2;2","CP-FP - SMALL OR MEDIUM-SCALE FOCUSED RESEARCH PROJECT (FUNDING SCHEME);CP-IP - LARGE-SCALE INTEGRATING PROJECT (FUNDING SCHEME);FP7-HEALTH - SPECIFIC PROGRAMME ""COOPERATION"": HEALTH (PROGRAMME);FP7-HEALTH-2012-INNOVATION-1 (CALL FOR PROPOSAL);FP7-NMP - SPECIFIC PROGRAMME ""COOPERATION"": NANOSCIENCES, NANOTECHNOLOGIES, MATERIALS AND NEW PRODUCTION TECHNOLOGIES (PROGRAMME);FP7-NMP-2011-LARGE-5 (CALL FOR PROPOSAL)","1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3204 IMMUNOLOGY;3206 MEDICAL BIOTECHNOLOGY;3211 ONCOLOGY AND CARCINOGENESIS","2;1;1;1","BIOENGINEERING;CANCER;CLINICAL RESEARCH;DIGESTIVE DISEASES;NANOTECHNOLOGY","1;1;1;1;1","CANCER","1","5.1 PHARMACEUTICALS","2","NOT SITE-SPECIFIC CANCER","1","1.4 CANCER PROGRESSION AND METASTASIS;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","1;1;1","A01 CLINICAL MEDICINE;A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY","1;1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_IOV",2013,211,13.563981042654,2.56872037914692,0.38929889298893,0.293838862559242,0.270142180094787,0.151658767772512,0.417061611374408,0,141,34,15,9,0.67,0.16,0.07,0.04,42.32,1.21293104295878,0.355450236966825,0.990521327014218,6.30970149253731,0.492492337679122,0.481336161187699,0.536551960280774,0.479366873940079,"VITTORINA ZAGONEL;VANNA CHIARION‐SILENI;UMBERTO BASSO;CARLO RICCARDO ROSSI;SARA LONARDI;ALFREDO FALCONE;FABLE ZUSTOVICH;FOTIOS LOUPAKIS;CHIARA CREMOLINI;ALESSANDRO TESTORI;LISA SALVATORE;ADOLFO FAVARETTO;MASSIMO RUGGE;FRANCESCA BERGAMO;PAOLO A. ASCIERTO;MARTA SCHIRRIPA;GIANLUCA MASI;GIOVANNI LO RE;CARLOTTA ANTONIOTTI;DONATO NITTI","27;22;18;16;16;14;13;13;13;12;12;11;10;10;10;10;10;9;9;8","VITTORINA ZAGONEL;VANNA CHIARION‐SILENI;CARLO RICCARDO ROSSI;UMBERTO BASSO;LAURA EVANGELISTA;PIERFRANCO CONTÉ;ALESSANDRO TESTORI;ADOLFO FAVARETTO;FABLE ZUSTOVICH;L CAMPANA;SARA LONARDI;IGNAZIO STANGANELLI;MASSIMO RUGGE;CARLO CASTORO;ALFREDO FALCONE;PAOLO A. ASCIERTO;GIUSEPPE LOMBARDI;MARCO RASTRELLI;ANTONELLA BRUNELLO;FOTIOS LOUPAKIS","2.27;1.97;1.89;1.8;1.54;1.28;1.14;1.01;1;0.96;0.94;0.92;0.9;0.87;0.82;0.8;0.75;0.75;0.74;0.73","VITTORINA ZAGONEL;VANNA CHIARION‐SILENI;UMBERTO BASSO;CARLO RICCARDO ROSSI;SARA LONARDI;FABLE ZUSTOVICH;ALESSANDRO TESTORI;ADOLFO FAVARETTO;MASSIMO RUGGE;FRANCESCA BERGAMO;PIERFRANCO CONTÉ;CARLO CASTORO;ANTONELLA BRUNELLO;LAURA EVANGELISTA;L CAMPANA;GIUSEPPE OPOCHER;GIUSEPPE LOMBARDI;CRISTINA FALCI;SARA VALPIONE;STEFANO INDRACCOLO","27;22;18;16;16;13;12;11;10;10;8;8;8;8;7;7;7;7;6;6","VITTORINA ZAGONEL;VANNA CHIARION‐SILENI;CARLO RICCARDO ROSSI;UMBERTO BASSO;LAURA EVANGELISTA;PIERFRANCO CONTÉ;ALESSANDRO TESTORI;ADOLFO FAVARETTO;FABLE ZUSTOVICH;L CAMPANA;SARA LONARDI;MASSIMO RUGGE;CARLO CASTORO;GIUSEPPE LOMBARDI;MARCO RASTRELLI;ANTONELLA BRUNELLO;SARA VALPIONE;CRISTINA FALCI;MARCO MARUZZO;ELEONORA CAPOVILLA","2.27;1.97;1.89;1.8;1.54;1.28;1.14;1.01;1;0.96;0.94;0.9;0.87;0.75;0.75;0.74;0.73;0.69;0.67;0.64","FEDERICA VIANELLO;VITTORINA ZAGONEL;PILAR SANTISTEBAN;AGNIESZKA CZARNIECKA;ALFRED K. LAM;ALI S. ALZAHRANI;BARBARA JARZĄB;BĚLA BENDLOVÁ;CATERINA MIAN;CHRISTINE J. O’NEILL;DAVID SIDRANSKY;DAVID VIOLA;DOUGLAS P. CLARK;EFISIO PUXEDDU;EYAL ROBENSHTOK;GARCILASO RIESCO‐EIZAGUIRRE;HIROTAKA NAKAYAMA;JAMES A. FAGIN;KATHRYN A. CARSON;LAURA FUGAZZOLA","876;859;857;847;847;847;847;847;847;847;847;847;847;847;847;847;847;847;847;847","FEDERICA VIANELLO;SARA LONARDI;VITTORINA ZAGONEL;VANNA CHIARION‐SILENI;STEFANO INDRACCOLO;VALERIA TOSELLO;ANTONIO ROSATO;MARCO MONTAGNA;ANTONELLA BRUNELLO;FRANCESCA BERGAMO;PAOLA ZANOVELLO;UMBERTO BASSO;MICHELE GREGIANIN;CARLO CASTORO;VITO BARBIERI;ERICH PIOVAN;CARLO RICCARDO ROSSI;GIUSEPPE OPOCHER;ALESSANDRO TESTORI;ALEXANDER M.M. EGGERMONT","876;822;802;711;644;642;603;506;376;365;348;331;292;290;263;246;238;231;224;224","VITTORINA ZAGONEL;VANNA CHIARION‐SILENI;UMBERTO BASSO;SARA LONARDI;CARLO RICCARDO ROSSI;ADOLFO FAVARETTO;FABLE ZUSTOVICH;FRANCESCA BERGAMO;PIERFRANCO CONTÉ;ANTONELLA BRUNELLO;LAURA EVANGELISTA;CRISTINA FALCI;CARLO CASTORO;GIUSEPPE OPOCHER;PASQUALE FIDUCCIA;STEFANO INDRACCOLO;L CAMPANA;MARCO RASTRELLI;ANTONIO ROSATO;JACOPO PIGOZZO","26;21;17;16;12;11;11;10;7;7;7;6;6;6;6;6;6;6;5;5","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;SOCIOLOGY;COMPUTER SCIENCE;MATHEMATICS;ECONOMICS;MATERIALS SCIENCE;ENGINEERING;HISTORY;PHILOSOPHY;PSYCHOLOGY;GEOGRAPHY;POLITICAL SCIENCE","198;80;16;14;10;6;4;3;3;2;2;2;2;1;1","INTERNAL MEDICINE;ONCOLOGY;CANCER RESEARCH;SURGERY;PATHOLOGY;GENETICS;GASTROENTEROLOGY;ENVIRONMENTAL HEALTH;BIOCHEMISTRY;RADIOLOGY;IMMUNOLOGY;PALEONTOLOGY;CELL BIOLOGY;NUCLEAR MEDICINE;OPTICS;UROLOGY;ENDOCRINOLOGY;PSYCHIATRY;DEMOGRAPHY;DERMATOLOGY;FAMILY MEDICINE;GYNECOLOGY;INTENSIVE CARE MEDICINE","170;97;61;59;47;36;33;25;24;24;22;16;15;14;13;12;11;8;7;7;7;7;7","CANCER;CHEMOTHERAPY;GENE;POPULATION;MELANOMA;LUNG CANCER;RANDOMIZED CONTROLLED TRIAL;RETROSPECTIVE COHORT STUDY;CONFIDENCE INTERVAL;DISEASE;RADIATION THERAPY;COHORT;STAGE (STRATIGRAPHY);ADVERSE EFFECT;CLINICAL TRIAL;INCIDENCE (GEOMETRY);TOXICITY;HEPATOCELLULAR CARCINOMA;IMMUNOHISTOCHEMISTRY;IMMUNE SYSTEM;RENAL CELL CARCINOMA;STEM CELL","132;56;42;25;19;18;17;17;16;16;16;14;14;13;12;11;10;9;9;8;8;8","BREAST CANCER;COLORECTAL CANCER;BEVACIZUMAB;CLINICAL ENDPOINT;PROSTATE CANCER;MUTATION;CISPLATIN;METASTASIS;GENOTYPE;HAZARD RATIO;DOCETAXEL;PHASES OF CLINICAL RESEARCH;IMMUNOTHERAPY;PROGRESSION-FREE SURVIVAL;GENE EXPRESSION;SUNITINIB;ADENOCARCINOMA;CARCINOGENESIS;CERVICAL CANCER;DOWNREGULATION AND UPREGULATION;ESOPHAGEAL CANCER;NEUTROPENIA;OVARIAN CANCER;PROSTATE;SORAFENIB;THYROID CANCER","45;34;16;16;14;13;12;12;9;9;8;8;7;7;6;6;5;5;5;5;5;5;5;5;5;5","IRINOTECAN;KRAS;OXALIPLATIN;PEMETREXED;SINGLE-NUCLEOTIDE POLYMORPHISM;ELECTROCHEMOTHERAPY;GERMLINE MUTATION;IPILIMUMAB;NEOADJUVANT THERAPY;PAPILLARY THYROID CANCER;ANDROGEN DEPRIVATION THERAPY;CARBOPLATIN;MAMMOGRAPHY;MASTECTOMY;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;TAMOXIFEN;BRCA MUTATION;CETUXIMAB;EPITHELIAL–MESENCHYMAL TRANSITION;HORMONAL THERAPY;METASTATIC BREAST CANCER;PRIMARY TUMOR;TRASTUZUMAB","8;8;8;7;6;5;5;5;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3","HUMANS;FEMALE;MALE;;MIDDLE AGED;AGED;BREAST NEOPLASMS;ADULT;MELANOMA;COLORECTAL NEOPLASMS;SKIN NEOPLASMS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ITALY;ANTINEOPLASTIC AGENTS;AGED, 80 AND OVER;ADENOCARCINOMA;TREATMENT OUTCOME;BIOMARKERS, TUMOR;FLUOROURACIL;LIVER NEOPLASMS","130;91;84;76;75;69;60;55;55;54;52;45;40;37;31;30;30;26;23;23","MELANOMA;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;ADVANCEMENTS IN LUNG CANCER RESEARCH;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;GLIOMAS;MALIGNANT PLEURAL MESOTHELIOMA RESEARCH;PREOPERATIVE CHEMORADIOTHERAPY FOR ESOPHAGEAL CANCER;RENAL CELL CARCINOMA;EPIDEMIOLOGY AND TREATMENT OF CHILDHOOD LEUKEMIA;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;APPLICATIONS OF ELECTROPORATION IN BIOTECHNOLOGY AND FOOD PROCESSING;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY;FRAILTY IN OLDER ADULTS AND GERIATRIC CARE;GLOBAL CANCER INCIDENCE AND MORTALITY PATTERNS;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;MALE BREAST CANCER AND GYNECOMASTIA RESEARCH;MAMMALIAN MAP KINASE SIGNALING PATHWAYS","15;12;7;6;6;6;6;6;6;5;5;5;4;4;3;3;3;3;3;3","MELANOMA;CLINICAL ENDPOINT;METASTATIC COLORECTAL CANCER;CANCER SUSCEPTIBILITY;BREAST CANCER;PEMETREXED;PROGRESSION-FREE SURVIVAL;REGIMEN;TREATMENT;METASTATIC BREAST CANCER;PET/CT;CANCER;CANCER INCIDENCE;CANCER RISK;ELECTROCHEMOTHERAPY;FOLFIRI;MEDULLARY THYROID CANCER;NEOADJUVANT THERAPY;BARRETT'S ESOPHAGUS;CANCER GENOMICS","17;16;13;12;11;7;7;7;7;6;6;5;5;5;5;5;5;5;4;4","BREAST CANCER;COLORECTAL CANCER;CANCER PATIENTS;PHASE II;METASTATIC COLORECTAL;PROSTATE CANCER;ELDERLY PATIENTS;LUNG CANCER;PATIENTS PTS;PATIENTS TREATED;PHASE III;CANCER MCRC;CELL CARCINOMA;II STUDY;RANDOMIZED PHASE;RENAL CELL;ACCESS PROGRAMME;CANCER CRPC;EXPANDED ACCESS;FIRST-LINE TREATMENT;METASTATIC RENAL;THYROID CANCER;CASTRATION-RESISTANT PROSTATE;CLINICAL OUTCOME;FINAL RESULTS;MELANOMA PATIENTS;MRNA EXPRESSION;NON-SMALL-CELL LUNG;OVARIAN CANCER;PLEURAL MESOTHELIOMA","23;22;21;14;13;9;8;8;7;7;7;6;6;6;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4","BREAST CANCER;COLORECTAL CANCER;TLR MICE;CANCER PATIENTS;CONFIDENCE INTERVAL;GENE EXPRESSION;HR CI;BRCA CARRIERS;BRCA MUTATION;MONTHS CI;PERIPHERAL BLOOD;CANCER RISK;LYMPH NODE;HR-HPV PREVALENCE;MEDIAN PFS;PATIENTS TREATED;CCA CELLS;MRNA EXPRESSION;MUTATION CARRIERS;OVARIAN CANCER;PLATINUM-BASED CHEMOTHERAPY;STAGE III;ACUTE MYELOID;BRAF VE;EXCISED LNS;INTERIM PET;MEDIAN FOLLOW-UP;METASTATIC COLORECTAL;MYELOID LEUKEMIA;PHASE II","32;14;14;13;13;12;12;11;11;11;11;10;10;9;9;9;8;8;8;8;8;8;7;7;7;7;7;7;7;7",71,0.34,6,4,1,1,0,1.25,7,0,1,4.5,0,1,3,0,3,1.25,1,2,1,0,0,90.5,90.5,3,0,2,2,0,0,0,1,0,0,0,0,2,1,2,0,6.8,6.27,2,0,4,3,0,0,1,0,0,2,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"BRONTE ENZO;CROSETTI MARCO;FRUTTERO ROBERTA;GASCO ALBERTO;LAZZARATO LORETTA;VIOLA ANTONELLA;BRONTE VINCENZO;CIMINALE VINCENZO;CORRADIN ALBERTO;D AGOSTINO DONNA MIA","4;4;4;4;4;4;1;1;1;1","HUMANITAS MIRASOLE SPA;ISTITUTO ONCOLOGICO VENETO IRCCS;CONSIGLIO NAZIONALE RICERCHE;ISTITUTO ONCOLOGICO VENETO;UNIV PADOVA","4;3;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS","6;3","VACCINE RELATED","2","5.1 PHARMACEUTICALS","2","A61K31/4245;A61P29/00;A61P35/00;C07D271/08;A61K31/41;A61P31/00;C07D413/00","2;2;2;2;1;1;1","A61P29/00;A61P31/00;A61P35/00;A61K31/4245;C07D271/08;A61P35/04;A61P37/04;C07D271/10;C07D498/04;C12N15/113","4;4;4;3;3;1;1;1;1;1",32,7.83,3075.34,14.48,17,0.53,81,1,1,9,1,13,0,0,7,0,27,2,0,0,0,0,0,0,20,10,2,29,3,0,0,0,0,0,0,0,0,"Italy;United States;United Kingdom;Belgium;Germany;Japan","11;7;4;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING;3215 REPRODUCTIVE MEDICINE;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;52 PSYCHOLOGY","30;27;8;2;2;2;2;2;1;1;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;AGING;BREAST CANCER;OVARIAN CANCER;PATIENT SAFETY;LUNG;LUNG CANCER;DIGESTIVE DISEASES;HEMATOLOGY;LYMPHOMA;PREVENTION;COLO-RECTAL CANCER;COMPARATIVE EFFECTIVENESS RESEARCH;GENETICS;ORPHAN DRUG;PROSTATE CANCER;UROLOGIC DISEASES","30;29;21;11;6;6;5;5;4;4;3;3;3;3;2;2;2;2;2;2","CANCER;INFECTION","28;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;5.1 PHARMACEUTICALS;6.4 SURGERY;7.1 INDIVIDUAL CARE NEEDS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;4.4 POPULATION SCREENING;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;7.3 MANAGEMENT AND DECISION MAKING","22;6;3;2;2;1;1;1;1;1;1","BREAST CANCER;MELANOMA;OVARIAN CANCER;LUNG CANCER;NON-HODGKIN'S LYMPHOMA;COLON AND RECTAL CANCER;PROSTATE CANCER;CERVICAL CANCER;ENDOMETRIAL CANCER;GENITAL SYSTEM, FEMALE;HEAD AND NECK CANCER;KIDNEY CANCER;LIVER CANCER;NOT SITE-SPECIFIC CANCER;SARCOMA;THYROID CANCER","6;5;5;4;3;2;2;1;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE","21;3;2;1;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,36,"PUBLIC LIBRARY OF SCIENCE;THE CAMBRIDGE STRUCTURAL DATABASE","33;3","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;42 HEALTH SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3105 GENETICS;3202 CLINICAL SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;49 MATHEMATICAL SCIENCES;3207 MEDICAL MICROBIOLOGY;37 EARTH SCIENCES;4905 STATISTICS;3103 ECOLOGY;3204 IMMUNOLOGY;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;3502 BANKING, FINANCE AND INVESTMENT;36 CREATIVE ARTS AND WRITING;3604 PERFORMING ARTS;3705 GEOLOGY;51 PHYSICAL SCIENCES;5106 NUCLEAR AND PLASMA PHYSICS","44;21;15;11;10;7;7;4;2;2;2;1;1;1;1;1;1;1;1;1","GENETICS;CANCER;RARE DISEASES;BREAST CANCER;PREVENTION;OVARIAN CANCER;HUMAN GENOME;INFECTIOUS DISEASES;AGING;CERVICAL CANCER;CLINICAL RESEARCH;EMERGING INFECTIOUS DISEASES;GENETIC TESTING;HEMATOLOGY;IMMUNIZATION;ORPHAN DRUG;SEXUALLY TRANSMITTED INFECTIONS;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;VACCINE RELATED","14;8;5;4;4;3;2;2;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;INFECTION","8;2","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;6.1 PHARMACEUTICALS;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","8;1;1;1;1","CLINICAL;POPULATION & SOCIETY;BIOMEDICAL","3;2;1","CLINICAL MEDICINE AND SCIENCE;PUBLIC HEALTH;BASIC SCIENCE","14;3;2","BREAST CANCER;OVARIAN CANCER;THYROID CANCER;CERVICAL CANCER;COLON AND RECTAL CANCER;GENITAL SYSTEM, FEMALE;KAPOSI'S SARCOMA;LIVER CANCER;SARCOMA","6;5;4;1;1;1;1;1;1",NA,NA
"IRCCS_IOV",2014,260,14.7153846153846,2.73461538461539,0.365682137834037,0.280769230769231,0.273076923076923,0.115384615384615,0.465384615384615,0,171,41,22,16,0.66,0.16,0.08,0.06,60.62,1.60403551698679,0.407692307692308,0.973076923076923,6.41382978723405,0.554651196530483,0.462799754047961,0.436211407639979,0.389299363057325,"VITTORINA ZAGONEL;ADOLFO FAVARETTO;VANNA CHIARION‐SILENI;UMBERTO BASSO;CARLO RICCARDO ROSSI;FRANCESCA BERGAMO;PIERFRANCO CONTÉ;UGO DE GIORGI;SARA LONARDI;ALFREDO FALCONE;MARCO SCARPA;GIUSEPPE PROCOPIO;L CAMPANA;FOTIOS LOUPAKIS;FRANCESCO MASSARI;GIUSEPPE LOMBARDI;CHIARA CREMOLINI;MASSIMO RUGGE;PAOLO A. ASCIERTO;FABLE ZUSTOVICH","24;24;20;20;15;15;15;15;14;13;13;13;12;12;12;11;11;10;10;10","CARLO RICCARDO ROSSI;VITTORINA ZAGONEL;ADOLFO FAVARETTO;VANNA CHIARION‐SILENI;LAURA EVANGELISTA;L CAMPANA;PIERFRANCO CONTÉ;MARCO SCARPA;UMBERTO BASSO;GIUSEPPE LOMBARDI;CARLO CASTORO;PATRIZIA FARINA;FRANCESCA BERGAMO;MASSIMO RUGGE;FABLE ZUSTOVICH;VALENTINA GUARNERI;SARA VALPIONE;M. PAIUSCO;ANNA RITA CERVINO;JACOPO PIGOZZO","2.17;2.08;2.05;1.64;1.63;1.62;1.61;1.4;1.34;1.34;1.22;1.19;1.1;1.04;1.02;0.98;0.97;0.93;0.91;0.91","VITTORINA ZAGONEL;ADOLFO FAVARETTO;VANNA CHIARION‐SILENI;UMBERTO BASSO;CARLO RICCARDO ROSSI;FRANCESCA BERGAMO;PIERFRANCO CONTÉ;SARA LONARDI;MARCO SCARPA;L CAMPANA;GIUSEPPE LOMBARDI;MASSIMO RUGGE;FABLE ZUSTOVICH;CARLO CASTORO;LAURA EVANGELISTA;JACOPO PIGOZZO;ROBERTA BERTORELLE;VALENTINA GUARNERI;MATTEO CAGOL;GIUSEPPE OPOCHER","24;24;20;20;15;15;15;14;13;12;11;10;10;10;10;9;9;8;8;8","CARLO RICCARDO ROSSI;VITTORINA ZAGONEL;ADOLFO FAVARETTO;VANNA CHIARION‐SILENI;LAURA EVANGELISTA;L CAMPANA;PIERFRANCO CONTÉ;MARCO SCARPA;UMBERTO BASSO;GIUSEPPE LOMBARDI;CARLO CASTORO;PATRIZIA FARINA;FRANCESCA BERGAMO;MASSIMO RUGGE;FABLE ZUSTOVICH;VALENTINA GUARNERI;SARA VALPIONE;M. PAIUSCO;ANNA RITA CERVINO;JACOPO PIGOZZO","2.17;2.08;2.05;1.64;1.63;1.62;1.61;1.4;1.34;1.34;1.22;1.19;1.1;1.04;1.02;0.98;0.97;0.93;0.91;0.91","VANNA CHIARION‐SILENI;AXEL HAUSCHILD;IVANA KRAJSOVÁ;JACOB SCHACHTER;CAROLINE ROBERT;REINHARD DUMMER;KEITH T. FLAHERTY;GEORGINA V. LONG;BOGUSŁAWA KARASZEWSKA;PIOTR RUTKOWSKI;ANDRZEJ MAĆKIEWICZ;D. STROIAKOVSKI;DIRK SCHADENDORF;FLORENT GRANGE;KAMIL DRUCIS;LAURENT MORTIER;M. LICHINITSER;PENG SUN;SHONDA M LITTLE;WENDY CRIST","3382;2781;2666;2666;2504;2504;2470;2467;2454;2454;2407;2407;2407;2407;2407;2407;2407;2407;2407;2407","VANNA CHIARION‐SILENI;GIACOMO DESANTIS;UMBERTO BASSO;ANTONIO ROSATO;CARLO RICCARDO ROSSI;RITA ZAMARCHI;PIERFRANCO CONTÉ;ROBERTA SOMMAGGIO;MARCO RASTRELLI;VALENTINA GUARNERI;SAVERIA TROPEA;STEFANO INDRACCOLO;MARIA VITTORIA DIECI;JACOPO PIGOZZO;ADOLFO FAVARETTO;FEDERICA VIANELLO;GIUSEPPE CURIGLIANO;FRANCESCA BERGAMO;VINCENZO CIMINALE;ELISABETTA ZULATO","3366;1816;1039;920;869;781;767;668;658;654;647;612;585;501;493;480;407;405;377;362","ADOLFO FAVARETTO;VITTORINA ZAGONEL;UMBERTO BASSO;VANNA CHIARION‐SILENI;FRANCESCA BERGAMO;PIERFRANCO CONTÉ;SARA LONARDI;CARLO RICCARDO ROSSI;MARCO SCARPA;L CAMPANA;LAURA EVANGELISTA;CARLO CASTORO;FABLE ZUSTOVICH;GIUSEPPE LOMBARDI;JACOPO PIGOZZO;ANTONIO ROSATO;FRANCESCO CAVALLIN;GIULIA PASELLO;MATTEO CAGOL;ROBERTA BERTORELLE","23;23;20;17;15;15;14;13;12;11;10;10;10;9;8;8;8;8;8;8","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;POLITICAL SCIENCE;MATHEMATICS;ENGINEERING;MATERIALS SCIENCE;GEOGRAPHY;SOCIOLOGY;PHILOSOPHY;PSYCHOLOGY;BUSINESS;ECONOMICS;ENVIRONMENTAL SCIENCE;HISTORY","242;80;27;18;8;8;7;6;6;5;5;3;3;2;2;2;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;CANCER RESEARCH;PATHOLOGY;GASTROENTEROLOGY;GENETICS;BIOCHEMISTRY;RADIOLOGY;IMMUNOLOGY;ENVIRONMENTAL HEALTH;NUCLEAR MEDICINE;PALEONTOLOGY;CELL BIOLOGY;OPTICS;UROLOGY;GENERAL SURGERY;MEDICAL PHYSICS;LAW;NURSING;ORGANIC CHEMISTRY","208;131;78;72;70;45;39;35;27;26;23;22;18;14;11;11;10;10;8;8;8","CANCER;CHEMOTHERAPY;GENE;MELANOMA;POPULATION;RADIATION THERAPY;RANDOMIZED CONTROLLED TRIAL;CLINICAL TRIAL;LUNG CANCER;CONFIDENCE INTERVAL;STAGE (STRATIGRAPHY);ALTERNATIVE MEDICINE;RETROSPECTIVE COHORT STUDY;ADVERSE EFFECT;RENAL CELL CARCINOMA;DISEASE;MULTIVARIATE ANALYSIS;IMMUNE SYSTEM;LYMPH NODE;COHORT;HEPATOCELLULAR CARCINOMA","153;65;44;26;23;21;20;17;17;16;16;15;15;14;13;12;12;11;10;9;9","COLORECTAL CANCER;BREAST CANCER;CLINICAL ENDPOINT;BEVACIZUMAB;CISPLATIN;METASTASIS;METASTATIC MELANOMA;MUTATION;PHASES OF CLINICAL RESEARCH;PLACEBO;IMMUNOTHERAPY;ADENOCARCINOMA;HAZARD RATIO;PROSTATE CANCER;DOCETAXEL;GEMCITABINE;PROGRESSION-FREE SURVIVAL;CARCINOGENESIS;SUNITINIB;UNIVARIATE ANALYSIS","35;28;15;14;13;13;12;12;12;12;11;10;9;9;8;8;8;7;7;7","KRAS;VEMURAFENIB;IPILIMUMAB;IRINOTECAN;ELECTROCHEMOTHERAPY;ANDROGEN DEPRIVATION THERAPY;BARRETT'S ESOPHAGUS;CETUXIMAB;DISCOVERY AND DEVELOPMENT OF MTOR INHIBITORS;MYELOID-DERIVED SUPPRESSOR CELL;PEMETREXED;CARBOPLATIN;ESOPHAGECTOMY;GERMLINE MUTATION;IFOSFAMIDE;METASTATIC BREAST CANCER;NEOADJUVANT THERAPY;PAZOPANIB;BRAIN METASTASIS;CAPECITABINE;ERLOTINIB;ESTROGEN RECEPTOR;FLUORESCENCE IN SITU HYBRIDIZATION;MISSENSE MUTATION;OXALIPLATIN;TRAMETINIB;VINORELBINE","12;9;8;7;6;5;5;5;5;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3","HUMANS;FEMALE;;MALE;MIDDLE AGED;AGED;MELANOMA;ADULT;AGED, 80 AND OVER;LUNG NEOPLASMS;RETROSPECTIVE STUDIES;ANTINEOPLASTIC AGENTS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;CARCINOMA, NON-SMALL-CELL LUNG;COLORECTAL NEOPLASMS;BIOMARKERS, TUMOR;BREAST NEOPLASMS;SKIN NEOPLASMS;ADENOCARCINOMA;TREATMENT OUTCOME","151;109;105;94;81;79;59;58;39;39;39;38;37;36;35;34;34;34;33;27","ADVANCEMENTS IN LUNG CANCER RESEARCH;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;RENAL CELL CARCINOMA;MAMMALIAN MAP KINASE SIGNALING PATHWAYS;MELANOMA;GLIOMAS;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;PREOPERATIVE CHEMORADIOTHERAPY FOR ESOPHAGEAL CANCER;APPLICATIONS OF ELECTROPORATION IN BIOTECHNOLOGY AND FOOD PROCESSING;SARCOMA RESEARCH AND TREATMENT;MACROPHAGE ACTIVATION AND POLARIZATION;PHEOCHROMOCYTOMA AND PARAGANGLIOMA;CANCER IMMUNOTHERAPY;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY;CHOLANGIOCARCINOMA;COLORECTAL CANCER RESEARCH AND TREATMENT;DIAGNOSIS AND TREATMENT OF LUNG CANCER;MICRORNA REGULATION IN CANCER AND DEVELOPMENT;PANCREATIC CANCER RESEARCH AND TREATMENT","16;14;13;11;10;9;8;7;6;6;5;5;4;4;4;4;4;4;4;4","MELANOMA;CLINICAL ENDPOINT;METASTATIC COLORECTAL CANCER;RENAL CELL CARCINOMA;BREAST CANCER;BARRETT'S ESOPHAGUS;NON-SMALL CELL LUNG CANCER;PROGRESSION-FREE SURVIVAL;TREATMENT;CONCOMITANT;INTRATUMOR HETEROGENEITY;BIOMARKER ANALYSIS;CANCER;EGFR MUTATIONS;TUMOR MICROENVIRONMENT;UNIVARIATE ANALYSIS;BRAF MUTATIONS;CANCER CELL METABOLISM;CANCER IMAGING;CANCER RISK","21;15;11;11;10;9;9;9;9;8;8;7;7;7;7;7;6;6;6;6","LUNG CANCER;COLORECTAL CANCER;BREAST CANCER;PATIENTS PTS;CANCER PATIENTS;PHASE III;CELL CARCINOMA;METASTATIC COLORECTAL;RENAL CELL;CELL LUNG;PHASE II;ELDERLY PATIENTS;NON-SMALL CELL;PROSTATE CANCER;CANCER MCRC;CANCER NSCLC;METASTATIC RENAL;RANDOMIZED PHASE;VERSUS PLACEBO;LOCALLY ADVANCED;PATIENTS TREATED;RETROSPECTIVE ANALYSIS;BEVACIZUMAB BEV;CUTANEOUS MELANOMA;II STUDY;PROGNOSTIC FACTORS;ADVANCED MELANOMA;BARRETTS ESOPHAGUS;BRAIN METASTASES;CASTRATION-RESISTANT PROSTATE","19;17;15;15;13;13;12;11;11;10;10;8;8;8;7;7;7;7;7;6;6;6;5;5;5;5;4;4;4;4","BRISTOL-MYERS SQUIBB;HR CI;ABSTRACT AIM;BREAST CANCER;PROGRESSION-FREE SURVIVAL;SURVIVAL OS;COLORECTAL CANCER;RESPONSE RATE;DISEASE CONTROL;ELDERLY PATIENTS;MEDIAN OS;PHASE III;ADVERSE EVENTS;MEDIAN AGE;MUTATION STATUS;SURVIVAL PFS;CELL LINES;MEDIAN PFS;MONTHS CI;PTS TREATED;RESEARCH FUNDING;WT PTS;BRCA MUTATION;CANCER PATIENTS;COMPLETE RESPONSE;CONTROL RATE;METASTATIC MELANOMA;PATIENTS TREATED;ADVISORY BOARD;ELI LILLY","29;21;20;19;19;18;17;17;15;15;14;13;12;12;12;12;11;11;11;11;11;11;10;10;10;10;10;10;9;9",93,0.36,7,6,2,1.25,1,5,3.5,1,1.25,6,1,1,4,1,1,1,1.75,3,2,0,0,83,83,1,0,0,2,0,1,1,0,0,0,0,0,0,2,2,0,6,3.38,2,0,4,4,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,"BRONTE ENZO;CROSETTI MARCO;FRUTTERO ROBERTA;GASCO ALBERTO;LAZZARATO LORETTA;VIOLA ANTONELLA","4;4;4;4;4;4","HUMANITAS MIRASOLE SPA;ISTITUTO ONCOLOGICO VENETO IRCCS","4;4","34 CHEMICAL SCIENCES;3402 INORGANIC CHEMISTRY","2;1",NA,NA,NA,NA,"A61K31/4245;A61P29/00;A61P35/00;C07D271/08","4;4;4;4","A61K31/4245;A61P29/00;A61P31/00;A61P35/00;C07D271/08","4;4;4;4;4",18,5.67,344,7.29,12,0.67,67,0,1,9,0,5,0,0,3,0,16,2,0,0,0,0,0,0,16,2,0,18,0,0,0,0,0,0,0,0,0,"Germany;Italy;Belgium;Netherlands;United Kingdom;United States","3;2;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES","18;15;9;1;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DIGESTIVE DISEASES;RARE DISEASES;BREAST CANCER;COLO-RECTAL CANCER;PATIENT SAFETY;AGING;GENETICS;ORPHAN DRUG;CARDIOVASCULAR;CHRONIC PAIN;COMPARATIVE EFFECTIVENESS RESEARCH;LUNG;LUNG CANCER;NEUROSCIENCES;PAIN RESEARCH;PREVENTION;PROSTATE CANCER","16;16;14;7;6;3;3;3;2;2;2;1;1;1;1;1;1;1;1;1","CANCER;GENERIC HEALTH RELEVANCE","14;1","6.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;7.1 INDIVIDUAL CARE NEEDS","16;1;1;1;1;1","BREAST CANCER;SARCOMA;COLON AND RECTAL CANCER;LIVER CANCER;LUNG CANCER;NOT SITE-SPECIFIC CANCER;STOMACH CANCER;BLADDER CANCER;ESOPHAGEAL / OESOPHAGEAL CANCER;PANCREATIC CANCER;PROSTATE CANCER;SKIN CANCER","4;4;3;2;2;2;2;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","14;2;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,9,"PUBLIC LIBRARY OF SCIENCE","9","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;3204 IMMUNOLOGY;31 BIOLOGICAL SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3009 VETERINARY SCIENCES;3105 GENETICS;3202 CLINICAL SCIENCES;3206 MEDICAL BIOTECHNOLOGY;52 PSYCHOLOGY","16;6;4;3;2;2;1;1;1;1;1;1","CANCER;DIGESTIVE DISEASES;GENETICS;RARE DISEASES;AGING;BIOTECHNOLOGY;BREAST CANCER;GENE THERAPY;GENETIC TESTING;IMMUNIZATION;ORPHAN DRUG;OVARIAN CANCER;PREVENTION;PROSTATE CANCER;UROLOGIC DISEASES;VACCINE RELATED","3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","CANCER","6","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS;5.2 CELLULAR AND GENE THERAPIES;6.1 PHARMACEUTICALS;6.4 SURGERY","4;1;1;1;1","BIOMEDICAL","2","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","5;2","BREAST CANCER;COLON AND RECTAL CANCER;OVARIAN CANCER;ESOPHAGEAL / OESOPHAGEAL CANCER;PROSTATE CANCER","2;2;2;1;1",NA,NA
"IRCCS_IOV",2015,283,14.2190812720848,2.68197879858657,0.372859025032938,0.279151943462898,0.321554770318021,0.144876325088339,0.462897526501767,2,179,60,19,10,0.63,0.21,0.07,0.04,45.78,1.22841749947362,0.381625441696113,0.968197879858657,6.7776769509982,0.572009621521718,0.382838283828383,0.448260932313465,0.401276230212296,"VITTORINA ZAGONEL;SARA LONARDI;PIERFRANCO CONTÉ;VANNA CHIARION‐SILENI;CARLO CASTORO;MATTEO CAGOL;UMBERTO BASSO;MARCO SCARPA;UGO DE GIORGI;FRANCESCA BERGAMO;GIOVANNI LO RE;LAURA EVANGELISTA;GIUSEPPE APRILE;ALFREDO FALCONE;STEFANO CASCINU;FOTIOS LOUPAKIS;GIUSEPPE LOMBARDI;RITA ALFIERI;GIORGIO BATTAGLIA;CHIARA CREMOLINI","33;29;23;21;21;16;16;15;15;14;14;14;14;13;12;12;12;12;12;12","CARLO CASTORO;VITTORINA ZAGONEL;PIERFRANCO CONTÉ;LAURA EVANGELISTA;GIORGIO BATTAGLIA;STEFANO INDRACCOLO;MATTEO CAGOL;SARA LONARDI;VANNA CHIARION‐SILENI;MARCO SCARPA;FRANCESCO CAVALLIN;ALESSANDRO ANTONELLO;RITA ALFIERI;CARLO RICCARDO ROSSI;UMBERTO BASSO;STEFANO REALDON;DAVIDE PASTORELLI;GIUSEPPE LOMBARDI;SARA VALPIONE;VALENTINA GUARNERI","2.33;2.18;2.15;1.98;1.97;1.89;1.84;1.79;1.71;1.58;1.34;1.33;1.33;1.3;1.26;1.22;1.16;1.07;1.04;1.02","VITTORINA ZAGONEL;SARA LONARDI;PIERFRANCO CONTÉ;VANNA CHIARION‐SILENI;CARLO CASTORO;MATTEO CAGOL;UMBERTO BASSO;MARCO SCARPA;FRANCESCA BERGAMO;LAURA EVANGELISTA;ALFREDO FALCONE;GIUSEPPE LOMBARDI;RITA ALFIERI;GIORGIO BATTAGLIA;CARLO RICCARDO ROSSI;CAMILLO ALIBERTI;FRANCESCO CAVALLIN;MARIA ORNELLA NICOLETTO;DAVIDE PASTORELLI;ADOLFO FAVARETTO","33;29;23;21;21;16;16;15;14;14;13;12;12;12;11;11;11;11;10;10","CARLO CASTORO;VITTORINA ZAGONEL;PIERFRANCO CONTÉ;LAURA EVANGELISTA;GIORGIO BATTAGLIA;STEFANO INDRACCOLO;MATTEO CAGOL;SARA LONARDI;VANNA CHIARION‐SILENI;MARCO SCARPA;FRANCESCO CAVALLIN;ALESSANDRO ANTONELLO;RITA ALFIERI;CARLO RICCARDO ROSSI;UMBERTO BASSO;STEFANO REALDON;DAVIDE PASTORELLI;GIUSEPPE LOMBARDI;SARA VALPIONE;VALENTINA GUARNERI","2.33;2.18;2.15;1.98;1.97;1.89;1.84;1.79;1.71;1.58;1.34;1.33;1.33;1.3;1.26;1.22;1.16;1.07;1.04;1.02","VANNA CHIARION‐SILENI;SARA LONARDI;JEAN‐JACQUES GROB;CAROLINE ROBERT;CÉLÈSTE LEBBÉ;VIRGINIA FERRARESI;ERIC VAN CUTSEM;FOTIOS LOUPAKIS;DIRK SCHADENDORF;SHAO-CHUN CHANG;GEORGINA V. LONG;DANIIL STROYAKOVSKIY;E. LEVCHENKO;KEITH T. FLAHERTY;FILIPPO DE BRAUD;ANTONI RIBAS;PAUL NATHAN;CHIARA CREMOLINI;ALFREDO FALCONE;AXEL HAUSCHILD","2979;2840;2753;2740;2520;2394;1931;1717;1657;1638;1601;1548;1548;1548;1544;1543;1543;1489;1473;1472","VANNA CHIARION‐SILENI;SARA LONARDI;NICOLA FAZIO;VITTORINA ZAGONEL;DAVIDE PASTORELLI;PIERFRANCO CONTÉ;FRANCESCA SCHIAVI;VALENTINA GUARNERI;CARLO CASTORO;CARLO RICCARDO ROSSI;ADOLFO FAVARETTO;LAURA EVANGELISTA;ROBERTA BERTORELLE;MARCO SCARPA;L CAMPANA;FRANCESCA BERGAMO;MARIA ORNELLA NICOLETTO;ALAN N. SANDLER;ARMANDO SANTORO;BRIAN SCHWARTZ","2943;2840;1074;871;831;644;494;400;323;315;296;289;289;282;277;274;265;246;246;246","VITTORINA ZAGONEL;SARA LONARDI;PIERFRANCO CONTÉ;CARLO CASTORO;VANNA CHIARION‐SILENI;MATTEO CAGOL;UMBERTO BASSO;MARCO SCARPA;FRANCESCA BERGAMO;LAURA EVANGELISTA;GIUSEPPE LOMBARDI;RITA ALFIERI;GIORGIO BATTAGLIA;CARLO RICCARDO ROSSI;FRANCESCO CAVALLIN;MARIA ORNELLA NICOLETTO;ADOLFO FAVARETTO;CAMILLO ALIBERTI;DAVIDE PASTORELLI;STEFANO INDRACCOLO","33;29;22;21;20;16;16;15;14;14;12;12;12;11;11;11;10;10;10;9","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;ENGINEERING;MATHEMATICS;MATERIALS SCIENCE;POLITICAL SCIENCE;BUSINESS;PHILOSOPHY;PSYCHOLOGY;SOCIOLOGY;ECONOMICS;GEOGRAPHY;GEOLOGY;HISTORY","267;81;20;19;13;9;9;7;6;4;4;3;3;1;1;1;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;GASTROENTEROLOGY;PATHOLOGY;CANCER RESEARCH;GENETICS;ENVIRONMENTAL HEALTH;BIOCHEMISTRY;RADIOLOGY;NUCLEAR MEDICINE;IMMUNOLOGY;PALEONTOLOGY;CELL BIOLOGY;UROLOGY;PHARMACOLOGY;NURSING;OPTICS;GENERAL SURGERY;GYNECOLOGY","242;157;92;75;61;51;42;36;34;33;19;17;15;14;13;12;9;9;7;7","CANCER;CHEMOTHERAPY;GENE;POPULATION;CLINICAL TRIAL;RANDOMIZED CONTROLLED TRIAL;CONFIDENCE INTERVAL;ADVERSE EFFECT;ALTERNATIVE MEDICINE;RETROSPECTIVE COHORT STUDY;DISEASE;PROPORTIONAL HAZARDS MODEL;REGIMEN;RADIATION THERAPY;MELANOMA;MULTIVARIATE ANALYSIS;STAGE (STRATIGRAPHY);COHORT;OVERALL SURVIVAL;POSITRON EMISSION TOMOGRAPHY","178;83;45;35;31;30;25;23;20;20;19;19;18;17;16;15;14;12;12;11","COLORECTAL CANCER;BREAST CANCER;CLINICAL ENDPOINT;PROGRESSION-FREE SURVIVAL;PHASES OF CLINICAL RESEARCH;BEVACIZUMAB;HAZARD RATIO;ESOPHAGEAL CANCER;PLACEBO;PROSTATE CANCER;GENOTYPE;CISPLATIN;GEMCITABINE;IMMUNOTHERAPY;OVARIAN CANCER;DOCETAXEL;NEUTROPENIA;METASTASIS;MUTATION;UNIVARIATE ANALYSIS","44;42;42;27;24;20;19;17;17;17;15;13;13;13;13;12;11;10;10;10","IRINOTECAN;KRAS;TRASTUZUMAB;ANDROGEN DEPRIVATION THERAPY;CARBOPLATIN;IPILIMUMAB;CETUXIMAB;METASTATIC BREAST CANCER;ANDROGEN RECEPTOR;ESOPHAGECTOMY;OXALIPLATIN;SINGLE-NUCLEOTIDE POLYMORPHISM;GERMLINE MUTATION;TAXANE;NIVOLUMAB;PHARMACOGENETICS;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;VEMURAFENIB;ELECTROCHEMOTHERAPY;GENOTYPING;TRAMETINIB;TRIPLE-NEGATIVE BREAST CANCER","18;12;12;9;9;9;8;8;7;7;7;7;6;6;5;5;5;5;4;4;4;4","HUMANS;;FEMALE;MALE;MIDDLE AGED;AGED;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ADULT;BREAST NEOPLASMS;MELANOMA;AGED, 80 AND OVER;ESOPHAGEAL NEOPLASMS;BIOMARKERS, TUMOR;RETROSPECTIVE STUDIES;TREATMENT OUTCOME;COLORECTAL NEOPLASMS;ANTINEOPLASTIC AGENTS;ADENOCARCINOMA;DISEASE-FREE SURVIVAL;ITALY","144;132;109;97;94;87;68;63;47;46;45;45;44;44;43;41;38;33;31;30","ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;PREOPERATIVE CHEMORADIOTHERAPY FOR ESOPHAGEAL CANCER;CANCER IMMUNOTHERAPY;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;GLIOMAS;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CHOLANGIOCARCINOMA;MAMMALIAN MAP KINASE SIGNALING PATHWAYS;PANCREATIC CANCER RESEARCH AND TREATMENT;RENAL CELL CARCINOMA;HEPATOCELLULAR CARCINOMA;MELANOMA;METABOLIC REPROGRAMMING IN CANCER BIOLOGY;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;ESOPHAGEAL INTERVENTION TECHNIQUES;HER2 SIGNALING IN BREAST CANCER TREATMENT;MALIGNANT PLEURAL MESOTHELIOMA RESEARCH;MOLECULAR CHARACTERIZATION OF COLORECTAL CANCER;SARCOMA RESEARCH AND TREATMENT","22;15;13;10;9;9;8;8;7;6;6;5;5;5;4;4;4;4;4;4","CLINICAL ENDPOINT;PROGRESSION-FREE SURVIVAL;REGIMEN;TREATMENT;MELANOMA;BREAST CANCER;METASTATIC COLORECTAL CANCER;CANCER TREATMENT;FOLFIRI;UNIVARIATE ANALYSIS;CANCER RISK;CARBOPLATIN;LAPATINIB;TUMOR MICROENVIRONMENT;ABIRATERONE ACETATE;CANCER SUSCEPTIBILITY;GLIOBLASTOMA;METASTATIC PROSTATE CANCER;PET-CT;RAMUCIRUMAB","43;29;18;16;15;12;12;10;10;10;9;9;9;9;8;8;8;8;8;8","BREAST CANCER;COLORECTAL CANCER;PHASE III;METASTATIC COLORECTAL;PATIENTS PTS;PROSTATE CANCER;CANCER PATIENTS;PHASE II;ESOPHAGEAL CANCER;LOCALLY ADVANCED;OVARIAN CANCER;CASTRATION-RESISTANT PROSTATE;CELL CARCINOMA;ELDERLY PATIENTS;PATIENTS TREATED;RANDOMIZED PHASE;II STUDY;PHASE TRIAL;RAMUCIRUMAB RAM;RENAL CELL;ADVANCED BILIARY;AINO ITALIAN;FIRST-LINE THERAPY;FIRST-LINE TREATMENT;ITALIAN ASSOCIATION;LUNG CANCER;METASTATIC CASTRATION-RESISTANT;PANCREATIC CANCER;TRIBE STUDY;ADVANCED HEPATOCELLULAR","28;23;23;18;18;16;15;13;10;10;9;8;8;8;8;8;7;7;7;7;6;6;6;6;6;6;6;6;6;5","HR CI;PADOVA ITALY;ITALY DEPARTMENT;PATIENTS TREATED;SURVIVAL OS;PROGRESSION-FREE SURVIVAL;BREAST CANCER;MEDIAN OS;MONTHS CI;ECOG PS;MEDIAN PFS;RESPONSE RATE;CANCER PATIENTS;SURVIVAL PFS;PRIMARY ENDPOINT;COLORECTAL CANCER;PADOVA PADOVA;PERFORMANCE STATUS;ITT POPULATION;MEDIAN AGE;ELDERLY PATIENTS;ADVERSE EVENTS;MEDIAN FOLLOW-UP;PHASE II;MULTIVARIATE ANALYSIS;SAFETY PROFILE;BASELINE AFP;ECOG PERFORMANCE;OBJECTIVE RESPONSE;OS HR","38;31;30;30;30;29;28;28;28;27;26;26;25;25;22;21;21;21;19;19;18;17;17;17;14;14;13;13;13;13",105,0.37,7,5,1,1,1.25,5,3.75,1,2,5,1,1,4,0,1,1,3,4,3,0,0,86,89,3,0,0,1,0,1,1,1,0,0,0,0,0,3,1,0,6,3.16,2,0,4,4,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,"BRONTE ENZO;CROSETTI MARCO;FRUTTERO ROBERTA;GASCO ALBERTO;LAZZARATO LORETTA;VIOLA ANTONELLA","4;4;4;4;4;4","HUMANITAS MIRASOLE SPA;ISTITUTO ONCOLOGICO VENETO IRCCS","4;4","32 BIOMEDICAL AND CLINICAL SCIENCES;34 CHEMICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY","2;2;1;1","VACCINE RELATED","1",NA,NA,"A61K31/4245;C07D271/08","4;1","A61P29/00;A61P31/00;A61P35/00;C07D271/10;C07D498/04;A61P35/04;A61P37/04;A61K31/4245;C07D271/08","3;3;3;3;3;2;2;1;1",22,5.67,353.19,9.95,15,0.68,71.14,0,0,10,1,8,0,0,3,0,19,2,0,0,0,0,0,0,20,2,0,21,1,0,0,0,0,0,0,0,0,"United States;Italy;Belgium;Germany;Australia;Japan","5;3;2;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;31 BIOLOGICAL SCIENCES;3105 GENETICS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING;49 MATHEMATICAL SCIENCES","21;19;13;2;1;1;1;1;1;1;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;DIGESTIVE DISEASES;BRAIN CANCER;BRAIN DISORDERS;NEUROSCIENCES;ORPHAN DRUG;BREAST CANCER;PATIENT SAFETY;BIOTECHNOLOGY;COLO-RECTAL CANCER;GENETICS;BIOMEDICAL IMAGING;COMPARATIVE EFFECTIVENESS RESEARCH;HEMATOLOGY;LUNG;LUNG CANCER;LYMPHOMA","21;18;16;12;7;5;5;4;4;3;3;2;2;2;1;1;1;1;1;1","CANCER;METABOLIC AND ENDOCRINE;ORAL AND GASTROINTESTINAL","20;1;1","6.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","19;1;1;1;1;1","BRAIN TUMOR;COLON AND RECTAL CANCER;ESOPHAGEAL / OESOPHAGEAL CANCER;NOT SITE-SPECIFIC CANCER;BREAST CANCER;LUNG CANCER;MELANOMA;NON-HODGKIN'S LYMPHOMA;OVARIAN CANCER;PANCREATIC CANCER;SARCOMA;STOMACH CANCER","5;3;3;3;2;2;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;2.3 INTERACTIONS OF GENES AND/OR GENETIC POLYMORPHISMS WITH EXOGENOUS AND/OR ENDOGENOUS FACTORS;3.2 NUTRITIONAL SCIENCE IN CANCER PREVENTION;5.1 LOCALIZED THERAPIES - DISCOVERY AND DEVELOPMENT","14;3;3;2;2;1;1;1;1",1,6620000,213548.39,5,31,12,1,100,271281.105990783,1.04319834205341,"ALACRIS (GERMANY);ARTTIC (FRANCE);BAYER (GERMANY);BOEHRINGER INGELHEIM (GERMANY);CHARITÉ - UNIVERSITY MEDICINE BERLIN;ELI LILLY (UNITED KINGDOM);EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER;GABO:MI;GERMAN CANCER RESEARCH CENTER;GILUPI (GERMANY);HEINRICH HEINE UNIVERSITY DÜSSELDORF;INSTITUT GUSTAVE ROUSSY;INSTITUTE CURIE;ISTITUTO ONCOLOGICO VENETO;LUXEMBOURG INSTITUTE OF HEALTH;MAX PLANCK SOCIETY;MEDICAL UNIVERSITY OF GRAZ;NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS;ORION CORPORATION (FINLAND);OSLO UNIVERSITY HOSPITAL","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","FP7-JTI - SPECIFIC PROGRAMME ""COOPERATION"": JOINT TECHNOLOGY INITIATIVES (PROGRAMME);IMI-JU-11-2013 (CALL FOR PROPOSAL);JTI-CP-IMI - JOINT TECHNOLOGY INITIATIVES - COLLABORATIVE PROJECT (IMI) (FUNDING SCHEME)","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3204 IMMUNOLOGY;3211 ONCOLOGY AND CARCINOGENESIS","1;1;1","BREAST CANCER;CANCER;CLINICAL RESEARCH","1;1;1","CANCER","1","4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","1;1","BREAST CANCER;LUNG CANCER","1;1","4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING","1;1;1","A01 CLINICAL MEDICINE","1",NA,NA,21,"PUBLIC LIBRARY OF SCIENCE;AMERICAN ASSOCIATION FOR CANCER RESEARCH","17;4","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;3105 GENETICS;4203 HEALTH SERVICES AND SYSTEMS;3202 CLINICAL SCIENCES;38 ECONOMICS;3801 APPLIED ECONOMICS;3103 ECOLOGY;3204 IMMUNOLOGY","31;14;12;11;7;7;2;2;2;1;1","CANCER;GENETICS;BREAST CANCER;PREVENTION;DIGESTIVE DISEASES;RARE DISEASES;AGING;CLINICAL RESEARCH;ESTROGEN;GENETIC TESTING;HUMAN GENOME;OVARIAN CANCER","5;4;3;3;2;2;1;1;1;1;1;1","CANCER","10","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;2.6 RESOURCES AND INFRASTRUCTURE (AETIOLOGY);4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS","7;3;1;1;1","CLINICAL;BIOMEDICAL","2;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","12;2","BREAST CANCER;OVARIAN CANCER;COLON AND RECTAL CANCER;ESOPHAGEAL / OESOPHAGEAL CANCER;EYE CANCER","6;3;2;1;1",NA,NA
"IRCCS_IOV",2016,327,16.6452599388379,2.76452599388379,0.361725663716814,0.293577981651376,0.284403669724771,0.235474006116208,0.590214067278288,1,235,50,17,11,0.72,0.15,0.05,0.03,32.3,0.994450704198698,0.36697247706422,0.978593272171254,6.81781045751635,0.550961879636051,0.571134824688907,0.582061579651941,0.5444216800149,"VITTORINA ZAGONEL;SARA LONARDI;PIERFRANCO CONTÉ;FRANCESCA BERGAMO;ALFREDO FALCONE;CHIARA CREMOLINI;FOTIOS LOUPAKIS;GIANLUCA MASI;GIUSEPPE TONINI;GIUSEPPE LOMBARDI;UMBERTO BASSO;CARLO RICCARDO ROSSI;STEFANO INDRACCOLO;GERARDO ROSATI;VANNA CHIARION‐SILENI;ALBERTO ZANIBONI;FRANCESCO LEONE;LISA SALVATORE;MARCO MARUZZO;FILIPPO PIETRANTONIO","56;46;30;29;24;22;21;18;18;17;17;16;15;14;14;14;13;13;13;13","VITTORINA ZAGONEL;PIERFRANCO CONTÉ;SARA LONARDI;GIUSEPPE LOMBARDI;CARLO RICCARDO ROSSI;SIMONE MOCELLIN;STEFANO INDRACCOLO;LUISA BELLU;UMBERTO BASSO;LAURA EVANGELISTA;ARDI PAMBUKU;FRANCESCA BERGAMO;L CAMPANA;FOTIOS LOUPAKIS;ALFREDO FALCONE;VANNA CHIARION‐SILENI;MARCO MARUZZO;ANTONIO ROSATO;CHIARA CREMOLINI;SANDRO PASQUALI","3.93;2.51;2.37;1.91;1.86;1.66;1.58;1.57;1.49;1.44;1.41;1.38;1.35;1.3;1.17;1.13;1.11;1.08;1.07;1.04","VITTORINA ZAGONEL;SARA LONARDI;PIERFRANCO CONTÉ;FRANCESCA BERGAMO;FOTIOS LOUPAKIS;GIUSEPPE TONINI;GIUSEPPE LOMBARDI;UMBERTO BASSO;CARLO RICCARDO ROSSI;STEFANO INDRACCOLO;VANNA CHIARION‐SILENI;MARCO MARUZZO;FRANCESCA BATTAGLIN;L CAMPANA;LUISA BELLU;SIMONE MOCELLIN;VALENTINA GUARNERI;CARMINE PINTO;ANTONIO ROSATO;PASQUALE FIDUCCIA","56;46;30;29;21;18;17;17;16;15;14;13;12;12;12;12;11;10;10;10","VITTORINA ZAGONEL;PIERFRANCO CONTÉ;SARA LONARDI;GIUSEPPE LOMBARDI;CARLO RICCARDO ROSSI;SIMONE MOCELLIN;STEFANO INDRACCOLO;LUISA BELLU;UMBERTO BASSO;LAURA EVANGELISTA;ARDI PAMBUKU;FRANCESCA BERGAMO;L CAMPANA;FOTIOS LOUPAKIS;VANNA CHIARION‐SILENI;MARCO MARUZZO;ANTONIO ROSATO;SANDRO PASQUALI;FRANCESCO SGALAMBRO;M. PAIUSCO","3.93;2.51;2.37;1.91;1.86;1.66;1.58;1.57;1.49;1.44;1.41;1.38;1.35;1.3;1.13;1.11;1.08;1.04;1;0.99","PIERFRANCO CONTÉ;FABRICE ANDRÉ;MARIO CAMPONE;THOMAS BACHELOT;VITTORINA ZAGONEL;MICHELLE C. MILLER;SARA LONARDI;CAROLINE GERMA;CARLOS L. ARTEAGA;DAVID CAMERON;ERIC P. WINER;FARIDA SOUAMI;FENGJUAN XUAN;GABE S. SONKE;JOYCE O’SHAUGHNESSY;KIMBERLY BLACKWELL;SALOMON M. STEMMER;SHANI PALUCH–SHIMON;SUNIL VERMA;WOLFGANG JANNI","2172;1947;1909;1897;1871;1691;1690;1578;1575;1575;1575;1575;1575;1575;1575;1575;1575;1575;1575;1575","PIERFRANCO CONTÉ;VITTORINA ZAGONEL;SARA LONARDI;FRANCESCA BERGAMO;VANNA CHIARION‐SILENI;ANTONIO ROSATO;MARIA VITTORIA DIECI;ANGELA DE PAOLI;VALENTINA GUARNERI;UMBERTO BASSO;GIAN LUCA DE SALVO;ILARIA MARIGO;STEFANO INDRACCOLO;MARCO MARUZZO;SANDRO PASQUALI;ALESSANDRO SINIGAGLIA;CARLO RICCARDO ROSSI;PAOLA ZANOVELLO;L CAMPANA;FRANCESCA BATTAGLIN","2160;1871;1533;1107;660;596;488;424;377;360;342;308;285;274;269;263;252;229;224;191","VITTORINA ZAGONEL;SARA LONARDI;FRANCESCA BERGAMO;PIERFRANCO CONTÉ;GIUSEPPE LOMBARDI;UMBERTO BASSO;STEFANO INDRACCOLO;VANNA CHIARION‐SILENI;CARLO RICCARDO ROSSI;MARCO MARUZZO;FRANCESCA BATTAGLIN;LUISA BELLU;L CAMPANA;ANTONELLA BRUNELLO;PASQUALE FIDUCCIA;VALENTINA GUARNERI;ANTONIO ROSATO;ARDI PAMBUKU;ANGELA DE PAOLI;MARIA VITTORIA DIECI","56;45;27;25;17;16;15;14;14;13;12;12;11;10;10;9;9;9;8;8","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;ECONOMICS;MATHEMATICS;POLITICAL SCIENCE;ENGINEERING;MATERIALS SCIENCE;SOCIOLOGY;PHILOSOPHY;PSYCHOLOGY;BUSINESS;ART;GEOGRAPHY","313;98;27;23;17;12;12;12;9;7;7;6;5;3;1;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;CANCER RESEARCH;GASTROENTEROLOGY;PATHOLOGY;GENETICS;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;IMMUNOLOGY;NURSING;PALEONTOLOGY;RADIOLOGY;CELL BIOLOGY;NUCLEAR MEDICINE;FAMILY MEDICINE;PSYCHIATRY;UROLOGY;LAW;ENDOCRINOLOGY;OPTICS","267;172;88;68;68;64;45;41;35;23;22;21;18;16;16;13;13;13;12;11;11","CANCER;CHEMOTHERAPY;GENE;CLINICAL TRIAL;POPULATION;RANDOMIZED CONTROLLED TRIAL;CONFIDENCE INTERVAL;MULTIVARIATE ANALYSIS;PROPORTIONAL HAZARDS MODEL;RADIATION THERAPY;MELANOMA;ADVERSE EFFECT;REGIMEN;DISEASE;QUALITY OF LIFE (HEALTHCARE);STAGE (STRATIGRAPHY);ALTERNATIVE MEDICINE;COHORT;GLIOBLASTOMA;RETROSPECTIVE COHORT STUDY","196;88;57;40;37;29;23;23;21;21;20;19;17;16;16;15;13;13;13;13","COLORECTAL CANCER;BREAST CANCER;BEVACIZUMAB;CLINICAL ENDPOINT;PROGRESSION-FREE SURVIVAL;PHASES OF CLINICAL RESEARCH;HAZARD RATIO;IMMUNOTHERAPY;METASTASIS;PROSTATE CANCER;PLACEBO;UNIVARIATE ANALYSIS;GENOTYPE;GENE EXPRESSION;NEUTROPENIA;CISPLATIN;DOCETAXEL;MUTATION;BLEOMYCIN;OVARIAN CANCER;SOFT TISSUE SARCOMA;TOLERABILITY","72;49;36;33;29;19;16;16;13;13;12;12;11;10;10;9;9;9;8;7;7;7","IRINOTECAN;OXALIPLATIN;CETUXIMAB;KRAS;METASTATIC BREAST CANCER;TRASTUZUMAB;ANDROGEN DEPRIVATION THERAPY;CAPECITABINE;IPILIMUMAB;SINGLE-NUCLEOTIDE POLYMORPHISM;ELECTROCHEMOTHERAPY;FEBRILE NEUTROPENIA;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;CARBOPLATIN;SENTINEL LYMPH NODE;ANDROGEN RECEPTOR;GERMLINE MUTATION;PRIMARY TUMOR;TAMOXIFEN;CHROMOPHOBE CELL;DNA METHYLATION;ESTROGEN RECEPTOR;NIVOLUMAB;REGORAFENIB;TAXANE","22;20;17;15;12;10;8;8;8;8;7;7;7;6;6;5;5;5;5;4;4;4;4;4;4",";HUMANS;FEMALE;MALE;AGED;MIDDLE AGED;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ADULT;ANTINEOPLASTIC AGENTS;BREAST NEOPLASMS;COLORECTAL NEOPLASMS;AGED, 80 AND OVER;BIOMARKERS, TUMOR;MELANOMA;TREATMENT OUTCOME;ADENOCARCINOMA;LUNG NEOPLASMS;SKIN NEOPLASMS;RETROSPECTIVE STUDIES;NEOPLASM RECURRENCE, LOCAL","177;143;104;88;74;72;62;56;51;45;35;32;31;31;30;28;27;27;26;24","ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;GLIOMAS;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;RENAL CELL CARCINOMA;CANCER IMMUNOTHERAPY;COLORECTAL CANCER RESEARCH AND TREATMENT;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;ADVANCEMENTS IN LUNG CANCER RESEARCH;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;MOLECULAR RESEARCH ON BREAST CANCER;GASTRIC CANCER RESEARCH AND TREATMENT;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;MAMMALIAN MAP KINASE SIGNALING PATHWAYS;MELANOMA;SARCOMA RESEARCH AND TREATMENT;HEPATOCELLULAR CARCINOMA;LYMPHOID NEOPLASMS;MALIGNANT PLEURAL MESOTHELIOMA RESEARCH;APPLICATIONS OF ELECTROPORATION IN BIOTECHNOLOGY AND FOOD PROCESSING;DIAGNOSIS AND MANAGEMENT OF GASTROESOPHAGEAL REFLUX DISEASE","34;15;10;10;8;8;8;7;7;7;6;6;6;6;6;5;5;5;4;4","METASTATIC COLORECTAL CANCER;CLINICAL ENDPOINT;PROGRESSION-FREE SURVIVAL;BREAST CANCER;REGIMEN;FOLFIRI;MELANOMA;TREATMENT;GLIOBLASTOMA;UNIVARIATE ANALYSIS;LAPATINIB;CABAZITAXEL;CANCER CELL METABOLISM;CANCER THERAPY;ELECTROCHEMOTHERAPY;HER2;METASTATIC GASTRIC CANCER;MICROTUBULE-TARGETING AGENTS;NEOADJUVANT THERAPY;PANITUMUMAB","38;33;29;18;17;16;14;14;12;12;9;7;7;7;7;7;7;7;7;7","COLORECTAL CANCER;METASTATIC COLORECTAL;PATIENTS PTS;BREAST CANCER;CANCER PATIENTS;LOCALLY ADVANCED;CANCER MCRC;PHASE III;PHASE II;PROSTATE CANCER;ADVANCED RECTAL;CELL CARCINOMA;PATIENTS TREATED;RENAL CELL;SOFT TISSUE;GLIOBLASTOMA GBM;RECTAL CANCER;BEVACIZUMAB BEV;CASTRATION-RESISTANT PROSTATE;GROWTH FACTOR;LUNG CANCER;OVARIAN CANCER;ADVANCED BREAST;CANCER MCRPC;CLINICAL TRIALS;GBM PATIENTS;II RANDOMIZED;III TRIAL;ITALIAN STUDY;METASTATIC CASTRATION-RESISTANT","40;33;28;27;17;17;16;16;13;13;10;10;10;9;9;8;8;7;7;7;7;7;6;6;6;6;6;6;6;6","HR CI;BREAST CANCER;CANCER PATIENTS;MEDIAN AGE;ARM AB;MEDIAN PFS;PADUA ITALY;PROGRESSION-FREE SURVIVAL;COLORECTAL CANCER;PATIENTS PTS;MEDIAN OS;MITOCHONDRIAL CA;MD PHD;SURVIVAL OS;ECOG PS;MCU SILENCING;RESPONSE RATE;ADVERSE EVENTS;PRIMARY ENDPOINT;CLINICAL TRIALS;METASTATIC COLORECTAL;PERFORMANCE STATUS;DISEASE PROGRESSION;PADOVA PADOVA;SURVIVAL PFS;PROGNOSTIC FACTORS;MCRC PATIENTS;PADOVA ITALYSEARCH;CA UPTAKE;PADUA PADUA","53;45;34;29;28;28;27;27;26;26;25;25;24;24;23;23;23;22;22;21;21;21;20;20;20;19;18;18;17;17",114,0.35,7.66,8,2,1,1,2,2,1,1,8.75,1,1,6,1,2,2,3,4,3.75,0,0,83.5,83.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_IOV",2017,354,15.4661016949153,2.75423728813559,0.363076923076923,0.251412429378531,0.26271186440678,0.11864406779661,0.632768361581921,2,236,60,30,10,0.67,0.17,0.08,0.03,42.62,1.44592382983896,0.409604519774011,0.983050847457627,7.00506512301013,0.546705470517186,0.523821570115524,0.572327431990624,0.547129506008011,"VITTORINA ZAGONEL;PIERFRANCO CONTÉ;SARA LONARDI;FOTIOS LOUPAKIS;VALENTINA GUARNERI;LAURA BONANNO;ALFREDO FALCONE;VANNA CHIARION‐SILENI;FRANCESCA BERGAMO;GIUSEPPE LOMBARDI;MASSIMO RUGGE;MARTA SCHIRRIPA;CAMILLO ALIBERTI;UGO DE GIORGI;CHIARA CREMOLINI;LAURA EVANGELISTA;DANIELE SANTINI;EMILIO BRIA;MATTEO FASSAN;GAIA GRIGUOLO","49;43;36;23;21;19;18;18;17;17;16;16;14;14;14;14;14;13;13;13","VITTORINA ZAGONEL;PIERFRANCO CONTÉ;LAURA EVANGELISTA;SARA LONARDI;GIUSEPPE LOMBARDI;FOTIOS LOUPAKIS;ANTONIO SOMMARIVA;CAMILLO ALIBERTI;MASSIMO RUGGE;VALENTINA GUARNERI;VANNA CHIARION‐SILENI;LAURA BONANNO;MARTA SCHIRRIPA;IVA ŠABOVIĆ;MASSIMO GION;ALINE S.C. FABRICIO;CHIARA TREVISIOL;RICCARDO CARANDINA;CARLO RICCARDO ROSSI;FRANCESCA BERGAMO","3.57;2.95;2.42;2.17;2.13;1.67;1.48;1.4;1.31;1.28;1.24;1.16;1.12;1.1;1.1;1.1;1.1;1.06;1.05;1.05","VITTORINA ZAGONEL;PIERFRANCO CONTÉ;SARA LONARDI;FOTIOS LOUPAKIS;VALENTINA GUARNERI;LAURA BONANNO;VANNA CHIARION‐SILENI;FRANCESCA BERGAMO;GIUSEPPE LOMBARDI;MARTA SCHIRRIPA;CAMILLO ALIBERTI;LAURA EVANGELISTA;GAIA GRIGUOLO;GIULIA PASELLO;MARCO SCARPA;MARIA VITTORIA DIECI;UMBERTO BASSO;STEFANO INDRACCOLO;GIAN LUCA DE SALVO;ENRICO ORVIETO","49;43;36;23;21;19;18;17;17;16;14;14;13;13;12;12;12;11;11;11","VITTORINA ZAGONEL;PIERFRANCO CONTÉ;LAURA EVANGELISTA;SARA LONARDI;GIUSEPPE LOMBARDI;FOTIOS LOUPAKIS;ANTONIO SOMMARIVA;CAMILLO ALIBERTI;VALENTINA GUARNERI;VANNA CHIARION‐SILENI;LAURA BONANNO;MARTA SCHIRRIPA;IVA ŠABOVIĆ;CHIARA TREVISIOL;RICCARDO CARANDINA;CARLO RICCARDO ROSSI;FRANCESCA BERGAMO;STEFANO INDRACCOLO;ANGELO CLAUDIO PALOZZO;ARDI PAMBUKU","3.57;2.95;2.42;2.17;2.13;1.67;1.48;1.4;1.28;1.24;1.16;1.12;1.1;1.1;1.06;1.05;1.05;1.04;1.04;1.03","PIERFRANCO CONTÉ;SARA LONARDI;ANNE ARMSTRONG;BINGHE XU;CARSTEN GOESSL;ELŻBIETA SENKUS;MARK E. ROBSON;NADINE TUNG;NORIKAZU MASUDA;SUZETTE DELALOGE;SARAH RUNSWICK;SUSAN M. DOMCHEK;SEOCK‐AH IM;WENTING WU;HEINZ‐JOSEF LENZ;WĚI LI;ANDREW G. HILL;SCOTT KOPETZ;MICHAEL A. MORSE;MICHAEL J. OVERMAN","3038;2736;2597;2597;2597;2597;2597;2597;2597;2597;2592;2592;2588;2588;2548;2544;2524;2409;2407;2407","PIERFRANCO CONTÉ;SARA LONARDI;VANNA CHIARION‐SILENI;CARLO RICCARDO ROSSI;VITTORINA ZAGONEL;UMBERTO BASSO;FEDERICA VIANELLO;SIMONA AGATA;STEFANO INDRACCOLO;GIUSEPPE OPOCHER;GIAN LUCA DE SALVO;ELEONORA BERGO;VALENTINA GUARNERI;ANTONIO ROSATO;FOTIOS LOUPAKIS;ADOLFO FAVARETTO;ANNAROSA DEL MISTRO;ANGELA DE PAOLI;FRANCESCA SCHIAVI;H. KOUSSIS","2991;2736;2164;1318;805;471;381;340;334;331;324;313;290;280;262;183;183;168;164;164","VITTORINA ZAGONEL;PIERFRANCO CONTÉ;SARA LONARDI;VALENTINA GUARNERI;FOTIOS LOUPAKIS;LAURA BONANNO;FRANCESCA BERGAMO;VANNA CHIARION‐SILENI;GIUSEPPE LOMBARDI;CAMILLO ALIBERTI;GIULIA PASELLO;LAURA EVANGELISTA;UMBERTO BASSO;MARCO SCARPA;CARLO CASTORO;STEFANO INDRACCOLO;GIAN LUCA DE SALVO;MARIA VITTORIA DIECI;RICCARDO CARANDINA;MARCO MARUZZO","47;37;36;19;19;18;17;16;16;14;13;13;12;12;11;11;10;10;10;9","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;PHYSICS;ECONOMICS;MATHEMATICS;POLITICAL SCIENCE;ENGINEERING;SOCIOLOGY;MATERIALS SCIENCE;PSYCHOLOGY;BUSINESS;PHILOSOPHY;GEOGRAPHY;HISTORY","337;112;34;23;18;11;11;9;8;6;5;4;3;3;1;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;GASTROENTEROLOGY;CANCER RESEARCH;PATHOLOGY;GENETICS;BIOCHEMISTRY;PALEONTOLOGY;ENVIRONMENTAL HEALTH;NURSING;RADIOLOGY;FAMILY MEDICINE;IMMUNOLOGY;CELL BIOLOGY;NUCLEAR MEDICINE;UROLOGY;ENDOCRINOLOGY;MEDICAL PHYSICS;PHARMACOLOGY","303;203;94;83;69;60;49;47;34;33;30;28;23;20;18;16;11;10;10;10","CANCER;CHEMOTHERAPY;GENE;CLINICAL TRIAL;CONFIDENCE INTERVAL;ADVERSE EFFECT;POPULATION;RADIATION THERAPY;RANDOMIZED CONTROLLED TRIAL;COHORT;STAGE (STRATIGRAPHY);PROPORTIONAL HAZARDS MODEL;LUNG CANCER;MULTIVARIATE ANALYSIS;RETROSPECTIVE COHORT STUDY;MELANOMA;QUALITY OF LIFE (HEALTHCARE);OVERALL SURVIVAL;IMMUNE SYSTEM;DISEASE;IMMUNOHISTOCHEMISTRY;PROSPECTIVE COHORT STUDY","216;96;65;43;39;32;32;28;26;24;24;23;21;21;21;19;16;15;14;13;13;13","COLORECTAL CANCER;BREAST CANCER;CLINICAL ENDPOINT;PROGRESSION-FREE SURVIVAL;HAZARD RATIO;BEVACIZUMAB;IMMUNOTHERAPY;PHASES OF CLINICAL RESEARCH;METASTASIS;GENOTYPE;PROSTATE CANCER;CISPLATIN;UNIVARIATE ANALYSIS;ADENOCARCINOMA;DOCETAXEL;METASTATIC MELANOMA;MUTATION;PROGRESSIVE DISEASE;TEMOZOLOMIDE;PLACEBO","66;55;42;35;31;22;22;20;19;17;15;14;14;12;12;12;11;11;11;10","METASTATIC BREAST CANCER;IRINOTECAN;OXALIPLATIN;KRAS;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;SINGLE-NUCLEOTIDE POLYMORPHISM;VEMURAFENIB;CETUXIMAB;NIVOLUMAB;IPILIMUMAB;MICROSATELLITE;ANDROGEN RECEPTOR;CIRCULATING TUMOR CELL;POLY ADP RIBOSE POLYMERASE;ANDROGEN DEPRIVATION THERAPY;CAPECITABINE;ESTROGEN RECEPTOR;REGORAFENIB;BARRETT'S ESOPHAGUS;BRCA MUTATION;CRIZOTINIB;PAZOPANIB;PEMETREXED;TRAMETINIB;VINORELBINE","18;15;13;12;12;12;11;10;10;8;8;7;7;7;6;6;6;6;5;5;5;5;5;5;5",";HUMANS;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;COLORECTAL NEOPLASMS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;BREAST NEOPLASMS;MELANOMA;ANTINEOPLASTIC AGENTS;BIOMARKERS, TUMOR;AGED, 80 AND OVER;ADENOCARCINOMA;SKIN NEOPLASMS;TREATMENT OUTCOME;ITALY;NEOPLASMS;ESOPHAGEAL NEOPLASMS","193;157;113;99;99;85;79;62;60;54;50;43;42;39;36;33;32;30;30;29","ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;GLIOMAS;ADVANCEMENTS IN LUNG CANCER RESEARCH;MOLECULAR RESEARCH ON BREAST CANCER;MAMMALIAN MAP KINASE SIGNALING PATHWAYS;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;HEPATOCELLULAR CARCINOMA;COLORECTAL CANCER RESEARCH AND TREATMENT;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;MOLECULAR CHARACTERIZATION OF COLORECTAL CANCER;PREOPERATIVE CHEMORADIOTHERAPY FOR ESOPHAGEAL CANCER;RENAL CELL CARCINOMA;GASTRIC CANCER RESEARCH AND TREATMENT;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;SARCOMA RESEARCH AND TREATMENT;CANCER IMMUNOTHERAPY;APPLICATIONS OF ELECTROPORATION IN BIOTECHNOLOGY AND FOOD PROCESSING;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER","28;17;16;11;10;9;9;7;7;7;7;7;7;6;6;6;5;4;4;4","CLINICAL ENDPOINT;PROGRESSION-FREE SURVIVAL;METASTATIC COLORECTAL CANCER;BREAST CANCER;MELANOMA;TREATMENT;TUMOR MICROENVIRONMENT;UNIVARIATE ANALYSIS;GLIOBLASTOMA;FOLFIRI;TEMOZOLOMIDE;REGIMEN;BARRETT'S ESOPHAGUS;CANCER THERAPY;METASTATIC BREAST CANCER;REFRACTORY (PLANETARY SCIENCE);CHEMORADIOTHERAPY;CIRCULATING TUMOR CELL;DNA MISMATCH REPAIR;MICROSATELLITE INSTABILITY","42;36;26;17;17;17;16;15;13;11;11;10;9;9;8;8;7;7;7;7","COLORECTAL CANCER;BREAST CANCER;METASTATIC COLORECTAL;PATIENTS PTS;CANCER PATIENTS;LUNG CANCER;CELL CARCINOMA;PHASE III;PATIENTS TREATED;PHASE II;PHASE TRIAL;PROSTATE CANCER;RENAL CELL;CIRCULATING TUMOR;METASTATIC BREAST;METASTATIC RENAL;CANCER MCRC;CELL LUNG;ITALIAN STUDY;RETROSPECTIVE ANALYSIS;CANCER NSCLC;ADVANCED BREAST;CANCER MBC;DNA MISMATCH;FINAL RESULTS;GASTRIC CANCER;GLIOBLASTOMA GBM;HEPATOCELLULAR CARCINOMA;II STUDY;MULTICENTER ITALIAN","40;36;28;26;25;16;14;14;12;12;12;12;11;10;10;10;9;9;9;9;8;7;6;6;6;6;6;6;6;6","BRISTOL-MYERS SQUIBB;HR CI;COLORECTAL CANCER;RESEARCH FUNDING;PROGRESSION-FREE SURVIVAL;MEDIAN AGE;SURVIVAL OS;BREAST CANCER;SURVIVAL PFS;METASTATIC COLORECTAL;ADVERSE EVENTS;CANCER PATIENTS;PATIENTS PTS;PATIENTS TREATED;ADVISORY BOARD;ENTITY RESPONSIBLE;LEGAL ENTITY;RESPONSE RATE;PERSONAL FEES;ARRAY BIOPHARMA;CLINICAL TRIAL;HAZARD RATIO;PRIMARY ENDPOINT;ECOG PS;MEDIAN FOLLOW-UP;NOVARTIS ROCHE;CLINICAL PRACTICE;MEDIAN OS;PADOVA ITALY;PATIENTS RECEIVING","93;65;59;47;44;43;40;39;38;33;32;32;32;32;31;29;29;29;28;27;27;27;27;26;26;24;23;23;23;23",150,0.42,7,6.75,2,2,1,4,2,1,1,8,1,1,7,1,3.5,1,5.75,5,4,0,0,61.75,60.75,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_IOV",2018,420,17.5690476190476,2.93333333333333,0.340909090909091,0.245238095238095,0.252380952380952,0.152380952380952,0.552380952380952,2,296,60,29,5,0.7,0.14,0.07,0.01,44.68,1.46455290348474,0.507142857142857,0.985714285714286,6.94559099437148,0.567596324817161,0.501681132223004,0.585718751395525,0.598611111111111,"VITTORINA ZAGONEL;SARA LONARDI;FOTIOS LOUPAKIS;ALFREDO FALCONE;CHIARA CREMOLINI;FRANCESCA BERGAMO;PIERFRANCO CONTÉ;MATTEO FASSAN;VANNA CHIARION‐SILENI;HEINZ‐JOSEF LENZ;VALENTINA GUARNERI;GIUSEPPE LOMBARDI;MARTA SCHIRRIPA;MASSIMO RUGGE;LORENZA RIMASSA;FILIPPO PIETRANTONIO;STEFANO INDRACCOLO;DANIELE SANTINI;GIANLUCA MASI;LAURA EVANGELISTA","60;54;37;32;32;30;26;24;22;22;21;21;20;19;19;19;18;18;17;17","VITTORINA ZAGONEL;LAURA EVANGELISTA;SARA LONARDI;FOTIOS LOUPAKIS;ALFREDO FALCONE;PIERFRANCO CONTÉ;MATTEO FASSAN;GIUSEPPE LOMBARDI;CHIARA CREMOLINI;FRANCESCA BERGAMO;HEINZ‐JOSEF LENZ;VALENTINA GUARNERI;GIULIA PASELLO;LEA CUPPARI;STEFANO INDRACCOLO;MASSIMO RUGGE;ANTONIO SOMMARIVA;VANNA CHIARION‐SILENI;M. PAIUSCO;MARCO SCARPA","3.64;3.16;2.75;2.17;1.78;1.76;1.72;1.65;1.62;1.61;1.59;1.53;1.52;1.44;1.41;1.41;1.39;1.39;1.36;1.29","VITTORINA ZAGONEL;SARA LONARDI;FOTIOS LOUPAKIS;ALFREDO FALCONE;CHIARA CREMOLINI;FRANCESCA BERGAMO;PIERFRANCO CONTÉ;VANNA CHIARION‐SILENI;HEINZ‐JOSEF LENZ;VALENTINA GUARNERI;GIUSEPPE LOMBARDI;MARTA SCHIRRIPA;MASSIMO RUGGE;LORENZA RIMASSA;STEFANO INDRACCOLO;LAURA EVANGELISTA;ALBERTO ZANIBONI;UMBERTO BASSO;MARIA VITTORIA DIECI;MARCO SCARPA","60;54;37;32;32;30;26;22;22;21;21;20;19;19;18;17;16;16;15;14","VITTORINA ZAGONEL;LAURA EVANGELISTA;SARA LONARDI;FOTIOS LOUPAKIS;ALFREDO FALCONE;PIERFRANCO CONTÉ;GIUSEPPE LOMBARDI;CHIARA CREMOLINI;FRANCESCA BERGAMO;HEINZ‐JOSEF LENZ;VALENTINA GUARNERI;GIULIA PASELLO;LEA CUPPARI;STEFANO INDRACCOLO;MASSIMO RUGGE;ANTONIO SOMMARIVA;VANNA CHIARION‐SILENI;M. PAIUSCO;MARCO SCARPA;GIOVANNI FAGGIONI","3.64;3.16;2.75;2.17;1.78;1.76;1.65;1.62;1.61;1.59;1.53;1.52;1.44;1.41;1.41;1.39;1.39;1.36;1.29;1.29","VITTORINA ZAGONEL;ANN‐LII CHENG;STEPHEN L. CHAN;ROBIN KATE KELLEY;VANNA CHIARION‐SILENI;SARA LONARDI;ANDREW G. HILL;DIRK SCHADENDORF;LORENZA RIMASSA;BRUNO DANIELE;NEVENA DAMJANOV;REINHARD DUMMER;JENNIFER J. KNOX;LUIGI BOLONDI;JEAN‐FRÉDÉRIC BLANC;ALLEN LEE COHN;CARMINE PINTO;ABBY B. SIEGEL;ANDREW X. ZHU;ARNDT VOGEL","5935;4179;4143;4127;3181;3092;2898;2876;2808;2767;2731;2657;2458;2316;2249;2156;2153;2147;2147;2147","VITTORINA ZAGONEL;VANNA CHIARION‐SILENI;SARA LONARDI;ALAIN HENDLISZ;ANDREW G. HILL;BART NEYNS;ERIC VAN CUTSEM;FABIO GELSOMINO;HEINZ‐JOSEF LENZ;JEAN-MARIE LEDEINE;KA YEUNG MARK WONG;MAGALI SVRCEK;MASSIMO AGLIETTA;MICHAEL A. MORSE;MICHAEL B. SAWYER;MICHAEL J. OVERMAN;RAY MCDERMOTT;REBECCA A. MOSS;SCOTT KOPETZ;SHITAL KAMBLE","5914;3181;3092;1677;1677;1677;1677;1677;1677;1677;1677;1677;1677;1677;1677;1677;1677;1677;1677;1677","VITTORINA ZAGONEL;SARA LONARDI;FOTIOS LOUPAKIS;FRANCESCA BERGAMO;PIERFRANCO CONTÉ;VANNA CHIARION‐SILENI;VALENTINA GUARNERI;GIUSEPPE LOMBARDI;STEFANO INDRACCOLO;LAURA EVANGELISTA;UMBERTO BASSO;MARTA SCHIRRIPA;MARIA VITTORIA DIECI;GIAN LUCA DE SALVO;ILARIA ATTILI;MARCO SCARPA;LUISA BELLU;ARDI PAMBUKU;M. PAIUSCO;GIULIA PASELLO","57;54;31;30;25;22;20;19;18;16;16;15;14;13;12;12;11;10;10;10","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;MATHEMATICS;ENGINEERING;MATERIALS SCIENCE;SOCIOLOGY;ECONOMICS;PHILOSOPHY;POLITICAL SCIENCE;PSYCHOLOGY;BUSINESS;GEOGRAPHY;GEOLOGY;HISTORY","394;143;47;27;24;18;15;13;13;10;7;6;5;1;1;1;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;CANCER RESEARCH;PATHOLOGY;GASTROENTEROLOGY;GENETICS;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;PALEONTOLOGY;RADIOLOGY;IMMUNOLOGY;NUCLEAR MEDICINE;CELL BIOLOGY;NURSING;PHARMACOLOGY;OPTICS;UROLOGY;ARTIFICIAL INTELLIGENCE;ENDOCRINOLOGY;GENERAL SURGERY","345;244;97;91;84;74;74;54;42;35;33;32;31;20;18;16;13;12;10;10;10","CANCER;CHEMOTHERAPY;GENE;CONFIDENCE INTERVAL;CLINICAL TRIAL;POPULATION;RANDOMIZED CONTROLLED TRIAL;ADVERSE EFFECT;RADIATION THERAPY;COHORT;STAGE (STRATIGRAPHY);ALTERNATIVE MEDICINE;MULTIVARIATE ANALYSIS;REGIMEN;DISEASE;PROPORTIONAL HAZARDS MODEL;IMMUNE SYSTEM;OVERALL SURVIVAL;RETROSPECTIVE COHORT STUDY;LUNG CANCER;MELANOMA","275;101;81;47;41;40;38;31;30;29;24;23;23;23;22;22;19;18;17;15;15","COLORECTAL CANCER;BREAST CANCER;CLINICAL ENDPOINT;HAZARD RATIO;BEVACIZUMAB;PROGRESSION-FREE SURVIVAL;IMMUNOTHERAPY;MUTATION;PHASES OF CLINICAL RESEARCH;METASTASIS;PLACEBO;GENOTYPE;PROSTATE CANCER;CISPLATIN;OVARIAN CANCER;TEMOZOLOMIDE;ALLELE;METASTATIC MELANOMA;UNIVARIATE ANALYSIS;EPIDERMAL GROWTH FACTOR RECEPTOR;SORAFENIB","111;60;54;42;37;34;29;22;22;21;20;19;16;14;14;14;12;12;12;10;10","KRAS;OXALIPLATIN;IRINOTECAN;CETUXIMAB;NIVOLUMAB;METASTATIC BREAST CANCER;REGORAFENIB;SINGLE-NUCLEOTIDE POLYMORPHISM;VEMURAFENIB;CAPECITABINE;IPILIMUMAB;GERMLINE MUTATION;TRASTUZUMAB;MICROSATELLITE;TRIPLE-NEGATIVE BREAST CANCER;CIRCULATING TUMOR CELL;ESTROGEN RECEPTOR;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;TRAMETINIB;TUMOR-INFILTRATING LYMPHOCYTES","33;30;23;19;15;14;13;13;11;10;10;9;9;8;8;7;7;7;7;7",";HUMANS;FEMALE;MALE;MIDDLE AGED;AGED;COLORECTAL NEOPLASMS;ADULT;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;BREAST NEOPLASMS;BIOMARKERS, TUMOR;ANTINEOPLASTIC AGENTS;ITALY;LUNG NEOPLASMS;MELANOMA;PROGNOSIS;AGED, 80 AND OVER;LIVER NEOPLASMS;NEOPLASM RECURRENCE, LOCAL;SKIN NEOPLASMS","234;180;138;128;109;100;82;79;78;51;47;46;46;44;44;43;40;40;39;39","ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;GLIOMAS;MAMMALIAN MAP KINASE SIGNALING PATHWAYS;CANCER IMMUNOTHERAPY;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;SARCOMA RESEARCH AND TREATMENT;MOLECULAR CHARACTERIZATION OF COLORECTAL CANCER;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;ADVANCEMENTS IN LUNG CANCER RESEARCH;HEPATOCELLULAR CARCINOMA;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;GASTRIC CANCER RESEARCH AND TREATMENT;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;PREOPERATIVE CHEMORADIOTHERAPY FOR ESOPHAGEAL CANCER;RADIOMICS IN MEDICAL IMAGING ANALYSIS;APPLICATIONS OF ELECTROPORATION IN BIOTECHNOLOGY AND FOOD PROCESSING;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;DEVELOPMENT AND APPLICATIONS OF RADIOPHARMACEUTICALS;MALIGNANT PLEURAL MESOTHELIOMA RESEARCH;MANAGEMENT OF BRAIN METASTASES IN CANCER PATIENTS","49;17;16;14;13;13;12;10;8;8;6;6;6;6;6;5;5;5;5;5","CLINICAL ENDPOINT;METASTATIC COLORECTAL CANCER;PROGRESSION-FREE SURVIVAL;REGIMEN;BREAST CANCER;FOLFIRI;GLIOBLASTOMA;FOLFOX;TEMOZOLOMIDE;TREATMENT;TUMOR MICROENVIRONMENT;MELANOMA;BIOMARKER ANALYSIS;REGORAFENIB;PET/CT;CANCER GENOMICS;UNIVARIATE ANALYSIS;CANCER RISK;METASTATIC BREAST CANCER;SOFT TISSUE SARCOMA","56;46;34;23;20;19;16;15;15;15;15;14;13;13;12;11;11;10;10;10","COLORECTAL CANCER;METASTATIC COLORECTAL;BREAST CANCER;CANCER PATIENTS;PATIENTS PTS;CANCER MCRC;PHASE III;PHASE II;LUNG CANCER;PROSTATE CANCER;CELL LUNG;RANDOMIZED PHASE;HEPATOCELLULAR CARCINOMA;NON-SMALL CELL;PATIENTS TREATED;PHASE TRIAL;SOFT TISSUE;ABSTRACT P--;ADVANCED HEPATOCELLULAR;TISSUE SARCOMA;WILD-TYPE METASTATIC;FINAL RESULTS;LIQUID BIOPSY;MCRC PATIENTS;METASTATIC BREAST;OVARIAN CANCER;CELL CARCINOMA;CYTOREDUCTIVE SURGERY;II TRIAL;MULTICENTER STUDY","66;60;35;35;26;21;20;15;14;14;12;11;10;10;10;10;10;8;8;8;8;7;7;7;7;7;6;6;6;6","BRISTOL-MYERS SQUIBB;HR CI;BREAST CANCER;PROGRESSION-FREE SURVIVAL;COLORECTAL CANCER;MERCK SERONO;SURVIVAL OS;ENTITY RESPONSIBLE;LEGAL ENTITY;RESEARCH FUNDING;CANCER PATIENTS;RESPONSE RATE;CELL LINES;HAZARD RATIO;METASTATIC COLORECTAL;SPEAKERS BUREAU;SURVIVAL PFS;MEDIAN PFS;ADVISORY BOARD;PATIENTS TREATED;AE AE;MEDIAN OS;PIERRE FABRE;CONFIDENCE INTERVAL;MULTIVARIATE ANALYSIS;PRIMARY ENDPOINT;ADVERSE EVENTS;NOVARTIS ROCHE;ADVISORY ROLE;CLINICAL TRIAL","101;97;51;51;46;45;45;39;39;38;37;36;35;35;33;33;33;32;31;31;30;30;29;28;28;27;26;26;25;25",170,0.4,9.94,10,2,1.5,2,5,2,0,2,11,1,1,11,1,2.25,2,6,8,6,0,0,73.75,73,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_IOV",2019,397,17.9697732997481,2.58438287153652,0.386939571150097,0.209068010075567,0.173803526448363,0.163727959697733,0.596977329974811,1,269,57,26,4,0.68,0.14,0.07,0.01,47.69,1.96129935179761,0.478589420654912,0.997481108312343,7.6374655647383,0.583483725047432,0.565521983925732,0.628589560526733,0.594420600858369,"SARA LONARDI;VITTORINA ZAGONEL;PIERFRANCO CONTÉ;ALFREDO FALCONE;FOTIOS LOUPAKIS;CHIARA CREMOLINI;FRANCESCA BERGAMO;VALENTINA GUARNERI;MATTEO FASSAN;FILIPPO PIETRANTONIO;VANNA CHIARION‐SILENI;GIUSEPPE LOMBARDI;LAURA BONANNO;DANIELE SANTINI;MASSIMO RUGGE;GIULIA PASELLO;GIUSEPPE APRILE;FILIPPO DE BRAUD;UGO DE GIORGI;UMBERTO BASSO","66;46;44;31;30;30;28;28;27;22;21;20;20;20;19;19;19;16;16;16","SARA LONARDI;PIERFRANCO CONTÉ;VITTORINA ZAGONEL;MATTEO FASSAN;VALENTINA GUARNERI;LAURA EVANGELISTA;FOTIOS LOUPAKIS;GIULIA PASELLO;ALFREDO FALCONE;GIUSEPPE LOMBARDI;FRANCESCA BERGAMO;LAURA BONANNO;JESSICA MENIS;CHIARA CREMOLINI;MASSIMO RUGGE;VANNA CHIARION‐SILENI;HEINZ‐JOSEF LENZ;UMBERTO BASSO;STEFANO INDRACCOLO;GIUSEPPE APRILE","3.42;3.36;2.97;1.91;1.89;1.77;1.69;1.67;1.6;1.59;1.5;1.44;1.43;1.42;1.32;1.15;1.05;1.05;0.98;0.97","SARA LONARDI;VITTORINA ZAGONEL;PIERFRANCO CONTÉ;FOTIOS LOUPAKIS;FRANCESCA BERGAMO;VALENTINA GUARNERI;MATTEO FASSAN;VANNA CHIARION‐SILENI;GIUSEPPE LOMBARDI;LAURA BONANNO;MASSIMO RUGGE;GIULIA PASELLO;UMBERTO BASSO;MARIA VITTORIA DIECI;GIAN LUCA DE SALVO;MARTA SCHIRRIPA;GAIA GRIGUOLO;STEFANO INDRACCOLO;SABINA MURGIONI;PAOLA DEL BIANCO","66;46;44;30;28;28;27;21;20;20;19;19;16;15;14;14;14;13;13;13","SARA LONARDI;PIERFRANCO CONTÉ;VITTORINA ZAGONEL;MATTEO FASSAN;VALENTINA GUARNERI;LAURA EVANGELISTA;FOTIOS LOUPAKIS;GIULIA PASELLO;GIUSEPPE LOMBARDI;FRANCESCA BERGAMO;LAURA BONANNO;JESSICA MENIS;MASSIMO RUGGE;VANNA CHIARION‐SILENI;UMBERTO BASSO;STEFANO INDRACCOLO;PAOLA DEL BIANCO;ALESSANDRA ZORZ;GIAN LUCA DE SALVO;ANTONELLA BRUNELLO","3.42;3.36;2.97;1.91;1.89;1.77;1.69;1.67;1.59;1.5;1.44;1.43;1.32;1.15;1.05;0.98;0.95;0.92;0.91;0.89","PIOTR RUTKOWSKI;DIRK SCHADENDORF;VANNA CHIARION‐SILENI;CÉLÈSTE LEBBÉ;PIERFRANCO CONTÉ;JEAN‐JACQUES GROB;JOHN B.A.G. HAANEN;PAOLO A. ASCIERTO;GEORGINA V. LONG;IVÁN MÁRQUEZ‐RODAS;MICHAEL SMYLIE;REINHARD DUMMER;MICHELE MAIO;RENÉ GONZÁLEZ;JEDD D. WOLCHOK;JAMES LARKIN;C. LANCE COWEY;PIER FRANCESCO FERRUCCI;F. STEPHEN HODI;JASMINE I. RIZZO","4815;4692;4579;4418;4371;4079;4062;4026;3987;3410;3383;3295;3242;3210;3073;3063;2991;2932;2900;2900","VANNA CHIARION‐SILENI;PIERFRANCO CONTÉ;SARA LONARDI;FOTIOS LOUPAKIS;MARIA VITTORIA DIECI;VALENTINA GUARNERI;VITTORINA ZAGONEL;FRANCESCA BERGAMO;LAURA BONANNO;UMBERTO BASSO;GIAN LUCA DE SALVO;PAOLA DEL BIANCO;MARCO RASTRELLI;JACOPO PIGOZZO;GIUSEPPE LOMBARDI;SUSANNA MANDRUZZATO;MARTA SCHIRRIPA;GIULIA PASELLO;ALBERTO PAVAN;ALESSANDRO DAL MASO","4579;4318;2698;2061;1093;822;749;604;516;513;481;454;441;336;304;297;292;230;218;207","SARA LONARDI;VITTORINA ZAGONEL;PIERFRANCO CONTÉ;FOTIOS LOUPAKIS;FRANCESCA BERGAMO;VALENTINA GUARNERI;VANNA CHIARION‐SILENI;LAURA BONANNO;GIUSEPPE LOMBARDI;GIULIA PASELLO;UMBERTO BASSO;GIAN LUCA DE SALVO;MARTA SCHIRRIPA;STEFANO INDRACCOLO;PAOLA DEL BIANCO;MARIA VITTORIA DIECI;SABINA MURGIONI;GAIA GRIGUOLO;VINCENZO DADDUZIO;ANTONELLA BRUNELLO","66;45;35;30;27;24;21;20;20;17;16;14;14;13;13;12;12;11;11;10","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;MATHEMATICS;SOCIOLOGY;MATERIALS SCIENCE;PSYCHOLOGY;PHILOSOPHY;ECONOMICS;BUSINESS;ART;GEOGRAPHY;HISTORY;ENGINEERING;GEOLOGY;POLITICAL SCIENCE","379;135;30;26;19;14;10;8;8;7;6;3;2;2;2;1;1;1","INTERNAL MEDICINE;ONCOLOGY;CANCER RESEARCH;PATHOLOGY;SURGERY;GASTROENTEROLOGY;GENETICS;BIOCHEMISTRY;PALEONTOLOGY;ENVIRONMENTAL HEALTH;IMMUNOLOGY;RADIOLOGY;CELL BIOLOGY;NUCLEAR MEDICINE;BIOINFORMATICS;NURSING;OPTICS;UROLOGY;MEDICAL PHYSICS;GYNECOLOGY","337;250;93;92;88;77;51;49;38;30;29;27;21;20;17;17;16;16;15;13","CANCER;CHEMOTHERAPY;GENE;CLINICAL TRIAL;RANDOMIZED CONTROLLED TRIAL;CONFIDENCE INTERVAL;ADVERSE EFFECT;RADIATION THERAPY;POPULATION;STAGE (STRATIGRAPHY);COHORT;LUNG CANCER;ALTERNATIVE MEDICINE;MELANOMA;DISEASE;PROPORTIONAL HAZARDS MODEL;IMMUNE SYSTEM;IMMUNOHISTOCHEMISTRY;DISCONTINUATION;REGIMEN","269;98;60;51;48;35;31;31;28;27;24;24;22;22;19;18;17;17;15;15","COLORECTAL CANCER;BREAST CANCER;CLINICAL ENDPOINT;IMMUNOTHERAPY;HAZARD RATIO;PROGRESSION-FREE SURVIVAL;BEVACIZUMAB;MUTATION;PHASES OF CLINICAL RESEARCH;PLACEBO;PROSTATE CANCER;ADENOCARCINOMA;CISPLATIN;TEMOZOLOMIDE;SOFT TISSUE SARCOMA;CHEMORADIOTHERAPY;DOCETAXEL;EPIDERMAL GROWTH FACTOR RECEPTOR;ALLELE;GENOTYPE;OVARIAN CANCER;UNIVARIATE ANALYSIS","95;57;54;34;27;27;23;21;21;17;15;12;12;12;11;10;10;10;9;9;9;9","NIVOLUMAB;OXALIPLATIN;IRINOTECAN;IPILIMUMAB;KRAS;CAPECITABINE;TRASTUZUMAB;REGORAFENIB;METASTATIC BREAST CANCER;CETUXIMAB;GERMLINE MUTATION;ANDROGEN RECEPTOR;ESTROGEN RECEPTOR;MICROSATELLITE;TAXANE;ANDROGEN DEPRIVATION THERAPY;ANTHRACYCLINE;DNA MISMATCH REPAIR;ESOPHAGECTOMY;HORMONE RECEPTOR;PEMBROLIZUMAB","23;23;17;16;14;12;12;11;10;9;9;8;8;8;8;6;6;6;6;6;6",";HUMANS;FEMALE;MALE;MIDDLE AGED;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;AGED;ADULT;COLORECTAL NEOPLASMS;AGED, 80 AND OVER;BREAST NEOPLASMS;LUNG NEOPLASMS;MELANOMA;SKIN NEOPLASMS;PROGNOSIS;RETROSPECTIVE STUDIES;ITALY;CARCINOMA, NON-SMALL-CELL LUNG;NEOPLASM RECURRENCE, LOCAL;TREATMENT OUTCOME","208;187;142;122;122;109;103;90;88;65;65;58;56;46;43;40;39;37;37;35","ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;CANCER IMMUNOTHERAPY;GLIOMAS;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;SARCOMA RESEARCH AND TREATMENT;ADVANCEMENTS IN LUNG CANCER RESEARCH;HEPATOCELLULAR CARCINOMA;HER2 SIGNALING IN BREAST CANCER TREATMENT;MAMMALIAN MAP KINASE SIGNALING PATHWAYS;MICRORNA REGULATION IN CANCER AND DEVELOPMENT;PREOPERATIVE CHEMORADIOTHERAPY FOR ESOPHAGEAL CANCER;RADIOMICS IN MEDICAL IMAGING ANALYSIS;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;LYMPHOID NEOPLASMS;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;MOLECULAR CHARACTERIZATION OF COLORECTAL CANCER;COLORECTAL CANCER RESEARCH AND TREATMENT;GASTRIC CANCER RESEARCH AND TREATMENT","35;23;15;14;12;10;10;8;8;8;8;7;7;7;6;6;6;6;5;5","CLINICAL ENDPOINT;METASTATIC COLORECTAL CANCER;BREAST CANCER;PROGRESSION-FREE SURVIVAL;TUMOR MICROENVIRONMENT;REGIMEN;DISCONTINUATION;FOLFIRI;MELANOMA;FOLFOX;TEMOZOLOMIDE;BIOMARKERS FOR IMMUNOTHERAPY;REGORAFENIB;ADJUVANT THERAPY;CHEMORADIOTHERAPY;HER2;METASTATIC GASTRIC CANCER;CONCOMITANT;TREATMENT;UNIVARIATE ANALYSIS","54;40;27;27;21;16;15;15;14;13;12;11;11;10;10;10;10;9;9;9","COLORECTAL CANCER;METASTATIC COLORECTAL;BREAST CANCER;CANCER PATIENTS;PHASE II;PATIENTS PTS;LUNG CANCER;PHASE III;CELL LUNG;CANCER MCRC;PROSTATE CANCER;RANDOMIZED PHASE;NON-SMALL CELL;PATIENTS TREATED;II STUDY;POOLED ANALYSIS;OVARIAN CANCER;ADVANCED BREAST;ADVANCED NON-SMALL;CASTRATION-RESISTANT PROSTATE;CELL CARCINOMA;COLON CANCER;EPIDERMAL GROWTH;HEPATOCELLULAR CARCINOMA;METASTATIC CASTRATION-RESISTANT;FIRST-LINE CHEMOTHERAPY;GROWTH FACTOR;PHASE TRIAL;STAGE III;WILD-TYPE METASTATIC","56;44;42;32;29;25;21;20;15;13;13;13;12;12;11;11;10;8;8;8;8;8;8;8;8;7;7;7;7;7","ADVISORY CONSULTANCY;RESEARCH GRANT;ACCOMMODATION EXPENSES;TRAVEL ACCOMMODATION;GRANT FUNDING;HR CI;FUNDING INSTITUTION;BREAST CANCER;SPEAKER BUREAU;EXPERT TESTIMONY;BUREAU EXPERT;PROGRESSION-FREE SURVIVAL;ADVERSE EVENTS;COLORECTAL CANCER;PATIENTS TREATED;SURVIVAL OS;CLINICAL TRIAL;CONSULTANCY TRAVEL;ENTITY RESPONSIBLE;LEGAL ENTITY;MEDIAN PFS;METASTATIC COLORECTAL;SURVIVAL PFS;CELL LINES;OVARIAN CANCER;INSTITUTION TRAVEL;MEDIAN OS;DISEASE PROGRESSION;ELI LILLY;MEDIAN FOLLOW-UP","262;97;96;96;95;80;79;75;70;59;57;51;42;38;37;36;35;34;34;34;33;30;30;29;29;26;26;25;25;25",174,0.44,11.66,10,2,1,0,5,2.5,1,1,12,1,1,10,1,3,2,7.75,8,6,0,0,73.75,73.75,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_IOV",2020,453,17.7152317880795,2.48565121412804,0.402309058614565,0.218543046357616,0.240618101545254,0.132450331125828,0.649006622516556,2,307,70,24,9,0.68,0.15,0.05,0.02,28.92,1.1477929611149,0.426048565121413,0.988962472406181,9.33850493653029,0.546099759217841,0.573015873015873,0.552864785396333,0.522008184449546,"SARA LONARDI;VITTORINA ZAGONEL;PIERFRANCO CONTÉ;VALENTINA GUARNERI;MATTEO FASSAN;FRANCESCA BERGAMO;FOTIOS LOUPAKIS;MARIA VITTORIA DIECI;UMBERTO BASSO;ANGELO PAOLO DEI TOS;MARCO MARUZZO;UGO DE GIORGI;FILIPPO PIETRANTONIO;CHIARA CREMOLINI;ANTONELLA BRUNELLO;DANIELE SANTINI;VANNA CHIARION‐SILENI;GIUSEPPE LOMBARDI;GIULIA PASELLO;ALBERTO ZANIBONI","58;57;44;39;34;27;26;25;25;23;21;21;21;21;19;19;18;18;18;17","VITTORINA ZAGONEL;VALENTINA GUARNERI;SARA LONARDI;PIERFRANCO CONTÉ;STEFANO INDRACCOLO;MATTEO FASSAN;MARIA VITTORIA DIECI;GIUSEPPE LOMBARDI;UMBERTO BASSO;ANTONIO ROSATO;LAURA EVANGELISTA;PIERLUIGI PILATI;FOTIOS LOUPAKIS;FRANCESCA BERGAMO;MARCO MARUZZO;ANGELO PAOLO DEI TOS;ANTONELLA BRUNELLO;ANTONIO SOMMARIVA;MARIO CACCESE;GIULIA PASELLO","4;2.96;2.91;2.83;2.22;2.14;2.07;1.96;1.71;1.61;1.46;1.44;1.4;1.39;1.38;1.31;1.24;1.24;1.24;1.2","SARA LONARDI;VITTORINA ZAGONEL;PIERFRANCO CONTÉ;VALENTINA GUARNERI;MATTEO FASSAN;FRANCESCA BERGAMO;FOTIOS LOUPAKIS;MARIA VITTORIA DIECI;UMBERTO BASSO;MARCO MARUZZO;ANTONELLA BRUNELLO;VANNA CHIARION‐SILENI;GIUSEPPE LOMBARDI;GIULIA PASELLO;ANTONIO ROSATO;STEFANO INDRACCOLO;MARIO CACCESE;PAOLA DEL BIANCO;GAIA GRIGUOLO;GIAN LUCA DE SALVO","58;57;44;39;34;27;26;25;25;21;19;18;18;18;17;15;14;14;14;13","VITTORINA ZAGONEL;VALENTINA GUARNERI;SARA LONARDI;PIERFRANCO CONTÉ;STEFANO INDRACCOLO;MATTEO FASSAN;MARIA VITTORIA DIECI;GIUSEPPE LOMBARDI;UMBERTO BASSO;ANTONIO ROSATO;LAURA EVANGELISTA;PIERLUIGI PILATI;FOTIOS LOUPAKIS;FRANCESCA BERGAMO;MARCO MARUZZO;ANTONELLA BRUNELLO;ANTONIO SOMMARIVA;MARIO CACCESE;GIULIA PASELLO;MARCO TONELLO","4;2.96;2.91;2.83;2.22;2.14;2.07;1.96;1.71;1.61;1.46;1.44;1.4;1.39;1.38;1.24;1.24;1.24;1.2;1.12","SARA LONARDI;TERUFUMI KATO;PIERFRANCO CONTÉ;THOMAS JOHN;LAURA BONANNO;FILIPPO DE MARINIS;AJLAN ATASOY;MARGARITA MAJEM;VITTORINA ZAGONEL;MARINA CHIARA GARASSINO;CHRISTIAN GROHÉ;CHARUWAN AKEWANLOP;CHONG‐JEN YU;FRANCES A. SHEPHERD;HUU-VINH VU;JIE HE;JONATHAN W. GOLDMAN;KYE YOUNG LEE;LINGMIN ZENG;MANUEL DÓMINE","2074;1874;1683;1389;1338;1336;1308;1296;1292;1269;1258;1256;1256;1256;1256;1256;1256;1256;1256;1256","SARA LONARDI;PIERFRANCO CONTÉ;LAURA BONANNO;VITTORINA ZAGONEL;VANNA CHIARION‐SILENI;FOTIOS LOUPAKIS;GIULIA PASELLO;VALENTINA GUARNERI;FRANCESCA BERGAMO;MARIA VITTORIA DIECI;MARCO RASTRELLI;ANTONELLA BRUNELLO;ALESSANDRO CRESTANI;GIAN LUCA DE SALVO;ANTONIO ROSATO;UMBERTO BASSO;FERNANDO A. BOZZA;STEFANO INDRACCOLO;SABINA MURGIONI;FILIPPO MONTEMURRO","2074;1630;1338;1292;1037;878;744;668;498;433;382;347;346;329;328;322;306;305;262;258","SARA LONARDI;VITTORINA ZAGONEL;PIERFRANCO CONTÉ;VALENTINA GUARNERI;FRANCESCA BERGAMO;FOTIOS LOUPAKIS;UMBERTO BASSO;MARCO MARUZZO;ANTONELLA BRUNELLO;MARIA VITTORIA DIECI;GIUSEPPE LOMBARDI;GIULIA PASELLO;VANNA CHIARION‐SILENI;STEFANO INDRACCOLO;PAOLA DEL BIANCO;MARIO CACCESE;GIAN LUCA DE SALVO;VINCENZO DADDUZIO;PIERLUIGI PILATI;MARTA SCHIRRIPA","58;57;34;32;27;26;24;21;19;19;18;18;18;15;14;13;13;12;11;11","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;PHYSICS;MATHEMATICS;POLITICAL SCIENCE;ECONOMICS;BUSINESS;PSYCHOLOGY;ENGINEERING;SOCIOLOGY;GEOGRAPHY;PHILOSOPHY;HISTORY;MATERIALS SCIENCE;ART;GEOLOGY","430;148;37;20;16;14;12;10;8;7;6;6;5;4;2;2;1;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;CANCER RESEARCH;GASTROENTEROLOGY;PATHOLOGY;GENETICS;ENVIRONMENTAL HEALTH;BIOCHEMISTRY;PALEONTOLOGY;IMMUNOLOGY;CELL BIOLOGY;UROLOGY;INTENSIVE CARE MEDICINE;RADIOLOGY;BIOINFORMATICS;NURSING;VIROLOGY;GYNECOLOGY;LAW;MEDICAL PHYSICS","397;290;113;106;99;88;66;57;55;45;43;22;22;19;17;15;15;15;13;12;12","CANCER;CHEMOTHERAPY;CONFIDENCE INTERVAL;GENE;POPULATION;CLINICAL TRIAL;RANDOMIZED CONTROLLED TRIAL;COHORT;DISEASE;STAGE (STRATIGRAPHY);LUNG CANCER;MELANOMA;ADVERSE EFFECT;RETROSPECTIVE COHORT STUDY;RADIATION THERAPY;IMMUNE SYSTEM;PROPORTIONAL HAZARDS MODEL;ADJUVANT;OVERALL SURVIVAL;RENAL CELL CARCINOMA","307;104;68;68;57;53;47;43;37;36;28;28;27;27;26;25;23;20;19;19","COLORECTAL CANCER;BREAST CANCER;CLINICAL ENDPOINT;IMMUNOTHERAPY;HAZARD RATIO;PROGRESSION-FREE SURVIVAL;METASTASIS;PHASES OF CLINICAL RESEARCH;INFECTIOUS DISEASE (MEDICAL SPECIALTY);BEVACIZUMAB;CISPLATIN;GENOTYPE;PROSTATE CANCER;2019-20 CORONAVIRUS OUTBREAK;CD8;SUNITINIB;SORAFENIB;ADENOCARCINOMA;DOCETAXEL;MUTATION;OVARIAN CANCER","95;90;65;56;52;35;25;23;21;20;16;16;16;15;14;14;13;12;12;12;12","OXALIPLATIN;NIVOLUMAB;METASTATIC BREAST CANCER;CORONAVIRUS DISEASE 2019 (COVID-19);IPILIMUMAB;TRASTUZUMAB;IRINOTECAN;KRAS;NEOADJUVANT THERAPY;PEMBROLIZUMAB;ESTROGEN RECEPTOR;MICROSATELLITE;PAZOPANIB;REGORAFENIB;CARBOPLATIN;CIRCULATING TUMOR CELL;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;TRIPLE-NEGATIVE BREAST CANCER;CAPECITABINE;CYTOREDUCTIVE SURGERY;GENOTYPING;POLY ADP RIBOSE POLYMERASE;SINGLE-NUCLEOTIDE POLYMORPHISM;TAXANE;TRABECTEDIN;VEMURAFENIB","29;28;22;21;16;16;15;14;12;12;9;9;8;8;7;7;7;7;6;6;6;6;6;6;6;6",";HUMANS;FEMALE;COLORECTAL NEOPLASMS;MALE;AGED;MIDDLE AGED;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;NEOPLASM RECURRENCE, LOCAL;ADULT;BREAST NEOPLASMS;PROGNOSIS;FLUOROURACIL;ITALY;MELANOMA;BIOMARKERS, TUMOR;LIVER NEOPLASMS;TREATMENT OUTCOME;RETROSPECTIVE STUDIES;AGED, 80 AND OVER","284;167;108;97;97;86;82;68;52;51;48;39;36;36;36;34;34;34;33;32","ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;CANCER IMMUNOTHERAPY;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;SARCOMA RESEARCH AND TREATMENT;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;RENAL CELL CARCINOMA;ADVANCEMENTS IN LUNG CANCER RESEARCH;MAMMALIAN MAP KINASE SIGNALING PATHWAYS;GLIOMAS;COLORECTAL CANCER RESEARCH AND TREATMENT;HEPATOCELLULAR CARCINOMA;MOLECULAR RESEARCH ON BREAST CANCER;CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY;HER2 SIGNALING IN BREAST CANCER TREATMENT;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;MANAGEMENT OF PERITONEAL CARCINOMATOSIS FROM DIGESTIVE TRACT;MELANOMA;MOLECULAR CHARACTERIZATION OF COLORECTAL CANCER;PREOPERATIVE CHEMORADIOTHERAPY FOR ESOPHAGEAL CANCER","31;20;19;16;15;15;15;14;12;11;10;10;10;8;8;7;7;7;7;7","CLINICAL ENDPOINT;METASTATIC COLORECTAL CANCER;PROGRESSION-FREE SURVIVAL;BREAST CANCER;NEOADJUVANT THERAPY;BIOMARKERS FOR IMMUNOTHERAPY;MELANOMA;TUMOR MICROENVIRONMENT;TREATMENT;ADJUVANT THERAPY;2019-20 CORONAVIRUS OUTBREAK;REGIMEN;FOLFIRI;FOLFOX;UNIVARIATE ANALYSIS;DISCONTINUATION;PANDEMIC;SOFT TISSUE SARCOMA;INTRATUMOR HETEROGENEITY;METASTATIC BREAST CANCER","65;35;34;24;20;19;19;18;17;14;13;13;12;12;12;11;11;11;10;10","BREAST CANCER;COLORECTAL CANCER;METASTATIC COLORECTAL;PHASE II;CANCER PATIENTS;LUNG CANCER;PATIENTS TREATED;CELL CARCINOMA;METASTATIC RENAL;PATIENTS PTS;PHASE III;RENAL CELL;II STUDY;CELL LUNG;LOCALLY ADVANCED;RANDOMIZED PHASE;ADVANCED BREAST;NEOADJUVANT CHEMOTHERAPY;PROSTATE CANCER;HEPATOCELLULAR CARCINOMA;NEGATIVE BREAST;NON-SMALL CELL;POOLED ANALYSIS;CLINICAL OUTCOMES;FIRST-LINE TREATMENT;METASTATIC BREAST;PROGNOSTIC ROLE;SOFT TISSUE;ABSTRACT P--;CANCER MCRC","55;45;32;27;26;19;19;17;17;17;16;15;13;12;12;12;10;10;10;9;9;9;9;8;8;8;8;8;7;7","HR CI;BREAST CANCER;PROGRESSION-FREE SURVIVAL;SURVIVAL OS;SURVIVAL PFS;MEDIAN OS;DISEASE PROGRESSION;COLORECTAL CANCER;RESPONSE RATE;ADVERSE EVENTS;HAZARD RATIO;PATIENTS TREATED;MONTHS CI;MEDIAN FOLLOW-UP;PRIMARY ENDPOINT;CONFIDENCE INTERVAL;SPEAKERS BUREAU;BARCELONA SPAIN;LUNG CANCER;PHASE III;CANCER PATIENTS;MEDIAN PFS;PATIENTS RECEIVED;STAGE III;ADVISORY COMMITTEES;ENTITYS BOARD;GROWTH FACTOR;INTERVAL CI;METASTATIC COLORECTAL;CIK CELLS","98;73;62;59;47;46;45;43;41;40;40;37;36;34;34;33;31;30;29;29;28;27;26;26;25;25;25;25;25;24",234,0.52,11.4,11,1,2,0,5,2,1,1.25,13.75,1,1,12.5,1.75,3,2,6.25,8,6,0,0,54.75,53,1,0,1,0,1,0,0,0,0,0,0,0,2,0,0,2,2,0.36,1,0,0,2,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"INDRACCOLO STEFANO;PINAZZA MARICA","2;2","ISTITUTO ONCOLOGICO VENETO IOV IRCCS;ISTITUTO ONCOLOGICO VENETO IOV-IRCCS","1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS","4;2","CANCER;CHILDHOOD LEUKEMIA;HEMATOLOGY;ORPHAN DRUG;PEDIATRIC;PEDIATRIC CANCER;PEDIATRIC RESEARCH INITIATIVE;RARE DISEASES","2;2;2;2;2;2;2;2",NA,NA,"A61P35/00;A61K31/505;A61K31/506;A61K31/573;A61K31/69;A61K45/06;A61K9/00;A61P35/02","2;1;1;1;1;1;1;1","A61K31/505;A61K31/573;A61K31/69;A61K45/06;A61K9/0053;A61P35/00;A61P35/02","2;2;2;2;2;2;2",54,5.11,862.08,18.49,39,0.72,108,0,4,15,1,23,0,2,9,0,45,8,0,0,0,0,0,0,47,4,3,53,1,0,0,0,0,0,0,0,0,"United States;Germany;Italy;Japan;Belgium;France;United Kingdom;Switzerland","13;5;3;3;2;2;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;4205 NURSING","53;45;28;6;5;5;2;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;DIGESTIVE DISEASES;PATIENT SAFETY;BREAST CANCER;LUNG;PREVENTION;COLO-RECTAL CANCER;LUNG CANCER;BIOMEDICAL IMAGING;GENETICS;HEMATOLOGY;LIVER CANCER;LIVER DISEASE;ORPHAN DRUG;UROLOGIC DISEASES;AGING;BIODEFENSE","52;50;38;20;14;13;8;8;7;6;6;4;3;3;3;3;3;3;2;2","CANCER","42","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;5.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;4.5 RESOURCES AND INFRASTRUCTURE (DETECTION);6.4 SURGERY;7.1 INDIVIDUAL CARE NEEDS;4.4 POPULATION SCREENING;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;7.3 MANAGEMENT AND DECISION MAKING","44;7;6;2;2;2;2;2;1;1;1","BREAST CANCER;COLON AND RECTAL CANCER;LUNG CANCER;MELANOMA;ESOPHAGEAL / OESOPHAGEAL CANCER;LIVER CANCER;BRAIN TUMOR;HEAD AND NECK CANCER;KIDNEY CANCER;LARYNGEAL CANCER;LEUKEMIA / LEUKAEMIA;ORAL CAVITY AND LIP CANCER;PANCREATIC CANCER;PHARYNGEAL CANCER;PROSTATE CANCER;SALIVARY GLAND CANCER;STOMACH CANCER;BLADDER CANCER;GALLBLADDER CANCER;NON-HODGKIN'S LYMPHOMA","9;8;7;4;3;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;2.4 RESOURCES AND INFRASTRUCTURE RELATED TO ETIOLOGY;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD","33;3;3;3;3;2;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,38,"FRONTIERS;AMERICAN ASSOCIATION FOR CANCER RESEARCH;PUBLIC LIBRARY OF SCIENCE;KARGER PUBLISHERS","16;11;10;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3204 IMMUNOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;31 BIOLOGICAL SCIENCES;3202 CLINICAL SCIENCES;3105 GENETICS;49 MATHEMATICAL SCIENCES;3205 MEDICAL BIOCHEMISTRY AND METABOLOMICS;4905 STATISTICS;46 INFORMATION AND COMPUTING SCIENCES;4612 SOFTWARE ENGINEERING","61;13;13;9;9;4;3;2;2;1;1","CANCER;BIOTECHNOLOGY;CLINICAL RESEARCH;GENETICS;DIGESTIVE DISEASES;PREVENTION;DIGESTIVE DISEASES - (PEPTIC ULCER);EMERGING INFECTIOUS DISEASES;INFECTIOUS DISEASES;VACCINE RELATED;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;OVARIAN CANCER;BREAST CANCER;HEMATOLOGY;HUMAN GENOME;IMMUNIZATION;LUNG;LUNG CANCER;LYMPHOMA","18;12;10;9;8;8;7;7;7;7;5;5;2;1;1;1;1;1;1;1","CANCER;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM","8;7;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.4 SURVEILLANCE AND DISTRIBUTION;6.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS","8;4;4;3;3","BIOMEDICAL;CLINICAL","13;2","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH;HEALTH SERVICES RESEARCH","20;10;2;1","STOMACH CANCER;LIVER CANCER;SARCOMA;BRAIN TUMOR;BREAST CANCER;MELANOMA;NOT SITE-SPECIFIC CANCER;OVARIAN CANCER;LUNG CANCER;NON-HODGKIN'S LYMPHOMA","8;4;3;2;2;2;2;2;1;1","3 GOOD HEALTH AND WELL BEING","3"
"IRCCS_IOV",2021,516,19.2577519379845,2.52906976744186,0.395402298850575,0.186046511627907,0.205426356589147,0.13953488372093,0.691860465116279,3,280,121,35,12,0.54,0.23,0.07,0.02,20.46,1.32674178979356,0.443798449612403,0.986434108527132,9.65189101260673,0.577498662924477,0.564805954279639,0.582945572476029,0.632451338199513,"SARA LONARDI;PIERFRANCO CONTÉ;VITTORINA ZAGONEL;VALENTINA GUARNERI;MATTEO FASSAN;UGO DE GIORGI;MARCO MARUZZO;MARIA VITTORIA DIECI;GIUSEPPE LOMBARDI;FOTIOS LOUPAKIS;UMBERTO BASSO;GIULIA PASELLO;VANNA CHIARION‐SILENI;ANGELO PAOLO DEI TOS;LAURA BONANNO;CHIARA CREMOLINI;SANDRO PIGNATA;FRANCESCA BERGAMO;ANGELO PORRECA;MARIO CACCESE","65;53;49;47;30;30;28;26;24;23;23;23;22;20;20;20;20;19;19;19","VITTORINA ZAGONEL;PIERFRANCO CONTÉ;SARA LONARDI;VALENTINA GUARNERI;FOTIOS LOUPAKIS;GIUSEPPE LOMBARDI;MARIO CACCESE;MARIA VITTORIA DIECI;GIULIA CERRETTI;MATTEO FASSAN;GIULIA PASELLO;MARTA PADOVAN;MARCO MARUZZO;UMBERTO BASSO;LAURA BONANNO;UGO DE GIORGI;GAIA GRIGUOLO;VANNA CHIARION‐SILENI;LUISA PICCIN;ANTONIO ROSATO","3.7;3.59;3.31;3.27;2.77;2.6;2.25;2.1;1.93;1.85;1.73;1.73;1.58;1.47;1.43;1.4;1.16;1.15;1.12;1.07","SARA LONARDI;PIERFRANCO CONTÉ;VITTORINA ZAGONEL;VALENTINA GUARNERI;MATTEO FASSAN;MARCO MARUZZO;MARIA VITTORIA DIECI;GIUSEPPE LOMBARDI;FOTIOS LOUPAKIS;UMBERTO BASSO;GIULIA PASELLO;VANNA CHIARION‐SILENI;LAURA BONANNO;FRANCESCA BERGAMO;ANGELO PORRECA;MARIO CACCESE;GAIA GRIGUOLO;GIULIA CERRETTI;PAOLO DEL FIORE;ANITA DE ROSSI","65;53;49;47;30;28;26;24;23;23;23;22;20;19;19;19;17;14;14;14","VITTORINA ZAGONEL;PIERFRANCO CONTÉ;SARA LONARDI;VALENTINA GUARNERI;FOTIOS LOUPAKIS;GIUSEPPE LOMBARDI;MARIO CACCESE;MARIA VITTORIA DIECI;GIULIA CERRETTI;MATTEO FASSAN;GIULIA PASELLO;MARTA PADOVAN;MARCO MARUZZO;UMBERTO BASSO;LAURA BONANNO;GAIA GRIGUOLO;VANNA CHIARION‐SILENI;LUISA PICCIN;ANTONIO ROSATO;ANGELO PORRECA","3.7;3.59;3.31;3.27;2.77;2.6;2.25;2.1;1.93;1.85;1.73;1.73;1.58;1.47;1.43;1.16;1.15;1.12;1.07;1.06","SARA LONARDI;UMBERTO BASSO;CAMILLO PORTA;AMISHI Y. SHAH;ANDREA B. APOLO;BURÇIN ŞIMŞEK;CARLOS H. BARRIOS;CRISTINA SUÁREZ;JAMES J. HSIEH;JOSHUA ZHANG;MARÍA T. BOURLON;MAURICIO BUROTTO;ROBERT J. MOTZER;THOMAS POWLES;TONI K. CHOUEIRI;JEFFREY C. GOH;JENS BEDKE;MARTIN EDUARDO RICHARDET;YOSHIHIKO TOMITA;ERIC VAN CUTSEM","1997;1424;1405;1309;1309;1309;1309;1309;1309;1309;1309;1309;1309;1309;1309;1287;1287;1287;1287;1280","SARA LONARDI;UMBERTO BASSO;FOTIOS LOUPAKIS;VANNA CHIARION‐SILENI;VALENTINA GUARNERI;VITTORINA ZAGONEL;PIERFRANCO CONTÉ;MARCO MARUZZO;MARIA VITTORIA DIECI;MATTEO FASSAN;LAURA BONANNO;ANGELO PORRECA;ALESSANDRA BALDONI;GAIA GRIGUOLO;FRANCESCA BERGAMO;GIUSEPPE LOMBARDI;PIERLUIGI PILATI;GIULIA PASELLO;GRAZIA MARIA VERNACI;SIMONA FREZZINI","1997;1424;914;765;745;633;489;399;323;315;296;295;288;273;264;244;233;231;222;221","SARA LONARDI;VITTORINA ZAGONEL;PIERFRANCO CONTÉ;VALENTINA GUARNERI;MARCO MARUZZO;GIUSEPPE LOMBARDI;UMBERTO BASSO;FOTIOS LOUPAKIS;VANNA CHIARION‐SILENI;MARIA VITTORIA DIECI;LAURA BONANNO;GIULIA PASELLO;FRANCESCA BERGAMO;MARIO CACCESE;ANGELO PORRECA;PAOLO DEL FIORE;ANITA DE ROSSI;MATTEO FASSAN;GIULIA CERRETTI;DARIO MARINO","65;48;44;40;28;24;23;22;22;21;20;20;19;18;17;14;14;14;14;13","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;MATHEMATICS;ECONOMICS;SOCIOLOGY;PSYCHOLOGY;ENGINEERING;PHILOSOPHY;POLITICAL SCIENCE;BUSINESS;MATERIALS SCIENCE;GEOGRAPHY;ENVIRONMENTAL SCIENCE;HISTORY","495;134;32;27;20;16;15;10;8;7;7;7;4;4;3;1;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;CANCER RESEARCH;PATHOLOGY;GASTROENTEROLOGY;GENETICS;IMMUNOLOGY;ENVIRONMENTAL HEALTH;BIOCHEMISTRY;UROLOGY;RADIOLOGY;PALEONTOLOGY;NUCLEAR MEDICINE;NURSING;CELL BIOLOGY;INTENSIVE CARE MEDICINE;OPTICS;VIROLOGY;GYNECOLOGY","450;312;116;99;94;81;69;65;59;40;38;34;29;25;23;17;16;16;15;14","CANCER;CHEMOTHERAPY;GENE;CLINICAL TRIAL;COHORT;CONFIDENCE INTERVAL;POPULATION;DISEASE;ADVERSE EFFECT;RETROSPECTIVE COHORT STUDY;IMMUNE SYSTEM;LUNG CANCER;RADIATION THERAPY;RANDOMIZED CONTROLLED TRIAL;MELANOMA;RENAL CELL CARCINOMA;PROPORTIONAL HAZARDS MODEL;HEPATOCELLULAR CARCINOMA;MULTIVARIATE ANALYSIS;ADJUVANT;IMMUNOHISTOCHEMISTRY;OVERALL SURVIVAL","327;94;70;66;60;60;58;50;49;44;40;35;35;34;27;27;26;24;23;20;20;20","COLORECTAL CANCER;BREAST CANCER;IMMUNOTHERAPY;CLINICAL ENDPOINT;HAZARD RATIO;PROSTATE CANCER;PROGRESSION-FREE SURVIVAL;INFECTIOUS DISEASE (MEDICAL SPECIALTY);BEVACIZUMAB;ALLELE;PHASES OF CLINICAL RESEARCH;SORAFENIB;UNIVARIATE ANALYSIS;METASTASIS;CABOZANTINIB;OVARIAN CANCER;CD8;PROSTATE;BLADDER CANCER;CISPLATIN;EPIDERMAL GROWTH FACTOR RECEPTOR;SOFT TISSUE SARCOMA;TOLERABILITY","96;83;69;62;46;28;27;26;20;19;19;19;18;17;16;16;15;15;14;12;12;12;12","NIVOLUMAB;CORONAVIRUS DISEASE 2019 (COVID-19);REGORAFENIB;KRAS;IPILIMUMAB;MICROSATELLITE;PEMBROLIZUMAB;OXALIPLATIN;TRASTUZUMAB;METASTATIC BREAST CANCER;NEOADJUVANT THERAPY;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;CETUXIMAB;IRINOTECAN;LENVATINIB;ERLOTINIB;PROSTATECTOMY;SINGLE-NUCLEOTIDE POLYMORPHISM;ESTROGEN RECEPTOR;TRIPLE-NEGATIVE BREAST CANCER;TUMOR-INFILTRATING LYMPHOCYTES","40;26;20;18;17;16;16;14;14;13;13;11;10;10;9;8;8;8;7;7;7",";HUMANS;FEMALE;COLORECTAL NEOPLASMS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;MALE;AGED;MIDDLE AGED;ADULT;RETROSPECTIVE STUDIES;MELANOMA;ITALY;BREAST NEOPLASMS;PROGNOSIS;SKIN NEOPLASMS;NEOPLASM RECURRENCE, LOCAL;COVID-19;NEOPLASMS;AGED, 80 AND OVER;IMMUNE CHECKPOINT INHIBITORS","301;209;104;101;98;87;73;71;57;56;49;48;47;42;42;37;31;30;26;26","ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;CANCER IMMUNOTHERAPY;GLIOMAS;RENAL CELL CARCINOMA;ADVANCEMENTS IN LUNG CANCER RESEARCH;HEPATOCELLULAR CARCINOMA;SARCOMA RESEARCH AND TREATMENT;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;CORONAVIRUS DISEASE 2019 RESEARCH;LYMPHOID NEOPLASMS;HER2 SIGNALING IN BREAST CANCER TREATMENT;MAMMALIAN MAP KINASE SIGNALING PATHWAYS;MELANOMA;PROSTATE CANCER RESEARCH AND TREATMENT;RADIOMICS IN MEDICAL IMAGING ANALYSIS;GASTRIC CANCER RESEARCH AND TREATMENT","31;27;24;22;20;18;17;16;13;12;12;11;9;9;8;7;7;7;7;6","CLINICAL ENDPOINT;METASTATIC COLORECTAL CANCER;BREAST CANCER;PROGRESSION-FREE SURVIVAL;BIOMARKERS FOR IMMUNOTHERAPY;MELANOMA;NEOADJUVANT THERAPY;REGORAFENIB;TREATMENT;TUMOR MICROENVIRONMENT;UNIVARIATE ANALYSIS;CABOZANTINIB;CANCER IMMUNOEDITING;MICROSATELLITE INSTABILITY;DISCONTINUATION;PANDEMIC;CANCER THERAPY;IMMUNE CHECKPOINT BLOCKADE;METASTATIC PROSTATE CANCER;REGIMEN","63;35;34;28;23;21;21;20;20;19;18;16;16;16;15;15;14;13;13;13","BREAST CANCER;COLORECTAL CANCER;METASTATIC COLORECTAL;PATIENTS PTS;PHASE II;CANCER PATIENTS;CELL CARCINOMA;LUNG CANCER;PROSTATE CANCER;HEPATOCELLULAR CARCINOMA;RENAL CELL;CELL LUNG;NON-SMALL CELL;RETROSPECTIVE STUDY;SOFT TISSUE;MULTICENTER STUDY;IMMUNE CHECKPOINT;LOCALLY ADVANCED;PATIENTS TREATED;PHASE III;CIRCULATING TUMOR;OVARIAN CANCER;PROGNOSTIC FACTORS;RECURRENT GLIOBLASTOMA;METASTATIC RENAL;TISSUE SARCOMA;GLIOBLASTOMA PATIENTS;ADVANCED BREAST;ADVANCED HEPATOCELLULAR;CANCER MCRC","48;43;37;26;26;24;24;23;21;20;17;16;15;15;13;12;11;11;11;11;10;10;10;10;9;9;8;7;7;7","HR CI;PROGRESSION-FREE SURVIVAL;BREAST CANCER;SURVIVAL OS;ADVISORY COMMITTEES;ENTITYS BOARD;MONTHS CI;PATIENTS TREATED;ADVERSE EVENTS;MEDIAN FOLLOW-UP;HAZARD RATIO;SURVIVAL PFS;MEDIAN AGE;RESPONSE RATE;CONFIDENCE INTERVAL;PRIMARY ENDPOINT;COLORECTAL CANCER;PATIENTS RECEIVED;RESEARCH FUNDING;MEDIAN OS;CANCER PATIENTS;MONTHS NA;INTERVAL CI;LUNG CANCER;ADVISORY ROLE;INSTITUTIONAL SPONSORFUNDING;MEDIAN PFS;RATIO HR;CLINICAL PRACTICE;COMPLETE RESPONSE","117;69;65;64;59;59;56;55;48;46;42;42;41;40;35;35;34;33;33;32;30;28;27;26;25;25;25;25;24;24",282,0.55,8.9,9,1,2,0,4,1,1,1,10,1,1,9,1,1,2,6,6,4,0,0,30.75,31,2,0,0,0,4,0,0,0,0,0,0,0,4,0,0,0,3.5,1.07,1,0,0,2,0,0,2,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"CARPANESE DEBORA;DALLA PIETA' ANNA;DE SALVO GIAN LUCA;INDRACCOLO STEFANO;LOMBARDI GIUSEPPE;MONTAGNER ISABELLA MONIA;ROSATO ANTONIO","2;2;2;2;2;2;2","ISTITUTO ONCOLOGICO VENETO IOV IRCCS;ISTITUTO ONCOLOGICO VENETO IOV-IRCCS","2;2","31 BIOLOGICAL SCIENCES;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3101 BIOCHEMISTRY AND CELL BIOLOGY;32 BIOMEDICAL AND CLINICAL SCIENCES;34 CHEMICAL SCIENCES;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY","4;2;2;1;1;1;1",NA,NA,"5.1 PHARMACEUTICALS;6.1 PHARMACEUTICALS","2;2","A61K31/44;A61K39/00;A61K39/39;G01N33/574;A61K38/43;A61P35/00;G01N33/50","2;2;2;2;1;1;1","A61K2039/55583;A61K31/44;A61K39/001106;A61K39/39;A61P35/00;C07K16/40;G01N2333/9015;G01N2440/14;G01N2800/52;G01N33/57407","2;2;2;2;2;2;2;2;2;2",35,4.63,319.71,10.9,29,0.83,81.14,0,2,16,0,15,0,0,2,0,33,2,0,0,0,0,0,0,33,2,0,35,0,0,0,0,0,0,0,0,0,"United States;Japan;Germany;United Kingdom;Belgium;Italy;Switzerland","11;4;3;3;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES","35;29;19;6;1;1;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;DIGESTIVE DISEASES;PATIENT SAFETY;LUNG;LUNG CANCER;BRAIN DISORDERS;BREAST CANCER;COLO-RECTAL CANCER;HEMATOLOGY;VACCINE RELATED;BIOTECHNOLOGY;BRAIN CANCER;GENETICS;LYMPHOMA;NEUROSCIENCES;ORPHAN DRUG;UROLOGIC DISEASES","33;32;28;10;6;6;4;4;3;3;3;3;3;2;2;2;2;2;2;2","CANCER","30","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;5.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","29;3;2;1","MELANOMA;LUNG CANCER;BREAST CANCER;COLON AND RECTAL CANCER;LIVER CANCER;NON-HODGKIN'S LYMPHOMA;SARCOMA;BLADDER CANCER;BRAIN TUMOR;ENDOMETRIAL CANCER;ESOPHAGEAL / OESOPHAGEAL CANCER;GALLBLADDER CANCER;STOMACH CANCER","5;4;3;3;3;3;3;2;2;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING","25;3;2",2,3139984,156999.2,4.5,10.5,4.5,0.5,3.5,31399.84,16.4332047551835,"ISTITUTO ONCOLOGICO VENETO;ABBVIE (UNITED STATES);ASTRAZENECA (SWEDEN);AUGUST PI I SUNYER BIOMEDICAL RESEARCH INSTITUTE;AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA;BOEHRINGER INGELHEIM (GERMANY);CENTRE FOR PROCESS INNOVATION;HOSPITAL CLÍNIC DE BARCELONA;LONZA (SWITZERLAND);LUND UNIVERSITY;MERCK (GERMANY);PFIZER (UNITED KINGDOM);RISE RESEARCH INSTITUTES OF SWEDEN;ROCHE (SWITZERLAND);SANOFI (GERMANY);SWEDISH RHEUMATISM ASSOCIATION;TEVA PHARMACEUTICALS (ISRAEL);UNIVERSITY COLLEGE LONDON;UNIVERSITY OF DUNDEE;UNIVERSITY OF PADUA","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION;ITALIAN ASSOCIATION FOR CANCER RESEARCH","1;1","COALITION S;EC & ERC - EUROPEAN UNION;ICRP - INTERNATIONAL CANCER RESEARCH PARTNERSHIP","1;1;1","H2020-EU.3.1. - SOCIETAL CHALLENGES - HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING (PROGRAMME);H2020-JTI-IMI2-2020-20-TWO-STAGE (CALL FOR PROPOSAL);RIA - RESEARCH AND INNOVATION ACTION (FUNDING SCHEME)","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;46 INFORMATION AND COMPUTING SCIENCES","1;1;1;1;1","CLINICAL RESEARCH;CANCER;GENETICS;ORPHAN DRUG;RARE DISEASES","2;1;1;1;1","CANCER;GENERIC HEALTH RELEVANCE","1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS;6.1 PHARMACEUTICALS","1;1;1","NOT SITE-SPECIFIC CANCER","1",NA,NA,"A01 CLINICAL MEDICINE;A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY","1;1",NA,NA,44,"FRONTIERS;FUTURE SCIENCE GROUP;KARGER PUBLISHERS;SPRINGER NATURE;ZENODO;PUBLIC LIBRARY OF SCIENCE;TAYLOR & FRANCIS GROUP","29;6;3;2;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;3207 MEDICAL MICROBIOLOGY;49 MATHEMATICAL SCIENCES;31 BIOLOGICAL SCIENCES;3105 GENETICS;40 ENGINEERING;4205 NURSING","81;38;30;7;7;4;2;2;1;1;1;1","CANCER;CLINICAL RESEARCH;BREAST CANCER;GENETICS;LUNG;LUNG CANCER;BIOENGINEERING;RARE DISEASES;UROLOGIC DISEASES;BIOMEDICAL IMAGING;DIGESTIVE DISEASES;PROSTATE CANCER;AGING;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;BIOTECHNOLOGY;ESTROGEN;PREVENTION;BRAIN CANCER;BRAIN DISORDERS;COLO-RECTAL CANCER","39;26;13;10;9;8;7;7;7;6;6;6;5;5;4;4;4;2;2;2","CANCER;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;RENAL AND UROGENITAL","35;2;2;1","4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;6.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY;7.1 INDIVIDUAL CARE NEEDS;8.1 ORGANISATION AND DELIVERY OF SERVICES","10;9;5;1;1;1;1;1;1","BIOMEDICAL;CLINICAL;HEALTH SERVICES & SYSTEMS;POPULATION & SOCIETY","13;10;1;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;HEALTH SERVICES RESEARCH","31;7;1","BREAST CANCER;LUNG CANCER;PROSTATE CANCER;NOT SITE-SPECIFIC CANCER;BRAIN TUMOR;COLON AND RECTAL CANCER;KIDNEY CANCER;LIVER CANCER;MELANOMA;ORAL CAVITY AND LIP CANCER;PANCREATIC CANCER","13;8;7;6;2;2;1;1;1;1;1","3 GOOD HEALTH AND WELL BEING","1"
"IRCCS_IOV",2022,489,19.2883435582822,2.9959100204499,0.333788395904437,0.21881390593047,0.249488752556237,0.14519427402863,0.736196319018405,1,285,79,19,17,0.58,0.16,0.04,0.03,12.28,1.37564994779025,0.439672801635992,0.98159509202454,9.23598484848488,0.585240056251164,0.586062352632958,0.618880358086475,0.609955005624297,"SARA LONARDI;MATTEO FASSAN;VITTORINA ZAGONEL;FRANCESCA BERGAMO;MARCO MARUZZO;VALENTINA GUARNERI;CHIARA CREMOLINI;PIERFRANCO CONTÉ;GIULIA PASELLO;GIUSEPPE LOMBARDI;VANNA CHIARION‐SILENI;FILIPPO PIETRANTONIO;UMBERTO BASSO;ANGELO PAOLO DEI TOS;UGO DE GIORGI;MARIO CACCESE;LAURA BONANNO;ANTONELLA BRUNELLO;LORENZO ANTONUZZO;ANTONIO ROSATO","87;56;46;37;32;30;29;26;25;23;22;22;22;21;21;19;19;18;17;17","SARA LONARDI;VITTORINA ZAGONEL;MATTEO FASSAN;MARIO CACCESE;VALENTINA GUARNERI;GIUSEPPE LOMBARDI;FRANCESCA BERGAMO;MARTA PADOVAN;GIULIA CERRETTI;GIULIA PASELLO;MARCO MARUZZO;ANTONIO ROSATO;PIERFRANCO CONTÉ;CHIARA CREMOLINI;VANNA CHIARION‐SILENI;ANGELO PAOLO DEI TOS;LAURA BONANNO;UMBERTO BASSO;ALESSANDRA BUJA;ANTONELLA BRUNELLO","5.33;3.95;3.76;2.22;2.21;2.18;2.14;2.1;1.84;1.69;1.68;1.63;1.57;1.34;1.32;1.25;1.22;1.15;1.09;1.08","SARA LONARDI;MATTEO FASSAN;VITTORINA ZAGONEL;FRANCESCA BERGAMO;MARCO MARUZZO;VALENTINA GUARNERI;PIERFRANCO CONTÉ;GIULIA PASELLO;GIUSEPPE LOMBARDI;VANNA CHIARION‐SILENI;UMBERTO BASSO;MARIO CACCESE;LAURA BONANNO;ANTONELLA BRUNELLO;ANTONIO ROSATO;DAVIDE BIMBATTI;MARTA PADOVAN;MARIA VITTORIA DIECI;GIULIA CERRETTI;VALENTINA ANGERILLI","87;56;46;37;32;30;26;25;23;22;22;19;19;18;17;16;16;16;14;13","SARA LONARDI;VITTORINA ZAGONEL;MATTEO FASSAN;MARIO CACCESE;VALENTINA GUARNERI;GIUSEPPE LOMBARDI;FRANCESCA BERGAMO;MARTA PADOVAN;GIULIA CERRETTI;GIULIA PASELLO;MARCO MARUZZO;ANTONIO ROSATO;PIERFRANCO CONTÉ;VANNA CHIARION‐SILENI;LAURA BONANNO;UMBERTO BASSO;ANTONELLA BRUNELLO;PAOLO DEL FIORE;DEL FIORE PAOLO;MARIA VITTORIA DIECI","5.33;3.95;3.76;2.22;2.21;2.18;2.14;2.1;1.84;1.69;1.68;1.63;1.57;1.32;1.22;1.15;1.08;1.05;1;0.99","SARA LONARDI;PAOLO A. ASCIERTO;PIOTR RUTKOWSKI;VANNA CHIARION‐SILENI;PAOLA QUEIROLO;REINHARD DUMMER;MICHELE DEL VECCHIO;PIERFRANCO CONTÉ;JEAN‐JACQUES GROB;DIRK SCHADENDORF;FILIPPO PIETRANTONIO;LUIS DE LA CRUZ‐MERINO;FRANCESCA BERGAMO;CAROLINE ROBERT;GEORGINA V. LONG;MATTEO S. CARLINO;CHIARA CREMOLINI;MARIO MANDALÁ;ALEXANDER M.M. EGGERMONT;JACEK MACKIEWICZ","1345;769;767;764;711;701;688;641;634;613;612;609;593;588;566;545;508;501;453;453","SARA LONARDI;VANNA CHIARION‐SILENI;PIERFRANCO CONTÉ;FRANCESCA BERGAMO;GIUSEPPE LOMBARDI;VITTORINA ZAGONEL;MATTEO FASSAN;VALENTINA GUARNERI;MARIA VITTORIA DIECI;ANTONIO ROSATO;FRANCESCA DANIEL;CATERINA SOLDÀ;FABIO GIRARDI;MARCO MARUZZO;LAURA BONANNO;UMBERTO BASSO;GAIA GRIGUOLO;JACOPO PIGOZZO;ROSSANA INTINI;SABINA MURGIONI","1345;764;641;593;407;339;285;256;204;202;199;193;170;162;158;154;134;123;121;119","SARA LONARDI;VITTORINA ZAGONEL;FRANCESCA BERGAMO;MATTEO FASSAN;MARCO MARUZZO;VALENTINA GUARNERI;GIUSEPPE LOMBARDI;PIERFRANCO CONTÉ;VANNA CHIARION‐SILENI;UMBERTO BASSO;LAURA BONANNO;MARIO CACCESE;ANTONELLA BRUNELLO;DAVIDE BIMBATTI;GIULIA PASELLO;MARTA PADOVAN;ANTONIO ROSATO;GIULIA CERRETTI;PAOLA DEL BIANCO;PIERLUIGI PILATI","87;46;37;33;30;26;23;23;22;22;19;19;18;17;16;16;14;13;13;13","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;PHYSICS;SOCIOLOGY;PSYCHOLOGY;ECONOMICS;MATHEMATICS;ENGINEERING;PHILOSOPHY;POLITICAL SCIENCE;BUSINESS;GEOGRAPHY;MATERIALS SCIENCE;HISTORY;ART","470;152;49;34;27;18;16;15;12;10;10;10;7;5;4;2;1","INTERNAL MEDICINE;ONCOLOGY;CANCER RESEARCH;SURGERY;PATHOLOGY;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;GENETICS;BIOCHEMISTRY;IMMUNOLOGY;PALEONTOLOGY;RADIOLOGY;NURSING;FAMILY MEDICINE;MEDICAL PHYSICS;NUCLEAR MEDICINE;UROLOGY;ARTIFICIAL INTELLIGENCE;DEMOGRAPHY;GENERAL SURGERY;PHARMACOLOGY;PSYCHIATRY","425;298;114;108;98;80;79;75;61;49;45;28;27;19;18;18;18;12;12;12;12;12","CANCER;CHEMOTHERAPY;GENE;POPULATION;CLINICAL TRIAL;COHORT;CONFIDENCE INTERVAL;DISEASE;STAGE (STRATIGRAPHY);RADIATION THERAPY;ADVERSE EFFECT;LUNG CANCER;RANDOMIZED CONTROLLED TRIAL;RENAL CELL CARCINOMA;IMMUNE SYSTEM;MELANOMA;RETROSPECTIVE COHORT STUDY;MULTIVARIATE ANALYSIS;QUALITY OF LIFE (HEALTHCARE);IMMUNOHISTOCHEMISTRY","313;100;90;78;71;43;38;37;34;33;32;30;29;26;24;24;24;22;22;20","COLORECTAL CANCER;IMMUNOTHERAPY;BREAST CANCER;CLINICAL ENDPOINT;HAZARD RATIO;PHASES OF CLINICAL RESEARCH;MUTATION;PROGRESSION-FREE SURVIVAL;BEVACIZUMAB;ADENOCARCINOMA;ALLELE;PROSTATE CANCER;METASTASIS;UNIVARIATE ANALYSIS;GENE EXPRESSION;CDKN2A;PROGRESSIVE DISEASE;TEMOZOLOMIDE;SOFT TISSUE SARCOMA;PLACEBO","93;78;71;54;34;27;25;25;24;22;20;18;17;17;16;14;14;14;13;12","NIVOLUMAB;KRAS;PEMBROLIZUMAB;IPILIMUMAB;MICROSATELLITE;CETUXIMAB;OXALIPLATIN;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;METASTATIC BREAST CANCER;CORONAVIRUS DISEASE 2019 (COVID-19);IRINOTECAN;TRASTUZUMAB;CARBOPLATIN;NEOADJUVANT THERAPY;GERMLINE MUTATION;IDH1;PTEN;TAXANE;ANTHRACYCLINE;POLY ADP RIBOSE POLYMERASE;VEMURAFENIB","50;26;21;20;19;16;16;15;11;10;10;10;9;9;8;8;8;8;7;7;7",";HUMANS;COLORECTAL NEOPLASMS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;FEMALE;MELANOMA;BREAST NEOPLASMS;MALE;RETROSPECTIVE STUDIES;LUNG NEOPLASMS;SKIN NEOPLASMS;COLONIC NEOPLASMS;PROGNOSIS;PROTO-ONCOGENE PROTEINS B-RAF;NIVOLUMAB;CARCINOMA, NON-SMALL-CELL LUNG;RECTAL NEOPLASMS;KIDNEY NEOPLASMS;NEOPLASMS;PROSPECTIVE STUDIES","256;228;90;81;55;51;48;48;44;39;37;36;36;34;32;29;24;23;23;23","ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;GLIOMAS;CANCER IMMUNOTHERAPY;RENAL CELL CARCINOMA;ADVANCEMENTS IN LUNG CANCER RESEARCH;MELANOMA;CHOLANGIOCARCINOMA;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;SARCOMA RESEARCH AND TREATMENT;HEPATOCELLULAR CARCINOMA;HER2 SIGNALING IN BREAST CANCER TREATMENT;LYMPHOID NEOPLASMS;POLY(ADP-RIBOSE) POLYMERASE INHIBITION IN CANCER THERAPY;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;PANCREATIC CANCER RESEARCH AND TREATMENT;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;MOLECULAR CHARACTERIZATION OF COLORECTAL CANCER;RADIOMICS IN MEDICAL IMAGING ANALYSIS;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;CANCER SURVIVORSHIP AND QUALITY OF LIFE","39;26;25;18;15;14;13;13;13;11;11;11;11;10;10;9;9;9;6;5","CLINICAL ENDPOINT;METASTATIC COLORECTAL CANCER;PROGRESSION-FREE SURVIVAL;TUMOR MICROENVIRONMENT;MELANOMA;MICROSATELLITE INSTABILITY;BREAST CANCER;CANCER IMAGING;GLIOBLASTOMA;NEOADJUVANT THERAPY;TREATMENT;UNIVARIATE ANALYSIS;TEMOZOLOMIDE;ATEZOLIZUMAB;HER2;CANCER GENOMICS;DISCONTINUATION;REGIMEN;RENAL CELL CARCINOMA;TOLERABILITY","56;43;27;24;23;19;18;17;17;17;17;16;14;13;13;12;12;12;12;12","COLORECTAL CANCER;METASTATIC COLORECTAL;BREAST CANCER;CANCER PATIENTS;CELL CARCINOMA;LUNG CANCER;RENAL CELL;PHASE II;CELL LUNG;NON-SMALL CELL;METASTATIC RENAL;PATIENTS PTS;PHASE III;PATIENTS TREATED;PROSTATE CANCER;CANCER MCRC;HEPATOCELLULAR CARCINOMA;STAGE III;CLINICAL TRIAL;NEWLY DIAGNOSED;NEXT-GENERATION SEQUENCING;PHASE TRIAL;SOFT TISSUE;CANCER TREATED;II STUDY;IMMUNE CHECKPOINT;ADVANCED NON-SMALL;CASTRATION-RESISTANT PROSTATE;CIRCULATING TUMOR;HEALTH-RELATED QUALITY","52;45;40;29;28;25;24;23;20;17;16;16;15;14;14;12;12;11;10;9;8;8;8;7;7;7;6;6;6;6","HR CI;PROGRESSION-FREE SURVIVAL;SURVIVAL OS;BREAST CANCER;PATIENTS TREATED;MEDIAN AGE;MONTHS CI;STAGE III;COLORECTAL CANCER;RESPONSE RATE;DISEASE CONTROL;MEDIAN FOLLOW-UP;SURVIVAL PFS;ADVERSE EVENTS;MEDIAN PFS;CLINICAL PRACTICE;MEDIAN OS;METASTATIC COLORECTAL;PATIENTS RECEIVED;MULTIVARIATE ANALYSIS;STATISTICALLY SIGNIFICANT;CANCER PATIENTS;CELL CARCINOMA;HAZARD RATIO;OBJECTIVE RESPONSE;PHASE II;CIK CELLS;CLINICAL TRIALS;MONTHS NA;PATIENTS PTS","82;70;70;61;46;45;43;43;40;40;39;39;39;37;36;35;33;32;32;30;30;28;27;26;26;26;25;25;24;24",261,0.53,9.55,12,2,1,0,4,1,1,1,14,1,1,13,0,1,2,6,8,5,0,0,21,21,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_IOV",2023,543,21.7495395948435,2.88397790055249,0.346743295019157,0.20073664825046,0.206261510128913,0.136279926335175,0.662983425414365,0,346,88,15,10,0.64,0.16,0.03,0.02,5.97,1.36259498802635,0.478821362799263,1,8.79777698099676,0.547532254891874,0.610332893869479,0.597184684684685,0.620137931034483,"SARA LONARDI;VALENTINA GUARNERI;FRANCESCA BERGAMO;MATTEO FASSAN;CHIARA CREMOLINI;MARCO MARUZZO;FILIPPO PIETRANTONIO;GIANLUCA MASI;VANNA CHIARION‐SILENI;MARIA VITTORIA DIECI;UMBERTO BASSO;SEBASTIANO BUTI;VITTORINA ZAGONEL;GIUSEPPE LOMBARDI;PAOLO A. ASCIERTO;DANIELE ROSSINI;GIUSEPPE FORNARINI;GAIA GRIGUOLO;LORENZO ANTONUZZO;UGO DE GIORGI","86;53;46;42;37;34;34;30;27;27;27;25;24;24;21;21;21;21;20;20","SARA LONARDI;VALENTINA GUARNERI;MATTEO FASSAN;FRANCESCA BERGAMO;MARCO MARUZZO;CHIARA CREMOLINI;FILIPPO PIETRANTONIO;GIUSEPPE LOMBARDI;MARIA VITTORIA DIECI;UMBERTO BASSO;ANTONIO ROSATO;MARIO CACCESE;VANNA CHIARION‐SILENI;VITTORINA ZAGONEL;GIANLUCA MASI;GIULIA CERRETTI;GAIA GRIGUOLO;MARTA PADOVAN;DAVIDE BIMBATTI;DANIELE ROSSINI","4.39;3.41;2.84;2.2;1.82;1.78;1.72;1.7;1.52;1.51;1.46;1.44;1.4;1.39;1.3;1.24;1.18;1.15;1.02;0.99","SARA LONARDI;VALENTINA GUARNERI;FRANCESCA BERGAMO;MATTEO FASSAN;MARCO MARUZZO;VANNA CHIARION‐SILENI;MARIA VITTORIA DIECI;UMBERTO BASSO;VITTORINA ZAGONEL;GIUSEPPE LOMBARDI;GAIA GRIGUOLO;MARIO CACCESE;PIERFRANCO CONTÉ;FEDERICA MIGLIETTA;GIULIA CERRETTI;FILIPPO DE BRAUD;ANGELO PAOLO DEI TOS;ANTONIO ROSATO;DAVIDE BIMBATTI;MARTA PADOVAN","86;53;46;42;34;27;27;27;24;24;21;18;17;16;15;15;15;15;14;14","SARA LONARDI;VALENTINA GUARNERI;MATTEO FASSAN;FRANCESCA BERGAMO;MARCO MARUZZO;GIUSEPPE LOMBARDI;MARIA VITTORIA DIECI;UMBERTO BASSO;ANTONIO ROSATO;MARIO CACCESE;VANNA CHIARION‐SILENI;VITTORINA ZAGONEL;GIULIA CERRETTI;GAIA GRIGUOLO;MARTA PADOVAN;DAVIDE BIMBATTI;PIERFRANCO CONTÉ;FEDERICA MIGLIETTA;VALENTINA ANGERILLI;SIMONE MOCELLIN","4.39;3.41;2.84;2.2;1.82;1.7;1.52;1.51;1.46;1.44;1.4;1.39;1.24;1.18;1.15;1.02;0.97;0.95;0.94;0.93","SARA LONARDI;ERIC VAN CUTSEM;VALENTINA GUARNERI;MARIA DI BARTOLOMEO;JOSEP TABERNERO;VANNA CHIARION‐SILENI;YELENA Y. JANJIGIAN;PAOLO A. ASCIERTO;TAKAYUKI YOSHINO;KOHEI SHITARA;FILIPPO PIETRANTONIO;LUCJAN WYRWICZ;POOJA BHAGIA;SUN YOUNG RHA;CHIARA CREMOLINI;JEAN‐JACQUES GROB;GIUSEPPE CURIGLIANO;JIANMING XU;UGO DE GIORGI;CARSTEN DENKERT","911;395;394;383;321;274;274;264;263;257;229;229;226;226;224;217;204;198;195;194","SARA LONARDI;VALENTINA GUARNERI;VANNA CHIARION‐SILENI;MARCO MARUZZO;LAURA BONANNO;FRANCESCA BERGAMO;PIERFRANCO CONTÉ;GIUSEPPE LOMBARDI;UMBERTO BASSO;MATTEO FASSAN;MARIA VITTORIA DIECI;SABINA MURGIONI;FLORIANA NAPPO;CATERINA SOLDÀ;FOTIOS LOUPAKIS;VITTORINA ZAGONEL;ANTONIO ROSATO;ANGELO PORRECA;GIULIA TASCA;VINCENZO BRONTE","907;369;270;188;186;169;164;163;138;102;88;81;79;76;71;70;66;63;60;53","SARA LONARDI;FRANCESCA BERGAMO;VALENTINA GUARNERI;MARCO MARUZZO;MATTEO FASSAN;VANNA CHIARION‐SILENI;UMBERTO BASSO;GIUSEPPE LOMBARDI;VITTORINA ZAGONEL;MARIA VITTORIA DIECI;MARIO CACCESE;GAIA GRIGUOLO;ANTONIO ROSATO;GIULIA CERRETTI;DAVIDE BIMBATTI;MARTA PADOVAN;ALBERTO FANTIN;GIULIA PASELLO;LAURA BONANNO;ANTONELLA BRUNELLO","86;46;45;34;29;26;26;24;23;18;18;18;16;15;14;14;13;12;12;12","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;ECONOMICS;MATHEMATICS;PSYCHOLOGY;PHILOSOPHY;SOCIOLOGY;ENGINEERING;POLITICAL SCIENCE;BUSINESS;MATERIALS SCIENCE;GEOGRAPHY;HISTORY","527;166;48;32;28;14;10;7;5;5;4;4;3;3;2;2","INTERNAL MEDICINE;ONCOLOGY;GASTROENTEROLOGY;CANCER RESEARCH;SURGERY;PATHOLOGY;GENETICS;BIOCHEMISTRY;IMMUNOLOGY;ENVIRONMENTAL HEALTH;PALEONTOLOGY;RADIOLOGY;UROLOGY;CELL BIOLOGY;GYNECOLOGY;OPTICS;PHARMACOLOGY;FAMILY MEDICINE;NUCLEAR MEDICINE;INTENSIVE CARE MEDICINE;MEDICAL PHYSICS","493;371;110;108;106;87;72;71;61;60;49;37;25;20;20;16;16;14;14;13;13","CANCER;CHEMOTHERAPY;GENE;CLINICAL TRIAL;CONFIDENCE INTERVAL;COHORT;POPULATION;ADVERSE EFFECT;RETROSPECTIVE COHORT STUDY;DISEASE;IMMUNE SYSTEM;RADIATION THERAPY;MELANOMA;RANDOMIZED CONTROLLED TRIAL;LUNG CANCER;STAGE (STRATIGRAPHY);PROPORTIONAL HAZARDS MODEL;ADJUVANT;LYMPHOMA;OVERALL SURVIVAL","365;129;92;71;64;62;60;52;41;40;36;36;33;32;31;30;28;25;24;24","IMMUNOTHERAPY;COLORECTAL CANCER;BREAST CANCER;CLINICAL ENDPOINT;HAZARD RATIO;PROGRESSION-FREE SURVIVAL;BEVACIZUMAB;PHASES OF CLINICAL RESEARCH;ALLELE;ADENOCARCINOMA;MUTATION;PROSTATE CANCER;GENE EXPRESSION;CISPLATIN;TUMOR MICROENVIRONMENT;METASTATIC MELANOMA;TOLERABILITY;PLACEBO;RITUXIMAB;UNIVARIATE ANALYSIS","126;106;86;55;45;34;33;30;28;27;22;20;19;18;18;16;16;15;15;15","NIVOLUMAB;PEMBROLIZUMAB;MICROSATELLITE;KRAS;IPILIMUMAB;CETUXIMAB;TRASTUZUMAB;METASTATIC BREAST CANCER;OXALIPLATIN;VEMURAFENIB;CARBOPLATIN;DNA MISMATCH REPAIR;IRINOTECAN;REGORAFENIB;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;LENVATINIB;NEOADJUVANT THERAPY;TRAMETINIB;TUMOR-INFILTRATING LYMPHOCYTES;POLY ADP RIBOSE POLYMERASE","66;38;26;22;17;16;16;14;14;12;11;11;11;11;11;10;9;9;9;8",";HUMANS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;RETROSPECTIVE STUDIES;FEMALE;COLORECTAL NEOPLASMS;BREAST NEOPLASMS;MALE;PROGNOSIS;MELANOMA;AGED;ADENOCARCINOMA;BRAIN NEOPLASMS;NEOPLASM RECURRENCE, LOCAL;MIDDLE AGED;COLONIC NEOPLASMS;PANCREATIC NEOPLASMS;ADULT;LUNG NEOPLASMS;MUTATION","309;226;71;68;63;55;53;42;39;36;35;33;31;30;29;28;27;26;26;26","ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;CANCER IMMUNOTHERAPY;GLIOMAS;RENAL CELL CARCINOMA;PANCREATIC CANCER RESEARCH AND TREATMENT;MOLECULAR CHARACTERIZATION OF COLORECTAL CANCER;ADVANCEMENTS IN LUNG CANCER RESEARCH;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;MAMMALIAN MAP KINASE SIGNALING PATHWAYS;CHOLANGIOCARCINOMA;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;LYMPHOID NEOPLASMS;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;HEPATOCELLULAR CARCINOMA;MANAGEMENT OF PERITONEAL CARCINOMATOSIS FROM DIGESTIVE TRACT;MOLECULAR RESEARCH ON BREAST CANCER;POLY(ADP-RIBOSE) POLYMERASE INHIBITION IN CANCER THERAPY;SARCOMA RESEARCH AND TREATMENT","42;35;25;21;17;16;15;15;13;13;12;12;11;11;10;10;9;9;9;9","CLINICAL ENDPOINT;METASTATIC COLORECTAL CANCER;PROGRESSION-FREE SURVIVAL;BREAST CANCER;ATEZOLIZUMAB;MICROSATELLITE INSTABILITY;BIOMARKERS FOR IMMUNOTHERAPY;MELANOMA;TREATMENT;TUMOR MICROENVIRONMENT;REGIMEN;GLIOBLASTOMA;NEOADJUVANT THERAPY;CANCER IMMUNOEDITING;TOLERABILITY;TUMOR MICROSATELLITE-INSTABILITY;DISCONTINUATION;UNIVARIATE ANALYSIS;IMMUNE CHECKPOINT BLOCKADE;TARGETED THERAPY","61;39;37;31;30;27;26;24;22;22;19;18;18;17;17;16;15;15;14;14","BREAST CANCER;COLORECTAL CANCER;METASTATIC COLORECTAL;CELL CARCINOMA;PATIENTS PTS;PHASE II;CANCER PATIENTS;RENAL CELL;LUNG CANCER;PROSTATE CANCER;PHASE III;PATIENTS TREATED;HEPATOCELLULAR CARCINOMA;METASTATIC RENAL;CANCER MCRC;CELL LUNG;IMMUNE CHECKPOINT;CHECKPOINT INHIBITORS;OBSERVATIONAL STUDY;GLIOBLASTOMA PATIENTS;UROTHELIAL CARCINOMA;BILIARY TRACT;CANCER TREATED;CARCINOMA MRCC;CLINICAL OUTCOMES;ELDERLY PATIENTS;NON-SMALL CELL;TARGETED THERAPY;ACUTE MYELOID;ADVANCED BREAST","57;46;44;27;26;24;23;22;20;18;17;16;15;15;14;13;13;11;10;9;9;8;8;8;8;8;8;8;7;7","HR CI;BREAST CANCER;MONTHS CI;SURVIVAL OS;PROGRESSION-FREE SURVIVAL;PATIENTS TREATED;RESPONSE RATE;MEDIAN OS;SURVIVAL PFS;MEDIAN FOLLOW-UP;ADVERSE EVENTS;MEDIAN AGE;PATIENTS RECEIVED;MEDIAN PFS;PRIMARY ENDPOINT;CONFIDENCE INTERVAL;DISEASE CONTROL;HAZARD RATIO;PATIENTS PTS;IMMUNE CHECKPOINT;OBJECTIVE RESPONSE;RATE ORR;COMPLETE RESPONSE;LUNG CANCER;PHASE II;DISEASE PROGRESSION;CLINICAL PRACTICE;CONTROL RATE;MULTIVARIATE ANALYSIS;STATISTICALLY SIGNIFICANT","98;84;83;75;70;68;67;62;61;55;54;48;40;39;34;32;32;32;31;29;29;27;26;26;26;25;24;24;24;24",202,0.37,11.04,11,1,2,0,4,0,1,0,13,1,1,12,0,1.75,2,6,7,4,0,0,10,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_IOV",2024,430,21.9093023255814,2.63488372093023,0.379523389232127,0.193023255813953,0.216279069767442,0.132558139534884,0.586046511627907,1,255,67,11,6,0.59,0.16,0.03,0.01,1.13,1.18018377185093,0.5,0.993023255813953,7.07822410147991,0.523337523561043,0.545677361853833,0.541522889348976,0.483720930232558,"SARA LONARDI;VALENTINA GUARNERI;MATTEO FASSAN;MARCO MARUZZO;FRANCESCA BERGAMO;SEBASTIANO BUTI;CHIARA CREMOLINI;GIUSEPPE FORNARINI;FILIPPO PIETRANTONIO;UMBERTO BASSO;DAVIDE BIMBATTI;LORENZO ANTONUZZO;GIANLUCA MASI;GIULIA PASELLO;ANGELO PAOLO DEI TOS;VANNA CHIARION‐SILENI;GIUSEPPE PROCOPIO;GIUSEPPE LOMBARDI;MARIA VITTORIA DIECI;MARIO SCARTOZZI","64;34;31;29;27;25;24;23;22;22;21;20;19;18;17;17;15;15;15;14","SARA LONARDI;VALENTINA GUARNERI;MATTEO FASSAN;SIMONA FREZZINI;MARCO MARUZZO;GIULIA PASELLO;UMBERTO BASSO;DAVIDE BIMBATTI;CHIARA CREMOLINI;SEBASTIANO BUTI;LAURA BONANNO;GIUSEPPE LOMBARDI;FRANCESCA BERGAMO;GIUSEPPE FORNARINI;FILIPPO PIETRANTONIO;PAOLA DEL BIANCO;ANTONIO ROSATO;VANNA CHIARION‐SILENI;ANTONIO SOMMARIVA;LORENZO ANTONUZZO","3.45;2.54;1.92;1.6;1.46;1.31;1.23;1.1;1.09;1.05;1.03;1.02;1.02;0.98;0.94;0.93;0.93;0.9;0.86;0.79","SARA LONARDI;VALENTINA GUARNERI;MATTEO FASSAN;MARCO MARUZZO;FRANCESCA BERGAMO;UMBERTO BASSO;DAVIDE BIMBATTI;GIULIA PASELLO;VANNA CHIARION‐SILENI;GIUSEPPE LOMBARDI;MARIA VITTORIA DIECI;PAOLA DEL BIANCO;ANTONELLA BRUNELLO;GIUSEPPE CURIGLIANO;ANTONIO ROSATO;LAURA BONANNO;GIULIA TASCA;ANTONIO SOMMARIVA;CATERINA SOLDÀ;STEFANO INDRACCOLO","64;34;31;29;27;22;21;18;17;15;15;13;12;11;11;11;10;10;10;9","SARA LONARDI;VALENTINA GUARNERI;MATTEO FASSAN;SIMONA FREZZINI;MARCO MARUZZO;GIULIA PASELLO;UMBERTO BASSO;DAVIDE BIMBATTI;LAURA BONANNO;GIUSEPPE LOMBARDI;FRANCESCA BERGAMO;PAOLA DEL BIANCO;ANTONIO ROSATO;VANNA CHIARION‐SILENI;ANTONIO SOMMARIVA;PIERLUIGI PILATI;SIMONE MOCELLIN;MARIA VITTORIA DIECI;ALESSANDRA FERRO;FRANCESCA CAUMO","3.45;2.54;1.92;1.6;1.46;1.31;1.23;1.1;1.03;1.02;1.02;0.93;0.93;0.9;0.86;0.78;0.74;0.74;0.72;0.7","SARA LONARDI;TAKAYUKI YOSHINO;VANNA CHIARION‐SILENI;GIUSEPPE CURIGLIANO;MARIA VITTORIA DIECI;MICHELE DEL VECCHIO;PAOLO A. ASCIERTO;VALENTINA GUARNERI;PIOTR RUTKOWSKI;THIERRY ANDRÉ;ERIC VAN CUTSEM;FRANCESCO SPAGNOLO;MATTEO LAMBERTINI;ELENA ÉLEZ;FABRICE ANDRÉ;GIAMPAOLO TORTORA;MARÍA LUISA LIMÓN;CHRISTELLE DE LA FOUCHARDIÈRE;HEINZ‐JOSEF LENZ;JAAFAR BENNOUNA","97;57;57;55;55;50;50;49;47;47;41;41;40;38;38;37;36;35;35;35","SARA LONARDI;VANNA CHIARION‐SILENI;MARIA VITTORIA DIECI;VALENTINA GUARNERI;LUISA PICCIN;GIULIA PASELLO;LAURA BONANNO;MARCO MARUZZO;MATTEO FASSAN;FRANCESCA BERGAMO;UMBERTO BASSO;ALESSANDRA FERRO;ANTONELLA BRUNELLO;DAVIDE BIMBATTI;GIUSEPPE CURIGLIANO;GIAN LUCA DE SALVO;GIULIA TASCA;C. MULARGIU;ALBERTO FANTIN;G.M. MARINATO","97;57;55;49;29;27;24;24;22;20;19;17;17;17;14;13;12;10;9;9","SARA LONARDI;MARCO MARUZZO;VALENTINA GUARNERI;FRANCESCA BERGAMO;MATTEO FASSAN;UMBERTO BASSO;DAVIDE BIMBATTI;GIULIA PASELLO;VANNA CHIARION‐SILENI;GIUSEPPE LOMBARDI;PAOLA DEL BIANCO;LAURA BONANNO;ANTONELLA BRUNELLO;MARIA VITTORIA DIECI;GIULIA TASCA;CATERINA SOLDÀ;ANTONIO SOMMARIVA;SIMONE MOCELLIN;PIERLUIGI PILATI;FEDERICA MIGLIETTA","64;29;28;27;23;22;21;17;17;15;13;12;12;12;10;10;10;9;8;7","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;PHYSICS;SOCIOLOGY;ECONOMICS;MATHEMATICS;PSYCHOLOGY;POLITICAL SCIENCE;MATERIALS SCIENCE;PHILOSOPHY;ENGINEERING;GEOGRAPHY;HISTORY;ART;GEOLOGY;BUSINESS;ENVIRONMENTAL SCIENCE","418;130;37;30;29;11;10;10;10;7;6;6;4;4;3;2;2;1;1","INTERNAL MEDICINE;ONCOLOGY;CANCER RESEARCH;PATHOLOGY;SURGERY;GENETICS;BIOCHEMISTRY;IMMUNOLOGY;GASTROENTEROLOGY;ENVIRONMENTAL HEALTH;PALEONTOLOGY;RADIOLOGY;MEDICAL PHYSICS;GENERAL SURGERY;GYNECOLOGY;FAMILY MEDICINE;UROLOGY;BIOINFORMATICS;NUCLEAR MEDICINE;INTENSIVE CARE MEDICINE;PHARMACOLOGY","371;279;101;85;68;59;49;44;39;33;31;28;22;20;19;17;17;15;15;14;14","CANCER;CHEMOTHERAPY;GENE;CLINICAL TRIAL;RETROSPECTIVE COHORT STUDY;COHORT;POPULATION;DISEASE;RANDOMIZED CONTROLLED TRIAL;IMMUNE SYSTEM;MELANOMA;RADIATION THERAPY;RENAL CELL CARCINOMA;CONFIDENCE INTERVAL;LUNG CANCER;ADVERSE EFFECT;STAGE (STRATIGRAPHY);ALTERNATIVE MEDICINE;OBSERVATIONAL STUDY;PROSPECTIVE COHORT STUDY","283;89;58;34;32;31;30;29;29;26;26;25;25;24;24;21;20;17;17;17","IMMUNOTHERAPY;COLORECTAL CANCER;BREAST CANCER;CLINICAL ENDPOINT;BEVACIZUMAB;HAZARD RATIO;OVARIAN CANCER;CISPLATIN;PROGRESSION-FREE SURVIVAL;ADENOCARCINOMA;PLACEBO;BLADDER CANCER;PROSTATE CANCER;ALLELE;METASTASIS;METASTATIC MELANOMA;PHASES OF CLINICAL RESEARCH;TUMOR MICROENVIRONMENT;LIQUID BIOPSY;PACLITAXEL","96;66;61;18;17;16;16;15;15;14;14;13;12;10;10;10;10;10;9;8","NIVOLUMAB;PEMBROLIZUMAB;IPILIMUMAB;METASTATIC BREAST CANCER;MICROSATELLITE;DNA MISMATCH REPAIR;NEOADJUVANT THERAPY;OXALIPLATIN;IRINOTECAN;KRAS;UROTHELIAL CARCINOMA;CARBOPLATIN;IMMUNE CHECKPOINT;CETUXIMAB;CORONAVIRUS DISEASE 2019 (COVID-19);POLY ADP RIBOSE POLYMERASE;TRASTUZUMAB;ERLOTINIB;MAMMOGRAPHY;PTEN;TRIPLE-NEGATIVE BREAST CANCER","39;31;10;10;10;9;9;9;8;8;8;7;7;6;6;6;6;5;5;5;5",";HUMANS;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;RETROSPECTIVE STUDIES;AGED, 80 AND OVER;PROGNOSIS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ITALY;PROSPECTIVE STUDIES;BREAST NEOPLASMS;MUTATION;ANTIBODIES, MONOCLONAL, HUMANIZED;COLORECTAL NEOPLASMS;LUNG NEOPLASMS;MELANOMA;NEOPLASMS","235;193;119;99;95;93;84;55;44;37;33;26;21;19;18;17;17;16;16;16","CANCER IMMUNOTHERAPY;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;RENAL CELL CARCINOMA;MELANOMA;ADVANCEMENTS IN LUNG CANCER RESEARCH;CHOLANGIOCARCINOMA;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;GASTRIC CANCER RESEARCH AND TREATMENT;GLIOMAS;MOLECULAR CHARACTERIZATION OF COLORECTAL CANCER;SARCOMA RESEARCH AND TREATMENT;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;MOLECULAR RESEARCH ON BREAST CANCER;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;MANAGEMENT OF PERITONEAL CARCINOMATOSIS FROM DIGESTIVE TRACT;PANCREATIC CANCER RESEARCH AND TREATMENT;HEPATOCELLULAR CARCINOMA;LYMPHOID NEOPLASMS;POLY(ADP-RIBOSE) POLYMERASE INHIBITION IN CANCER THERAPY","27;25;22;15;12;12;12;12;11;11;11;10;10;9;8;8;7;6;6;6","METASTATIC COLORECTAL CANCER;MELANOMA;TUMOR MICROENVIRONMENT;CLINICAL ENDPOINT;ATEZOLIZUMAB;BREAST CANCER;NEOADJUVANT THERAPY;ADJUVANT THERAPY;BIOMARKERS FOR IMMUNOTHERAPY;PROGRESSION-FREE SURVIVAL;TREATMENT;CANCER IMMUNOEDITING;RENAL CELL CARCINOMA;MICROSATELLITE INSTABILITY;BILIARY TRACT CANCER;LIQUID BIOPSY;RADIOTHERAPY;BIOMARKER ANALYSIS;CANCER IMMUNOTHERAPY;METASTATIC PROSTATE CANCER","33;21;19;18;17;17;17;16;15;15;14;12;12;10;9;9;9;8;8;8","BREAST CANCER;COLORECTAL CANCER;METASTATIC COLORECTAL;CELL CARCINOMA;RENAL CELL;LUNG CANCER;CANCER MCRC;CANCER PATIENTS;CELL LUNG;PHASE III;PHASE II;PROSTATE CANCER;LOCALLY ADVANCED;RETROSPECTIVE STUDY;LIQUID BIOPSY;MEET-URO STUDY;PATIENTS PTS;IMMUNE CHECKPOINT;NON-SMALL CELL;PATIENTS RECEIVING;PATIENTS TREATED;UROTHELIAL CARCINOMA;BILIARY TRACT;BRAIN METASTASES;CHECKPOINT INHIBITORS;HEPATOCELLULAR CARCINOMA;NIVOLUMAB NIVO;OBSERVATIONAL STUDY;OVARIAN CANCER;ADJUVANT CHEMOTHERAPY","39;37;29;27;20;18;13;13;13;13;11;11;10;10;9;9;9;8;8;8;8;8;7;7;7;7;7;7;7;6","BREAST CANCER;HR CI;PROGRESSION-FREE SURVIVAL;SURVIVAL OS;CROSSREF PUBMED;GENETIC TESTING;PATIENTS TREATED;PUBMED SCOPUS;SURVIVAL PFS;CLINICAL PRACTICE;COLORECTAL CANCER;LUNG CANCER;MONTHS CI;ADVERSE EVENTS;CLINICAL TRIALS;IMMUNE CHECKPOINT;CHECKPOINT INHIBITORS;GENETIC COUNSELING;MEDIAN OS;PROGNOSTIC FACTORS;CANCER PATIENTS;MEDIAN FOLLOW-UP;RESPONSE RATE;LYNCH SYNDROME;NSCLC PATIENTS;CELL CARCINOMA;CONFIDENCE INTERVAL;HAZARD RATIO;PATIENTS RECEIVED;PD-L EXPRESSION","48;43;37;35;32;32;32;32;32;30;30;30;27;25;24;24;23;23;22;22;21;21;21;18;18;17;17;17;17;17",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
